Updated 06.21.2021 CURRICULUM VITAE
Gary S. Francis, M.D., F.A.C.C., F.A.H.A., F.A.C.P., F.H.F.S.A. U.S. Citizen
Office Physical Address: Office Mailing Current Position: University of Minnesota Address: Professor Emeritus Variety Club Research 420 Delaware Street, University of Minnesota Center SE Cardiovascular Division MMC 508 401 East River Road Minneapolis, MN Minneapolis, MN 55455 55455 Direct Phone: (612) 626- 4895 Office Phone: (612) 624- 8970 FAX: (612) 626-4411 E-mail: [email protected] Exec.Administrator, Kitty Tincher
Education:
Degree Institution Date Degree Granted None University of Minnesota (1963-1965) None Honors Course MD Creighton University School of Medicine 1969 (early entry, 2 scholarships, AOA) Internship Creighton University School of Medicine 1969-1970 and Affiliated Hospitals
Residency in Internal Medicine U.S. Navy 1970-1972 CV Disease Fellowship Naval Regional Medical Center 1972-1974 San Diego, California
National Awards
Master Teacher Award – University of Miami – May 26, 1996 Master Teacher Award – University of Miami – May 25, 2002 Annual Laennec Clinician Educator Award – American Heart Association – November 2006 Distinguished Teacher Award – American College of Cardiology – March 21, 2014 Lifetime Achievement Award – Heart Failure Society of America – September 15, 2014
Scholarly Overview
Total publications – 560 (about 14-15 papers per year) h-index – 88, 83, 84 (various services) Total citations – 50,946 Views on internet – 382,539 (Mendeley) First/last author citations – 7740 Top 1% of scientists world-wide, as noted by Heart Failure Society of America using SCOPUS 2019
Academic Appointments:
Professor Emeritus – University of Minnesota January 1, 2021 Gary S. Francis, M.D. Curriculum Vitae
Executive Medical Director - Cardiovascular Service Line-M-Heart (Univ 2014-2018 MN and Fairview affiliated hospitals) Fred C. and Katherine B. Andersen Foundation Chair in Adult Clinical Cardiology, University of Minnesota 2014 - 2017 Professor of Medicine with tenure – University of Minnesota, 2008-2020 Cardiovascular Division Professor of Medicine – Cleveland Clinic Lerner College of Medicine of Case Western Reserve University 2004 - 2008 Professor of Medicine, Ohio State University, Health Sciences Center 1999 - 2004 Professor of Medicine, University of Minnesota Medical School 1988 - 1997 Associate Professor of Medicine, University of Minnesota Medical School 1982 - 1988 Director, Echo Laboratory VA Medical Center, Minneapolis, MN 1980 - 1988 Principal Investigator VA Cooperative Study on Vasodilator Therapy in 1979 - 1985 Congestive Heart Failure (V-HeFT I) - University of Minnesota Associate Chairman and Principal Investigator VA Cooperative Study on 1979 - 1982 Vasodilator Therapy of Acute Myocardial Infarction - VA Hospital; Minneapolis, Minnesota; University of Minnesota Assistant Professor of Medicine, University of Minnesota Medical School 1977 - 1982 Director, George E. Fahr Cardiac Care Unit, Hennepin County Medical 1977 - 1979 Center; University of Minnesota Clinical Instructor in Medicine, University of California, San Diego, School 1976 - 1977 of Medicine Naval Regional Medical Center, San Diego, CA - Branch Head: 1976 - 1977 Department of Critical Care (1500-bed major tertiary teaching hospital)
Academic Administrative Appointments:
Interim Chief of Cardiology, University of Minnesota 2014 - 2017 Executive Medical Director, Cardiovascular Service Line, MHealth 2014 - 2017 Associate Director, Lillehei Clinical Research Unit – University of Minnesota 2009 - 2014 Interim Head, Heart Failure and Heart Transplantation – University of Minnesota 2009 - 2014 Head, Clinical Cardiology Section, Cleveland Clinic Foundation 2004 - 2008 Ad Hoc Committee Membership on Tenure and Promotion - Harvard Medical 2016- School
Clinical/Hospital Appointments:
Chairman, Management Committee and Executive Medical Director of the 2014-2018 Cardiovascular Service Line for University of Minnesota Hospital and Fairview affiliated hospitals Associate Director – General Clinical Research Center (NIH) Cleveland Clinic 2003 - 2004 Foundation (co-PI of Grant) Director, Coronary Intensive Care Unit, Cleveland Clinic Foundation 1997 - 2004 Director, Acute Cardiac Care, University of Minnesota Hospitals and Clinics 1990 - 1997 Research Director, Rasmussen Heart Failure Treatment Center, University of 1994 - 1997 Minnesota Director of Cardiovascular Research, VA Medical Center, Minneapolis, MN 1979 - 1989 Director, George Fahr Coronary Care Unit, HCMC, Minneapolis, MN 1977 - 1979 Director, CCU and Branch Head of Critical Care; Naval Regional Medical Center, 1976-1977 San Diego
Consulting Positions: 2
Gary S. Francis, M.D. Curriculum Vitae
Member, Lillehei Heart Institute 2009- Steering Committee, Lillehei Heart Institute 2009 - 2016
Current Membership and Offices in Professional Organizations:
American Heart Association - Fellow 1977- American College of Cardiology - Fellow 1977- Heart Failure Society of America – President 2004-2006 Editor-in-Chief, Journal of Cardiac Failure 2010-2014 American College of Physicians - Fellow 1977- Heart Failure Society of America, Founding Member, Fellow 1996
Certification, Licenses:
National Board of Medical Examiners 1970-present American Board of Internal Medicine #37025 1972-present American Board of Internal Medicine, Subspecialty - Cardiovascular Disease #37025 1975-present Minnesota License Number #23871 2008-present American Board of Internal Medicine - Advanced Heart Failure /Heart Transplant #37025 2010-present
Endowed Lectureships (18)
Experimental left ventricular remodeling: molecular and physiological considerations. Survival trials in congestive heart failure. University of Toronto Center for Cardiovascular Research Distinguished Speaker Series. Toronto, Ontario, Canada. May 3, 1994.
25th Annual Richter Lecture: “Looking back 20 years and forward 20 years at heart failure.” University of Indiana. December 8th, 2000. Indianapolis, IN
Vincent Runco Visiting Professor Lecture. “History of Heart Failure Research: Have we reached certain limits?” April 16 –19th, 2002. Creighton University
The Dr. Salomon Jorge Lecture- Lessons from Heart Failure Mega Trials. XIX Congress of Dominican Republic Cardiology. Santo Domingo, Dominican Republic. August 21, 2003
Presidential Address- Heart Failure Society of America-Annual Meeting “Creativity and Science”; Seattle, Washington, Sept 11, 2006
Distinguished Lecture Series – University of British Columbia, Vancouver, Canada. Nov. 3, 2006
William Gaasch, M.D. Lecture – University of Massachusetts; Worcester, Massachusetts, October 12, 2006
Annual AHA Laennec Lecturer – The Treatment of Acute Decompensated Heart Failure in 2006; AHA Meeting, Nov. 2006; Chicago, IL
Ehlers Visiting Cardiovascular Research Professor – Mayo Clinic, Nov 28-29th, 2007 (John Burnett's laboratory)
Ehlers Visiting Professor – How the heart and the kidney communicate. Mayo Clinic; Rochester, MN. Nov 28-29, 2007. 3
Gary S. Francis, M.D. Curriculum Vitae
James F. Sullivan Visiting Professorship and Lecture: The Cardiorenal Syndrome. – March 4, 5, 2008. Creighton University.
Annual Paul Wood Speaker – Imperial College, London, U.K. October 3, 2008. (invited by Prof. Philip Poole-Wilson)
Annual Jay N. Cohn Lecture – The Cardiorenal Syndrome. April 30th, 2009. University of Minnesota.
Earl Bakken Lecture, Bakken Heart-Brain Institute, Cleveland Clinic; Neurohormonal Control of Cardiac Function; March 26, 2010.
Earl Bakken Lecture – Neurohumoral Control of Cardiac Function; Cleveland Clinic, Cleveland, OH. March 26, 2010.
Annual Champion Lecture Series – Harvard University Massachusetts General Hospital – May 26, 2010 - Cardiorenal Syndrome Brigham and Women’s Hospital – May 27, 2010 - How the Heart and the Kidneys Communicate
James K. Alexander Annual Visiting Professorship and Lecture. Baylor University Medical School. April 22-23, 2012. Houston, Texas
Gottlieb Lecture, Heart Failure with Preserved Ejection Fraction, Mid-America Heart Institute, Kansas City, MO. October 29, 2015
Visiting Professorships and Invited Grand Rounds (University and Major Teaching Hospitals only): 108 (First 19 not recorded)
20. Problems in Measuring Efficacy of Therapy in CHF. University of Miami, Jackson Memorial Hospital, Miami, FL. August 1987.
21. Neurohumoral Mechanisms in Congestive Heart Failure. Albert Einstein College of Medicine, Bronx, NY. March 1988.
22. Congestive Heart Failure: From Bench to Bedside. Mayo Clinic, Rochester, MN. April 1989.
23. The Sympathetic Nervous System in Congestive Heart Failure. Brigham and Womens’ Hospital. Harvard Medical School, Boston, MA. September 1989.
24. Neurohumoral Abnormalities in Congestive Heart Failure. University of Missouri, Columbia, OH. September 1989.
25. Molecular Biology of Neurohormone Induced Remodeling. University of Alberta, Edmonton, Canada, February 2, 1990.
26. Pathophysiology of Congestive Heart Failure. Hahnamann University Medical Center, Philadelphia, PA. April 8, 1990.
27. Basic Mechanisms of Left Ventricular Remodeling, University of Virginia, Charlottesville, VA. March 13, 1990.
28. Neuroendocrine Influences on Left Ventricular Remodeling, University of Arizona, Tucson, AZ. July 12, 1990.
29. Neuroendocrine Mechanisms in Congestive Heart Failure, Yale University, New Haven, CT. November 1, 1990.
4
Gary S. Francis, M.D. Curriculum Vitae
30. Neuroendocrine Mechanisms of Left Ventricular Remodeling, University of California, San Francisco, CA. April 20, 1991.
31. Left Ventricular Remodeling and Hypertrophy in Response to Myocardial Injury. University of Kentucky, Lexington, KY. May 7, 1991.
32. Basic Mechanisms of Left Ventricular Remodeling. Tokyo University, Tokyo, Japan, June 27, 1991.
33. A Review of Clinical Trials in Heart Failure - SOLVD and V-HeFT. University of Iowa, Iowa City, IA. August 15, 1991.
34. Left Ventricular Remodeling: Mechanisms of Hypertrophy and Dilatation. University of Wisconsin, Madison, WI. August 23, 1991.
35. Clinical Trials in Heart Failure - SOLVD and V-HeFT. Massachusetts General Hospital, Harvard University, Boston, MA. September 25, 1991.
36. Left Ventricular Remodeling: Cellular and Molecular Considerations. Cardiovascular Science Research Center. Manitoba University, Winnipeg, Canada. November 5, 1991.
37. Neuroendocrine Abnormalities in Congestive Heart Failure. McMaster University, Hamilton, Ontario, Canada. November 6, 1991.
38. Cellular and Molecular Mechanisms of Left Ventricular Remodeling. University of Toronto (Sunnybrook), Toronto, Ontario, Canada. December 3, 1991.
39. Treatment of Congestive Heart Failure. All Union Cardiology Research Center, USSR Academy of Medical Sciences, Moscow, Russia, January 28, 1992.
40. Survival Trials in Congestive Heart Failure. University of Vermont, Burlington, VT. February 7, 1992.
41. Left Ventricular Remodeling. Cedars-Sinai/UCLA Medical Center, Los Angeles, CA. February 18, 1992.
42. Left Ventricular Remodeling: Cellular and Molecular Considerations. Dalhousie University, Halifax, Nova Scotia, Canada, May 11, 1992.
43. Left ventricular remodeling: cellular and therapeutic implications. University of Minnesota, Minneapolis, MN, June 4, 1992.
44. Heart Failure and Remodeling. Cleveland Clinic, Cleveland, OH. September 18, 1992.
45. Clinical trials in CHF. University of Texas. San Antonio, TX. February 10, 1993.
46. Experimental Remodeling: cellular and molecular considerations. Baylor University, Houston, TX. February 11, 1993.
47. Left ventricular hypertrophy in response to injury. University of Texas, Houston, TX. February 11, 1993.
48. Response to myocardial injury: cellular, molecular and therapeutic implications. Women’s Medical College - International Heart Institute. Tokyo, Japan. October 16, 1993.
5
Gary S. Francis, M.D. Curriculum Vitae
49. Lessons from recent survival trials in CHF: reduction of ischemic events. Tokyo University, Tokyo, Japan. October 18, 1993.
50. Left ventricular remodeling: molecular, cellular and therapeutic implications. Keio University, Tokyo, Japan. October 19, 1993.
51. Response to myocardial injury: cellular, molecular and therapeutic implications. Kyoto University, Kyoto, Japan. October 20, 1993.
52. Experimental left ventricular remodeling: molecular and physiological considerations. Survival trials in congestive heart failure. University of Toronto Center for Cardiovascular Research Distinguished Speaker Series. Toronto, Ontario, Canada. May 3, 1994.
53. Structural basis of congestive heart failure: mechanical, neuroendocrine and molecular considerations. University of Ottawa Heart Institute. Ottawa, Ontario, Canada. May 4, 1994.
54. Lessons from recent clinical trials. University Gent, Brussels, Belgium. May 24, 1994.
55. Structural basis of heart failure - molecular and pharmacologic considerations. University Leuven, Brussels, Belgium. May 25, 1994.
56. How do ACE inhibitors reduce myocardial events? Academic Hospital, Nijmegen, Netherlands. May 26, 1994.
57. How do ACE inhibitors reduce myocardial events? Academic Hospital - Amsterdam, Netherlands. May 27, 1994.
58. Neurohumoral mechanisms in CHF. Academic Hospital - Groningen, Netherlands. May 27, 1994.
59. Arrhythmias in congestive heart failure. Siriraj University Hospital: Bangkok, Thailand. August 15, 1994.
60. Treatment of congestive heart failure. Chiang Mai University Hospital; Chiang Mai, Thailand. August 15, 1994.
61. Heart Failure 1994 - Clinical Trials. Chulalongkorn University Hospital, Bangkok, Thailand. August 17, 1994.
62. ACE Inhibitors and Ischemic Events: University of Zurich, Switzerland; September 7, 1994. University of Lausanne, Switzerland; September 8, 1994. University of Basal, Switzerland; September 8, 1994.
63. Left ventricular remodeling: molecular, physiologic and pharmacologic considerations. Emory University Hospital, Atlanta, GA. December 8, 1994.
64. Experimental left ventricular remodeling: physiologic and therapeutic considerations. Harvard University: Brigham and Women’s Hospital, Boston, MA. December 15, 1994.
65. Left ventricular remodeling: experimental and clinical considerations. Tufts University - New England Medical Center, Boston, MA. December 16, 1994.
66. Visiting Professor - Montreal Heart Institute (Montreal University), Montreal, Quebec, Canada. May 17-19, 1995.
67. Left-ventricular remodeling: molecular, physiologic and therapeutic considerations. University of Chicago, Chicago, IL. July 25, 1995.
6
Gary S. Francis, M.D. Curriculum Vitae
68. Morphometric considerations in left ventricular remodeling. University of Alberta, Edmonton; Alberta, Canada. May 8, 1996.
69. Left ventricular remodeling: molecular, physiologic and pharmacologic consideration. University of British Columbia. Vancouver, B.C., Canada. June 20, 1996.
70. Neuroendocrine and morphometric abnormalities in heart failure. Hong Kong University, Hong Kong, China. July 27, 1996.
71. ß-blockers and congestive heart failure. University of Minnesota, Minneapolis, MN. August 29, 1996.
72. 20 year perspective on the treatment of heart failure. Mayo Clinic, Rochester, MN, February 14, 1997.
73. ß-adrenergic blockers in the treatment of heart failure. Indiana University Medical Center, Indianapolis, IN. May 21, 1997.
74. Left ventricular remodeling: morphometric and pharmacologic implications, and the potential role of β-adrenergic blockers in reverse remodeling. Cleveland Clinic Foundation, Cleveland, OH. October 17, 1997.
75. β-adrenergic blockers and heart failure. Michael Reese Hospital. Chicago, IL. March 5, 1998.
76. Left ventricular remodeling: morphometric and pharmacologic implications. University of Alabama. Birmingham, AL. August 26, 1998.
77. Troponin T : Implications for clinical practice. Cleveland Clinic Grand Rounds with Eric Topol. Cleveland, OH. August 11, 1999.
78. Revascularization in a patient with severe left ventricular dysfunction. Italian Hosp. - Univ. Of Buenos Aires; Buenos Aires, Argentina. August 20, 1999.
79. Lessons learned from recent clinical trials – the emerging role of B-blockers in heart failure. Medical Grand Rounds. University of Pittsburgh, Pittsburgh, PA. June 30, 2000.
80. Current therapy of heart failure. University of Minnesota. Department of Medicine Grand Rounds. Minneapolis, MN. January 4, 2001.
81. Heart Failure Management over the coming decade(s): Where are we heading? Davis Heart and Lung Research Institute. Ohio State University. Columbus, OH. Feb. 10, 2001. 82. Future directions in the treatment of heart failure. University of Cincinnati Medical Center. Cincinnati, OH. February 20, 2001.
83. Twenty years of research in heart failure – looking back and looking forward. Case Western Reserve University. Cleveland, OH. April 5, 2001.
84. Scientific basis for the management of heart failure in 2001. University of Arizona, Tucson, AZ. June 1, 2001.
85. Heart Failure – a modern historical perspective. Columbia University, New York, NY. December 18, 2001.
86. Does B-Type Natriuretic Peptide Change My Practice in 2003? Yale University, New Haven, CT. Sept. 19, 2003.
87. Futuristic Management of CHF – University of California, San Diego, CA. March 2, 2005.
7
Gary S. Francis, M.D. Curriculum Vitae
88. The Cardiorenal Syndrome. Beth Israel Hospital – Albert Einstein College of Medicine, New York, NY. April 17, 2006.
89. The Cardiorenal Syndrome. (3rd Annual Wm. Gaasch Lecture).University of Massachusetts. Burlington, MA. Oct 12, 2006.
90. The Cardiorenal Syndrome. Georgetown University, Washington, DC. Dec 15, 2006.
91. The Cardiorenal Syndrome. Massachusetts General Hospital-Harvard Medical School. Boston, MA. Jan 5, 2007.
92. Ehlers Visiting Professor – How the heart and the kidney communicate. Mayo Clinic; Rochester, MN. Nov 28-29, 2007.
93. Jame S. Sullivan Visiting Professorship -The Cardio-Renal Syndrome. Creighton University, Omaha, NE. March 4-5, 2008.
94. Visiting AOA Professorship. Creighton University, Omaha, NE. March 6, 2008.
95. Cardio-Renal Syndrome. University of Chicago, Chicago, IL. Feb. 6, 2009.
96. Cardio Renal Syndrome. University of California-San Francisco. San Francisco, CA. April 15, 2009.
97. Cardio-Renal Syndrome. Jay N. Cohn Lecture. University of Minnesota, Minneapolis, MN. April 30, 2009.
98. Cardio-Renal Syndrome. Johns Hopkins Hospital, Baltimore, MD. January 6, 2010.
99. Earl Bakken Lecture – Neurohumoral Control of Cardiac Function; Cleveland Clinic, Cleveland, OH. March 26, 2010.
100. Annual Champion Lecture. Cardio-Renal Syndrome. Massachusetts General Hospital, Boston, MA. May 26, 2010.
101. Annual Champion Lecture. Cardio-Renal Syndrome. Brigham and Women’s Hospital, Boston, MA. May 27, 2010.
102. Albert Einstein University. Cardio-Renal Syndrome. New York, NY. November 23, 2010.
103. James Alexander Visiting Professor, Baylor University. Lecture: The Heart and the Kidney. Houston, TX. April 21- 23, 2012.
104. The Neurohumoral Axis in Heart Failure: Is there anything left to block? University of Minnesota. Cardiology Grand Rounds. September 18, 2013.
105. HFpEF. What is it? How do you manage it? University of Minnesota. Department of Medicine Grand Rounds. Minneapolis, MN. September 19, 2013.
106. HFpEF. University of Iowa. Grand Rounds. Iowa City, IA. October 16, 2013.
107. Heart Failure with Preserved Ejection Fraction. Mid-America Heart Institute-St. Lakes;Annual Gottlieb Lecture, Kansas City, MO; October 29, 2015.
108. HFpEF, Minneapolis VA Medical Center Grand Rounds, Minneapolis, MN, November 20, 2015.
8
Gary S. Francis, M.D. Curriculum Vitae
Military Service
Commander USNR, Naval Regional Medical Center (1,500 Bed Teaching Hospital) San Diego CA. Branch Head – Critical Care 1974-1977. (Dr. Francis promoted to Commander at age 33, one of the youngest to achieve this rank in the Navy).
National and International Leadership Roles in Design and Performance of Randomized Clinical Trials (14):
Associate Chairman and Executive Committee - V.A. Co-operative study (#19) on Vasodilator Therapy of Acute Myocardial Infarction, 1979-1982. (P.I. Univ. MN)
Planning Committee and Executive Committee - V.A. Co-operative Study on Vasodilators in Heart Failure (V-HeFT I), 1979-1985 (P.I. Univ. MN) Planning Committee and Executive Committee- V.A. Co-operative Study on Vasodilators in Heart Failure (V-HeFT II), 1985-1991 (P.I. Univ. MN)
Planning Committee and Steering Committee - Studies of Left Ventricular Function (SOLVD) - NIH 1984-1991 (Co-P.I. Univ. MN)
Planning Committee - V.A. Co-operative Study on Anti-arrhythmic Therapy in Congestive Heart Failure (CHF-STAT), 1987
Planning Committee, Steering Committee, Executive Committee - Digitalis Investigators Group (D.I.G.), N.H.L.B.I. 1988-2000 (U.S. PI)
Steering Committee; Chairman, Mortality Committee; Milrinone Survival Study (PROMISE). 1988-1991
Steering Committee - RESOLVE (oral levosimendan) 1997-1998
Planning Committee, Steering Committee - V.A. Co-operative Study on the Effects of Treatment on Central Sleep Apnea - Hypopnea on Survival in Patients with Heart Failure. 1997-2000
National Co-Chairman (with Douglas Weaver, M.D.) of VALIANT (valsartan in acute myocardial infarction). 1997 – 2003
Planning Committee - V.A. Co-operative Survival Trial in Diastolic Heart Failure – 1999 (I-PRESERVE)
Steering Committee - Erythropoetin – α Treatment in Heart Failure Patients with Anemia; (EPOCH) Ortho Biotech – Johnson and Johnson 2001 – 2003
Co-Chairman-Publications Committee-NHLBI ESCAPE Trial 2004-2009
Protocol Committee – GUIDE-IT (NIH sponsored trial – natriuretic peptide as a guide to therapy in heart failure)
Member of Data and Safety Monitoring Boards for Major Clinical Trials: 41
MTT (Myocarditis Treatment Trial, Chairman - NHLBI) 1985-1991 PRAISE I (amlodipine in heart failure) 1990-1995 PRAISE II (amlodipine in dilated cardiomyopathy) 1995-2001 RADIANCE (digitalis in heart failure) 1990-1992 BEST (ß -blockers in heart failure - N.H.L.B.I.) 1994-1999 MOXCOM (moxonidine in heart failure) 1998-1999 9
Gary S. Francis, M.D. Curriculum Vitae
RENAISSANCE/RECOVER (TNF- blocker in heart failure) 1998-2001 ENABLE I and II (bosentan in heart failure) 1999-2002 MIRACLE (Multicenter InSync Randomized Clinical Evaluation – Chairman) 1999-2001 WATCH (anti-coagulation in heart failure) 1999-2003 OPERA (omapatrilat in hypertension) 1999-2001 Use of CDC – 501 (thalidomide analog) for treatment of heart failure (Celgene) 2001-2003 AQUVIT – CIB – SR 121463B for treatment of heart failure (Sanofi) 2001-2003 HEAAL – Different doses of losartan and morbidity and mortality in heart failure 2002-2008 ACORN device to reduce LV remodeling - Chairman 2001-2004 SHOCK II – L-MMNA in Cardiogenic Shock 2003-2006 VERITAS – Tezosentan in Acute Heart Failure 2002-2004 FUSION II – Follow-up Serial Infusions of Natricor 2004-2007 TACTICS – Tezosentan in Cardiac Surgery 2006-2008 Pre-RELAX-AHF/AHF-relaxin in patients with acute heart failure 2007-2008 RELAX-AHF 2009-2012 GUIDE-IT – NIH Clinical Trial, Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (NHLBI) 2014-2016 APOLLO – Aliskerin Prevention of Later Life Outcomes Trial – Peter Sleight, MD; Chairman. 2010 – 2012 ANTHEM – HF (Vagal stimulation in HF – Inder Anand, P.I.) – 2012-2014 AQCLAIM –A Qsymia Cardiovascular Morbidity and Mortality Study in Subjects with Documented Cardiovascular Disease (Michael Lincoff – PI) 2013-on hold LCZ 696 Program 2009-ongoing (multiple trials) – PARADIGM, PARAGON, PARALLEL, PARALLAX, PARADISE, PERSPECTIVE, PIONEER HF, etc. PARADIGM HF Study: Evaluated the superiority of ENTRESTO vs enalapril on HF hospitalization and mortality reduction in patients with chronic HF with reduced ejection fraction (HFrEF). Provided evidence to support the replacement of ACE inhibitors or ARBs with ENTRESTO in the management of chronic HFrEF. (Stopped early- paper published in NEJM 2015) PARAGON Study: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to Valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. PARALLEL Study: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in Japanese patients with chronic heart failure and reduced ejection fraction. PARALLAX Study: NT-pro-BNP, exercise, safety in HFpEF (Germany) PARADISE MI Study: A randomized, double-blind, active controlled trial comparing LCZ696 to ramipril in high risk post-AMI patients. PERSPECTIVE Study: Prospective Evaluation of cognitive function in heart failure: A Randomized double-blind Study in Patients with Preserved Ejection fraction Cardiac failure Treated with Valsartan or LCZ696. PIONEER HF Study: Comparison Of Sacubitril/valsartan versus Enalapril on Effect on NT-pro-BNP in patients stabilized from an acute heart failure episode. (Eight-week study surrogate only [nt-proBNP]-E. Braunwald-PI.) VICTORIA Study: VerICiguaT GlObal study in patients with heart failure and Reduced ejection fraction. (Soluble guanylate cyclase modulator [vericiguat] in patients with HF and reduced EF-Merck-McMurray-Chair of DSMB, Paul Armstrong-P.I. of study.) 2SCORED and SOLOIST - Sotagliflozin program (SGLT-2i trial in patients with cardiovascular risk and chronic renal insufficiency and in patients with heart failure). (Deepak Bhatt, P.I.) PARAGLIDE Study: sacubrutil/valsartan vs. valsartan in patients with HFpEF admitted to hospital with acute, decompensated heart failure. (Rob Mintz, P.I.) VALOR-HMC: Mavacampen in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. (Steve Nissen, P.I.)
National and International Leadership Roles: 10
Gary S. Francis, M.D. Curriculum Vitae
Intensive Care Committee - American Heart Association 1988-1990 Heart Failure Committee - American Heart Association 2005- 2011 (Co-Chairman 2007-2010) American College of Cardiology Ad Hoc Committee to study V.A. Funding for Research 1988 1996 International Advisory Board - Advanced Drug Research in Heart and Vascular Disease 1990-1994 Educational Committee- the Inter-American Society of Hypertension 1991-1993 Scientific Advisory Board-International Society of Heart Failure 1991 American College of Cardiology - Ad Hoc Task Force Committee on Clinical Research 1991- 1992 Principal Author - ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology: Clinical Competence for Performing Temporary Pacing 1991 Program Committee - 5th International Symposium on Cardiovascular Pharmacotherapy, Mpls, MN. Aug .16-20, 1993 AMA Consultant - Drug Evaluation 1992-1993 Consultant - V.A. Co-operative Studies Program 1990- Scientific Advisory Board - European Task Force on Heart Failure 1995-1997 Founding Member - Heart Failure Society of America 1995 Board of Directors (Corporate) Criterion Health Care Network, 1995-1996 Chairman - 1st Annual Meeting of the Heart Failure Society of America. Baltimore, MD. Sept. 21-24, 1997 Chairman - 2nd Annual Meeting of the Heart Failure Society of America. Boca Raton, FL. Sept. 13-16, 1998 Executive Council - Heart Failure Society of America 1998-2010; ex-officio 2010-2015 Secretary-Heart Failure Society of America, 2001-2002 Vice President-Heart Failure Society of America, 2002-2004 President-Heart Failure Society of America 2004-2006 Life-Time-Achievement Award Committee-Heart Failure Society of America 2005-2012 Nominating Committee-Heart Failure Society of America, Chairman 2007-2008 American College of Cardiology Major Committees: 1. Editorial Board – JACC 2001 - 2005 2. Emergency Cardiac Care Committee 1998 - 2004 3. Writing Committee – ACC/AHA Guidelines on the Evaluation and Management of Heart Failure; writing committee; published 2005 JACC/Circulation 4. ACC/AHA Writing Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure 2000 - 2002; 2003 - 2004; 2008 - 2009 Focused Update 5. Annual Scientific Program Committee 2000 - 2002, 2007 6. Councilor – ACC Chapter, Minnesota 2009 - 2011 Study Sections (Primary Reviewer) Program Projects (NIH) NIDA (NIH) Special Consultant – PPG’s (NHLBI) CLRT Review Board – R34 Program (NHLBI) CRC (Clinical Research Program) - NIH MRC - Canada, New Zealand Merit Review Program - V.A., V.A. Co-operative Program American College of Cardiology/AHA - Expert Writing Committee on Heart Failure Guidelines 1995, 2005, 2009 ACC/AHA Update - Expert Writing Committee on Heart Failure Guidelines 1999-2000; 2003- 2005, 2009 American College of Cardiology - Committee on Emergency Cardiac Care 1998-2003 International Advisory Committee - XVII Meeting of the International Society for Heart Research; Winnipeg, Canada. July 6-11, 2001 Program Committee - 3rd Annual Meeting Heart Failure Society of America. San Francisco, CA. Sept. 22-24, 1999 Program Committee - 4th Annual Meeting Heart Failure Society of America. Boca Raton, FL. Sept. 11-13, 2000 Program Committee-Annual Meeting, American College of Cardiology 2000-2001 Chairman-Spotlight Committee-Clinical Cardiology, ACC Annual Meeting, New Orleans, LA. March 2007 Co-Chairman with Joshua Hare, MD – American Heart Association, Heart Failure and Transplant Committee; 2007 – 2010 Representative (AHA/ACC Joint Committee) 11
Gary S. Francis, M.D. Curriculum Vitae
Chairman – AHA Committee on Heart Failure and Heart Transplantation, 2009 -2011 Member – AHA Leadership Committee, 2009 – 2011 Chairman-ACCF/AHA/ACP Clinical Competence Statement on Management of Patients with Advanced Heart Failure 2007-2010 ACC/AHA Expert Writing Committee on Heart Failure Guidelines – Update 2007 - 2009 American Board of Internal Medicine (ABIM) Member-Specialty Board-Heart Failure and Heart Transplantation; 2008- 2012 Principal Author – ACCF/AHA/HFSA/ISHLT/ACP 2010 Clinical Competence Statement on Management of Patients with Advanced Heart Failure and Cardiac Transplantation; 2010 Member of Heart Group – Editors-and-Chiefs of leading Cardiac journals who meet regularly at AHA, ACC and ESC; 2009 –2014 NHLBI Workshop Participant. August 5th, 6th 2010. Bethesda, Md. Cardiac Transplant Research in the Next Decade: A Goal to Evidence Based Outcomes (by invitation). Program Committee – AHA Annual Meeting 2011-2012 NHLBI Protocol Writing Committee (Chair) for GUIDE-IT protocol 2012
Local Committees:
Research Committee - American Heart Association, Minnesota Chapter, 1983-85, 1989, 1990 Executive Committee of the Cardiology Division - University of Minnesota, 1979-90 Human Studies Subcommittee (IRB) - Minneapolis VA Medical Center, 1984-89 Board of Directors - American Heart Association, Minnesota Affiliate, 1984-86, 1989-90 Faculty House Staff Representative, 1989; University of Minnesota Chairman - Research Committee; AHA, MN Chapter, 1989-90 Co-Chairman - Critical Care Task Force; University Hospital Strategic Planning Committee, 1992 All University Senate 1994-95; University of Minnesota Chairman - Department of Medicine Search Committee for Head, Division of Health Outcomes Research - 1996; University of Minnesota Director - Student Clerkships in Cardiology; University of Minnesota Hospital, 1993-96 Hospital Ethics Committee, 1996-1997; University of Minnesota Search Committee for Head of Cardiovascular Division, 1996-1997; University of Minnesota Clinical Policies: Standards of Care and Practice Committee, 1997; University of Minnesota Patient Satisfaction Committee - The Cleveland Clinic, 1997 Chairman-Research Day at the Cleveland Clinic-- October 1, 1998 Abst. Reviewer – Research Day at Cleveland Clinic - October 2003 Search Committee – Chairman, Dept. of Medicine, Cleveland Clinic Foundation – 2003 Search Committee – Chairman, Dept. of Cell Biology, Lerner Institute, Cleveland Clinic 2002-2003 Search Committee – Director, Bakken Heart & Brain Institute – 2005 Cleveland Clinic Search Committee – Cardiology Division Chief, University Hospital, CWRU – 2005 Executive Committee – General Clinical Research Center 2001-2007, Cleveland Clinic Member, Cardiovascular Research Council 2005-Cleveland Clinic Member, Steering Committee for Cardiovascular Genetics 2006-Cleveland Clinic Search Committee – Chairman, Clinical Pathology 2007-2008- Cleveland Clinic Research Committee – Heart and Vascular Institute; 2007-2008- Cleveland Clinic Advisory Board – Fuad Jubran, MD Center for Mideast Education 2007-2008- Cleveland Clinic Promotions and Tenure Committee –Academic Health Center 2009 – 2010, University of Minnesota Promotion and Tenure Committee, University of Minnesota Academic Health Center, 2011-2012 Leadership Committee-Department of Medicine 2014- 2017, University of Minnesota Mentoring Committee, Department of Medicine, 2016-, University of Minnesota Promotion and Tenure Committee, Department of Medicine 2017- Search Committee - Engdahl Chair in Heart Failure, 2017-2018, University of Minnesota Search Committee-Chairman, Physical and Rehabilitative Medicine, University of Minnesota, 2018 12
Gary S. Francis, M.D. Curriculum Vitae
Editorial Board Member:
Circulation, 1990-93 Journal of the American College of Cardiology, 1987-91, 1993-97, 2001 – 2005 (Elite Reviewer 2005-2010) American Journal of Cardiology, 1990-current American Heart Journal, 1991-current Journal of Cardiovascular Pharmacology, 1984-1996 Cardiology, 1990-(Section Head: Coronary Care) Index and Reviews in Congestive Heart Failure, 1988-1995 Practical Cardiology, 1990-91 Advances in Therapy, 1991-current International Journal of Cardiology, 1992-2016 Journal of Cardiac Failure (Executive Editorial Board), 1993-2001; reappointed 2002; Editor-in-Chief 2010-2014 Journal of Cardiovascular Pharmacology and Therapeutics, 1994- Congestive Heart Failure, 1994-2012 Heart Failure Reviews, 1995-current Heart Failure, 1996-2013 Translational Research. Formerly The Journal of Laboratory and Clinical Medicine, 1998 -2008 Heart Failure Society News – 1999-2006 Cleveland Clinic Journal of Medicine -1999-current Mayo Clinic Proceedings – 1999-2011 Cardiovascular Drugs and Therapy – 1999 – 2001 The American Heart Hospital Journal – 2002 -2006 ACC – Cardiosource (website) – clinical trials-2004 Current Heart Failure Reports-2004 Current Problems in Cardiology-2014
Editorships:
Editor-in-Chief, Journal of Cardiac Failure 2010 – 2014 (5 years) Editor-in-Chief – Heart Advisor, Cleveland Clinic 1999-2008 (9 years) Special Section Editor: AHA News, November 1996 Editor-In-Chief: Current Treatment Options in Cardiovascular Medicine – 1998-2001 (3 years) Guest Editor: Treatment of Heart Failure: Current Insights and New Treatment J Cardiovasc Pharmacol Suppl 32; 1:S16- 21, 1998. Executive Editor: Journal of Cardiac Failure; 1993-2005 Guest Editor: Acute Coronary Syndromes Series: Clev Clinic J Med 1999-2000 Guest Editor: Can We Prevent Heart Failure? Clinical Cardiology 23 (Suppl IV) IV4-IV15, 2000 Editor – Heart Failure Society of America Newsletter 2004 - 2006 Guest Editor: The Cardiology Report. 3:1-48, 2006. Guest Editor: Unresolved Problems in Heart Failure: Edema, Hyponatremia, and Renal Insufficiency. Cleveland Clinic J Med 2006 (Suppl 2), Vol 73, S1-S33.
Editorial Consultant (reviewer):
Circulation Circulation Research Journal of Clinical Investigation New England Journal of Medicine American Journal of Cardiology Annals of Internal Medicine 13
Gary S. Francis, M.D. Curriculum Vitae
Hypertension Journal of Cardiovascular Pharmacology Journal of Medicinal Chemistry American Heart Journal NY State Medical Journal Chest Journal of the American College of Cardiology Journal of the American Medical Association (JAMA) Life Sciences Journal of Pharmacology and Experimental Therapeutics Journal of Heart and Lung Transplantation Diabetes Cardiac Catheterization and Diagnosis Journal of Critical Illness Cardiovascular Drugs and Therapy American Journal of Medicine Journal of Cellular and Molecular Cardiology American Journal of Physiology International Journal of Cardiology European Heart Journal Proceedings of the Society for Experimental Biology and Medicine The Canadian Journal of Cardiology Journal of Myocardial Ischemia Medical Principles and Practice American Journal of Hypertension The American Journal of Geriatric Cardiology Journal of Cardiac Failure Evidence Based Cardiovascular Medicine Nature Medicine Annals of Clinical Biochemistry
Hospital Consultant Appointments
Mt. Sinai Hospital, Minneapolis, MN, 1977-79 Hennepin County Medical Center, Minneapolis, MN; 1977-1979 Veterans Affairs Medical Center, Minneapolis, MN; 1990-1997 University of Minnesota Hospitals, Minneapolis, MN; 1990-1997 Cleveland Clinic Foundation; Cleveland, Ohio; 1997-2008 University of Minnesota-Fairview Hospitals, Minneapolis, MN; 2008-current
Honors and Awards for Research Work, Teaching, Public Engagement, and Service
Undergraduate Honors Program – University of Minnesota 1964-1965 Medical School – Shrameck Scholarship Member, AOA Honorary Medical Society Mentor Award - Class of 1989, University of Minnesota Medical School Mentor Award - Class of 1991, University of Minnesota Medical School Listed in “Best Doctors in America”, 2nd Edition, Woodward/White, 1994-1995 Listed in “International Leaders in Achievement”, 3rd Edition, International Biographical Center, Cambridge, England, 1995, 2011 Listed in “Best Doctors in America”, 4th Edition, Woodward/White, 1998-2010 Listed in “Best Doctors in America”, 2001 – 2015 14
Gary S. Francis, M.D. Curriculum Vitae
Listed in “Best Doctors in Cleveland” - Cleveland Magazine – 1998, 2002, 2003, 2004, 2005, 2006, 2007, 2008 Listed in Top Doctors in Minneapolis/St. Paul Magazine – 2012, 2013, 2014, 2015 Named to Good Housekeeping “Best Heart Doctors in America”, March 1996 Listed in “Best Doctors in Minneapolis and St. Paul” – 2011, 2012, 2013, 2014, 2015 “Master Teacher” Award, University of Miami, May 26, 1996 (National Award) Distinguished Teacher Award- Cleveland Clinic Foundation, 2000 “Master Teacher” Award; University of Miami; May 25, 2002 (National Award) AHA Annual Laennec Clinician/Educator Lecture Award, November, 2006. AOA Honorary Medical Society Visiting Professor and Annual Lecture: Heart Failure: Creativity, Paradigm Shifts, Recent Successes and Unresolved Problems. March 6, 2008; Creighton University. Member-ABIM Specialty – Heart Failure/Heart Transplant; Writing Committee 2008-2012 Simon Dack Award – For outstanding scholarship and reviewing – Journal of the American College of Cardiology – ACC Meeting, March 14, 2010. Most Popular Professors Award – University of Minnesota Medical Student Association- 2010 President, Heart Failure Society of America 2004-2006 Heart and Stroke Hero Award, Physician Researcher Category, American Heart Association/American Stroke Association- Honored at Gala Dinner on October 16, 2010 2014 Distinguished Teacher Award – American College of Cardiology – Annual Meeting, Washington, DC; March 21, 2014 2014 Life-Time Achievement Award; Heart Failure Society of America – Annual Meeting, Las Vegas,Nevada; September 15, 2014 2015 University of Minnesota Medical School’s Wall of Scholarship Commemorative Award, Dean’s Distinguished Research Lectureship, Minneaplis, MN; October 14, 2015 Award-Publication (1st author) of paper cited > 1,000 times (Francis, GS, et.al. Circulation 1990:82;1724). (Dr. Francis has 4 manuscripts on the "Wall of Scholarship"). 2019 – Named among the top 1% of scientists worldwide according to SCOPUS citation data – honored at the HFSA annual meeting, plenary session, Philadelphia, PA, September 14, 2019.
Research and Scholarship
Principal Investigator (Minneapolis) VA Cooperative Study on Vasodilator Therapy in Congestive Heart Failure (V-HeFT II) - University of Minnesota 1985-1989
Professional Societies
President, Heart Failure Society of America, 2004-2006; founding member, 1995 Fellow, American College of Physicians, 1976- Fellow, American Heart Association, 1977- Council Representative (Term 1982-85), (1991-94) Fellow, Council on Clinical Cardiology, American Heart Association, 1984- Fellow, Council on Pulmonary, Peri-operative and Critical Care, American Heart Association, 1992-93 Fellow, American College of Cardiology, 1976- Fellow, American Physiological Society, 1994-1995 Member, American Heart Association, 1972- Member, American Society of Echocardiography, 1976-1979 Member, American Federation for Clinical Research, 1976- Member, American Association for the Advancement of Science, 1982- Member, Central Society for Clinical Research, 1985- Member, International Society for Heart and Lung Transplantation, 1996- Fellow, Council on Geriatric Cardiology, 1997- Member – International Society of Heart Research; 1995 – Fellow, International Academy of Cardiovascular Sciences (selected 2004) 15
Gary S. Francis, M.D. Curriculum Vitae
Fellow, American Heart Association 2001 – Board of Governors – ACC Minnesota Chapter 2008 – 2009; re-elected 2010 – 2011 Fellow, Heart Failure Society of America, 2015
Principal Investigator (Extramural Grant Support)
V.A. Cooperative Study - Nitroprusside in Acute Myocardial Infarction, 1979-82 V.A. Merit Review - Neurohumoral Mechanisms in CHF, 1983-86 V.A. Merit Review - Sodium Retention Mechanisms in CHF, 1986-89 V.A. Cooperative Study - Vasodilator Therapy in Heart Failure (V-HeFT I), 1980-86 V.A. Cooperative Study - Vasodilator Therapy in Heart Failure (V-HeFT II), 1986-90 (Co-PI) Studies of Left Ventricular Dysfunction (SOLVD) - NIH, 1986-91 VA/NHLBI Collaborative Study on the Effect of Digitalis on Mortality in CHF, 1989-1996 RPC 6760 “Functional Analysis of Gene Expression Changes in Human Dilated Cardiomyopathy” with Meredith Bond, Ph.D. 2002
Co-Investigator
NIH - ROI HL22977, Neurohumoral mechanisms in clinical heart failure (Jay N. Cohn - P.I.) NIH - POI HL32427, Program project grant in congestive heart failure (Jay N. Cohn - P.I.) NIH - T32 HL07184, Training Grant (Jay N. Cohn - P.I.) NIH - I - MOI - RR018390 - 01, General Clinical Research Center (Ass. Medical Director) NIH - SCCOR 1 - P50 - HL077107-01 Molecular Determinants of Coronary Artery Disease (Edward Plow, PI) - Core Lab Director NIH - SCCOR 1 - P50 - HL081011-01 Genetic & Cellular Determinants of Arterial Thrombosis (Roy Silverstein, PI) - Core Lab Director
Mentored Research Fellows
Steven Goldsmith, MD – Professor of Medicine, University Minnesota Kenneth McDonald, MD – Professor of Medicine, University College, Dublin, Ireland W.H. Wilson Tang, MD – Professor of Medicine, Lerner College of Medicine, Cleveland Clinic of Case Western Reserve University Anne Kanderian, MD – Private Practice, Fairfax, Virginia Hani Jneid, M.D. – Research Fellow, Harvard University, Mass. General Hospital; Associate Professor, Baylor University
Presentations at National and International Scientific Meetings: 335 (34 countries)
1. The accuracy of continuous echocardiographic recording method for assessing aortic root size. American College of Cardiology. New York, NY. February 1974.
2. Echocardiographic criteria of normal left atrial size in adults. American Heart Association. Dallas, TX. November 1974.
3. Echocardiography-fundamentals and new developments in cardiac ultrasound. American College of Cardiology, faculty member. San Diego, CA. June 1975.
4. An echocardiographic study of interventricular septal motion in the Wolf-Parkinson-White syndrome. American Heart Association. Anaheim, CA. November 1975.
5. Echocardiography-fundamentals and new developments. American College of Cardiology, faculty member. San Diego, CA. June 1976. 16
Gary S. Francis, M.D. Curriculum Vitae
6. Echocardiography-fundamentals and new developments. American College of Cardiology, faculty member. San Diego, CA. June 1977.
7. Nitroglycerin ointment - a review. American College of Angiology, faculty member. Newport Beach, CA. February 1977.
8. Comparison of dobutamine and dopamine in acute low-output cardiac failure. American Heart Association Scientific Sessions. Anaheim, CA. November 1979.
9. Coronary artery bypass surgery in end-stage renal failure, renal dialysis, and transplant patients. American Heart Association Scientific Sessions. Anaheim, CA. November 1979.
10. Symposium on congestive heart failure. Three talks. Manila, Philippines, January 1981.
11. The sympathetic response to exercise in patients with congestive heart failure. American College of Cardiology. San Francisco, CA. March 1981.
12. Strategies in the management of severe heart failure. American College of Physicians Annual Meeting, co-chairman and faculty member. Kansas City, MO. April 1981.
13. Drugs for cardiovascular diseases: New agents and new uses. Dopamine vs. Dobutamine for pump failure. University of Minnesota Medical School, Minneapolis, MN. October 1981.
14. The acute effects of nitroprusside on plasma norepinephrine, renin activity and arginine vasopressin in patients with congestive heart failure. American College of Cardiology. Atlanta, GA. April 1982.
15. Vasodilators in acute myocardial infarction. International Congress of Chest Physicians. Toronto, Ontario, Canada. October 1982.
16. General concepts of afterload reduction - the neurohumoral axis in congestive heart failure. International Workshop on Heart Failure. Heidelberg, Germany. February 1983.
17. Treatment of acute myocardial infarction. CONSENSUS Conference. Stockholm, Sweden. June 1983.
18. Heart failure - drugs. American Heart Association 56th Annual Scientific Sessions, co-chairman. Anaheim, CA. November 1983.
19. Heart rate, blood pressure and plasma norepinephrine as a function of oxygen use during exercise in congestive heart failure. American Heart Association 56th Annual Scientific Sessions. Anaheim, CA. November 1983. 20. The role of vasodilator agents for afterload and preload reduction in patients with heart failure and cardiogenic shock. Emergency Cardiac Care Meeting. Chicago, IL. November 1983.
21. Mechanisms and management of hypertensive crises. Emergency Cardiac Care Meeting. Chicago, IL. November 1983.
22. The neurohumoral axis in congestive heart failure. Satellite Conference. American College of Cardiology (based in Washington, DC). March 1984.
23. Strategies in the management of severe heart failure. 65th Annual Session, American College of Physicians, workshop co-director. Atlanta, GA. April 1984.
17
Gary S. Francis, M.D. Curriculum Vitae
24. Management of cardiovascular crisis: New Concepts in the Management of Pulmonary Edema Pharmacologic Support for Cardiogenic Shock: Dobutamine, Dopamine and Nitroprusside, Current Status of New Inotropic Agents Vasodilator Therapy for Chronic Congestive Heart Failure: Emphasis on Converting Enzyme Inhibitors, The Modern Management of Hypertensive Crises. Heart House, American College of Cardiology. Bethesda, MD. June 1984.
25. The acute vasoconstrictor response to intravenous furosemide in patients with congestive heart failure. American Heart Association Scientific Sessions. Miami, FL. November 1984.
26. Heart failure - drugs. American Heart Association 57th Annual Scientific Sessions, co-chairman. Miami, FL. November 1984.
27. Management of arrhythmias in patients with congestive heart failure. International Congress of Cardiology - Satellite Conference - The development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. Vancouver, British Columbia. June 1984.
28. Advances in the treatment of congestive heart failure. Fifth Scientific Sessions of the International Society for Heart Transplantation. Anaheim, CA. March 1985.
29. Management of cardiovascular crisis - 1985. Management of shock, new oral inotropic agents, new approaches to pulmonary edema and malignant hypertension. Heart House, American College of Cardiology. Bethesda, MD. June 1985.
30. Vasodilator therapy in left ventricular dysfunction. American College of Chest Physicians, 51st Annual Scientific Assembly, Chairman, luncheon panel. New Orleans, LA. October 1985.
31. Hemodynamic and neurohumoral response to exercise. Symposium on metabolic exercise testing in heart disease. Satellite Conference, American College of Cardiology. Atlanta, GA. March 1986.
32. Management of arrhythmias in patients with congestive heart failure. American Heart Association, Satellite Conference. The development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. Washington, D.C. November 1985.
33. Strategies in the management of severe heart failure. Workshop for American College of Physicians. San Francisco, CA. April 1986.
34. Meet the experts - treatment of heart failure. American College of Cardiology Annual Scientific Sessions. Atlanta, GA. March 1986.
35. Determinants of survival in patients with congestive heart failure: does treatment alter prognosis? Satellite Conference - American College of Cardiology. Atlanta, GA. March 1986.
36. Digitalis. International Symposium on Future Directions in Cardiology. Toulouse, France. April 1986.
37. Neurohumoral mechanisms in heart failure. American Heart Association 59th Scientific Sessions, Plenary Session. Dallas, TX. November 1986.
38. Clinical colloquium on therapeutic strategies in chronic left ventricular failure. Chairman. 52nd Annual Scientific Assembly of the American College of Chest Physicians. San Francisco, CA. September 1986.
39. How-to session - How to treat heart failure. American Heart Association 59th Scientific Sessions. Dallas, TX. November 1986.
18
Gary S. Francis, M.D. Curriculum Vitae
40. Meet the Professor. 52nd Annual Scientific Assembly of the American College of Chest Physicians. San Francisco, CA. September 1986.
41. The influence of neurohumoral factors on survival in patients with heart failure. Captopril Symposium. San Francisco, CA. September 1986.
42. Influence of vasodilator therapy on CHF arrhythmias. AHA Satellite symposium. Dallas, TX. November 1986.
43. Development of arrhythmias in patients with congestive heart failure: pathophysiology, prevalence and prognosis. 14th Annual ACC Program on New Clinical Applications. Park City, UT. February 1987.
44. Influence of vasodilator therapy on arrhythmias in congestive heart failure: neurohumoral mechanisms. 14th Annual ACC Program on New Clinical Applications. Park City, UT. February 1987.
45. Assessing prognosis and functional capacity in chronic heart failure. Meet the Experts. American College of Cardiology. New Orleans, LA. March 1987.
46. Treatment of arrhythmias in CHF: traditional and/or vasodilator therapy. Recent Advances in Cardiovascular Disease: A Speakers Bureau Update. San Francisco, CA. January 1987.
47. Pathophysiology aspects of heart failure with emphasis on neurohumoral and endocrine factors. Advances in Congestive Heart Failure, Norwegian Society of Cardiology. Oslo, Norway. March 1987.
48. Vasodilator drug therapy. State-of-the-Art Cardiology, sponsored by Pacific Presbyterian Medical Center. San Francisco, CA. April 1987.
49. Prognosticators of survival and implications for therapy. Evolving Concepts in Clinical Cardiology. Dr. Eugene Braunwald, Chairman. San Diego, CA. May 1987.
50. Extra-cardiac features of heart failure. International Symposium on Heart Failure. Dr. Lionel Opie, Chairman. Cannes, France. September 1987.
51. Problems in the intensive care unit - symposium, chairman. Annual Sessions, American College of Chest Physicians. Atlanta, GA. October 1987.
52. Treatment of heart failure - Meet the Professor. American College of Chest Physicians. Northbrook, IL. October 1987.
53. An interactive debate - moderator of debate between Drs. Kanu Chatterjee and Eric Prystowsky: Arrhythmias in CHF. Dr. Milton Packer, chairman; American Heart Association Satellite Symposium. Anaheim, CA. November 1987.
54. Ventricular arrhythmias in congestive heart failure. Norwegian Society of Cardiology; Dr. John Kjekshus, chairman. Oslo, Norway. December 1987.
55. Interaction of the sympathetic nervous system and electrolytes in heart failure. ACC Satellite Symposium; Dr. Milton Packer, chairman. March 1988.
56. Treatment of congestive heart failure - meet the experts; with Dr. Kanu Chatterjee. American College of Cardiology. Atlanta, GA. March 1988.
57 Neurohumoral mechanisms in heart failure, workshop co-chaired with Dr. John Bayliss. Robinson College, Cambridge, England. April 1988. 19
Gary S. Francis, M.D. Curriculum Vitae
58. Aggressive management of cardiovascular emergencies - 1988. American College of Cardiology, Heart House (Dr. Gordon Ewy, chairman). Optimal Therapy of Patients with Chronic Heart Failure; Management of Cardiogenic Shock, Bethesda, MD. June 1988.
59. Vasodilator and inotropic therapy for severe chronic heart failure - 1988. American College of Cardiology, Heart House (Dr. Milton Packer, chairman). Measurement of Neurohormones: Methodology and Clinical Significance, Dopaminergic Systems, Direct-Acting Vasodilators, Interventional Studies with Direct-Acting Vasodilators. Bethesda, MD. June 1988.
60. Treatment of congestive heart failure. Spanish Cardiology Society, Oviedo Medical School. Oviedo, Spain, June 1988.
61. The use of digitalis in the long-term treatment of cardiac insufficiency. XXI National Cardiology Congress. Bilbao, Spain. October 1988.
62. Circulatory control in heart failure. Cardiovascular conference, moderator. American Heart Association Scientific Sessions. Washington, D.C. November 1988.
63. Antiarrhythmic therapy in heart failure: update. American College of Cardiology, (based out of Washington, DC). March 1989.
64. New concepts in the pharmacologic management of CHF: role of beta blockers, Ca++ antagonists, ACE inhibitors. American College of Cardiology, (based out of Washington, DC). March 1989.
65. Pathophysiology of heart failure. Danish Society of Cardiology. Copenhagen, Denmark. May 1989.
66. Pathophysiology and treatment of heart failure. Workshop co-chairman. Montpellier Conference. Montpellier, France. July 1989.
67. Natural history of heart failure. XVI Argentine Congress of Cardiology. Buenos Aires, Argentina. October 1989.
68. Overview of Clinical Trials in Heart Failure. International Society and Federation of Cardiology. Rome, Italy. October 1989.
69. Sudden death in heart failure patients. Cardiovascular Conference. Annual Scientific Session AHA Meeting. New Orleans, LA. November 1989.
70. Selection of a first-line agent in congestive heart failure (chairman). Cardiovascular conference. Annual Scientific Session. AHA Meeting. New Orleans, LA. November 1989.
71. State of the Art: Treatment of Congestive Heart Failure. Norwegian Society of Cardiology. Bergen, Norway. December 8, 1989.
72. Preliminary Neurohumoral SOLVD Results. Reduction of Mortality in Heart Failure. Dr. Bertrum Pitt, Chairman. New Orleans, LA. ACC Satellite Symposium. March 23, 1990.
73. Signal processing and the molecular biology of hypertrophy. International Symposium on Cardiac Insufficiency. Bilbao, Spain. March 23, 1990.
74. Neurohormone mechanisms in heart failure. Workshop. Gothenberg, Sweden. June 15-17, 1990.
20
Gary S. Francis, M.D. Curriculum Vitae
75. Pitfalls and usefulness of measuring neurohormones in patients with heart failure. Cardiostim Meeting. Nice, France. June 21-23, 1990.
76. Neurohormone mechanisms in heart failure. Workshop. Montpellier, France. September 7-9, 1990.
77. Direct Acting Vasodilator. Plenary Session. 63rd Scientific Sessions, American Heart Association, Dallas, TX. November 12-15, 1990.
78. Treatment of CHF in Cardiomyopathy. Cardiovascular Conference, 63rd Scientific Sessions. American Heart Association. Dallas, TX. November 14, 1990.
79. State of the Art Lecture. Neurohormonal mechanisms in CHF. 63rd Scientific Sessions. American Heart Association. Dallas, TX. November 13, 1990.
80. Cellular remodeling in left ventricular hypertrophy. The Inter-American Society of Hypertension. Rio de Janeiro, Brazil. March 8, 1991.
81. Neurohumoral activation in pre-clinical heart failure: Remodeling and the potential for intervention. Development, Early Treatment, and Prevention of Heart Failure - European Society of Cardiology. Wurzburg, Germany. May 16- 18, 1991.
82. Results from V-HeFT II. XIII Scandinavia Congress of Cardiology. Oslo, Norway. July 5-7, 1991.
83. Neurohormones in CHF. V-HeFT II. Advanced concepts in the treatment of heart failure. Tokyo, Japan. June 28- 30, 1991.
84. Mechanisms of left ventricular hypertrophy. Neuroendocrine activation in left ventricular dysfunction and congestive heart failure. Eighth Santa Fe Colloquium on Cardiovascular Therapy: The contemporary treatment of left ventricular dysfunction and congestive heart failure. ACC Course - Jonathan Abrams, Santa Fe, NM. October 10-11, 1991.
85. Co-Chairman. Humoral regulation of cardiorenal homeostasis. 64th Scientific Sessions, American Heart Association. Anaheim, CA. November 11, 1991.
86. Measurement of Drug Efficacy. Vascular role of promising therapies in heart failure. American Heart Association Satellite Symposium. Anaheim, CA. November 9, 1991.
87. Measurement of Neurohormones in SOLVD. Recent Advances in the Management of Heart Failure. Cologne, Germany. November 23, 1991.
88. Early Left Ventricular Dysfunction: Mechanisms and Management. Vienna, Austria. January 25, 1992.
89. Aggressive Management of Cardiovascular Emergencies. Heart House - Bethesda, MD. (Dr. Gordon Ewy-Chairman) March 16-18, 1992. Treatment of Hypertensive Crisis. Vasopressors, Vasodilators and Inotropes in the Acutely Ill Patient. Optimal Therapy for Patients with Advanced Chronic Heart Failure. Management of the Patient with Acute Cardiovascular Collapse. Arrhythmias in the Patient with CHF.
90. SOLVD: Neurohormonal attenuation by enalapril. In: Prevention of ventricular enlargement and heart failure - a new medical imperative. European Society of Cardiology and the National Heart and Lung Institute, England - Prof. Phillip Poole-Wilson, Chairman. London, England. March 21, 1992. 21
Gary S. Francis, M.D. Curriculum Vitae
91. American College of Cardiology - Annual Session Mini-Course - Conceptual and Therapeutic Advances in Heart Failure. Milton Packer - Chairman. Dallas, TX. April 22, 1992.
92. Update in Cardiovascular Drug Therapy: How to select the optimal program for your patient with hypertension, congestive heart failure, hyperlipidemia, arrhythmia, angina and infarction. (Dr. Ron Vliestra-Chairman). The patient with heart failure I, II. Heart House, Bethesda, MA. May 4-6, 1992.
93. Prevention of left ventricular hypertrophy following myocardial damage. Session on Left Ventricular Mass and Function. American Society of Hypertension, New York, NY. May 7, 1992.
94. Paracrine and autocrine considerations in the RAAS; Clinical trials versus clinical practice. The McGill Conference. McGill University. Alan Sniderman, M.D. Chairman. Montreal, Canada. May 29-30, 1992.
95. Chairman, Neurohormones and congestive heart failure. Survival and ventricular enlargement (SAVE), Bologna, Italy. June 22-23, 1992.
96. Inhibition of neuroendocrine systems in heart failure: Clinical, prognostic and therapeutic implications. Robinson College, Cambridge University, Cambridge, U.K. July 17-19, 1992.
97. Visiting Professor, Cellular and molecular considerations in left ventricular remodeling. Cleveland Clinic, Cleveland, OH. September 17-18, 1992.
98. New inotropic agents: prevention of ischemic events with ACE inhibitors - SOLVD. XIX Argentine Congress of Cardiology, Buenos Aires, Argentina. September 24-26, 1992.
99. Co-Chairman, Advances in the management of heart failure. Plenary Session. American Heart Association 65th Scientific Sessions, New Orleans, LA. November 16-19, 1992.
100. How to diagnose diastolic heart failure with William H. Gaasch and Michael R. Zile. How-to session. American Heart Association 65th Scientific Sessions. New Orleans, LA. November 16-19, 1992.
101. Hormonal profile in early heart failure. Post-graduate evening seminar. Jay N. Cohn, Chairman. American Heart Association 65th Scientific Sessions. New Orleans, LA. November 16-19, 1992.
102. Left ventricular remodeling - pathophysiology and therapeutic implications; lessons from survival trials in congestive heart failure. Williamsburg Conference on Heart Disease. Dr. William Roberts, Chairman. Williamsburg, VA. December 7, 1992.
103. The renin-angiotensin system and hypertrophy: molecular and cellular consideration. International Symposium on Hypertensive Heart Disease. Bilbao, Spain, February 18-19, 1993.
104. American College of Cardiology 42nd Annual Scientific Session. Luncheon Panel on “Update on Recent Clinical Trials in Congestive Heart Failure.” Anaheim, CA. March 16, 1993.
105. American College of Cardiology 42nd Annual Scientific Session. Co-Chairman with Dr. William Parmley. Symposium: Plenary Session: Treatment Strategies in the Management of CHF, Anaheim, CA. March 16, 1993.
106. American College of Cardiology 42nd Annual Scientific Session. Co-Chairman of Original Contribution Session: controlled clinical trials in heart failure III: vasodilators and inotropic agents. Anaheim, CA. March 17, 1993.
22
Gary S. Francis, M.D. Curriculum Vitae
107. Treatment of Congestive Heart Failure - Vasodilators (with Drs. Michael Bristow and Arthur Feldman). 74th Annual Session - American College of Physicians. Washington, D.C. April 3, 1993.
108. VIII International Meeting on Clinical Cardiology - Hellenic Cardiological Society and the European Society of Cardiology. Left ventricular remodeling: molecular, cellular and therapeutic implications. Athens, Greece. April 22- 24, 1993.
109. Molecular and cellular considerations in left ventricular remodeling: possibilities of intervention. Biologia celular y molecular del sistema cardiovascular. Oviedo, Spain. May 7-8, 1993.
110. 2nd International symposium on Heart Failure - Mechanisms and Management. “Cellular and molecular consideration of left ventricular remodeling and potential for intervention.” “Potential mechanisms by which coronary ischemic events are reduced” (Session Chairman). “ACE inhibitors in CHF: New results” (Session Chairman). Geneva, Switzerland. May 16-20, 1993.
111. What have the recent trials taught us? Heart Failure Trials, Tribulations and Therapy. University of Calgary, Banff, Canada. June 29-30, 1993.
112. Treatment options for preventing cardiac remodeling. Symposium on “Cardiac Enlargement and Remodeling, a Harbinger of End-Stage Heart Disease - Detection and Prevention.” RAI Conference Center, Amsterdam, the Kingdom of the Netherlands. June 11, 1993.
113. Prevention of major coronary ischemic events in patients with left ventricular dysfunction: clinical evidence supporting the use of ACE inhibitors. Arrythmias in Heart Failure. Cambridge University (Robinson College), Cambridge, England. July 16-18, 1993.
114. Prognosis in heart failure. ACC Course on Critical Care Cardiology (Dr. Kanu Chatterjee). San Francisco, CA. August 7, 1993.
115. 5th International Symposium on Cardiovascular Pharmacology, Minneapolis, MN. August 16-20, 1993. a. Controversy: Heart Failure: “Maximal Exercise Testing is a Useful Guide to Drug Efficacy in Heart Failure.” Protagonist: Milton Packer, M.D. Antagonist: Gary S. Francis, M.D. b. Sympathetic Nervous System: “Receptor Systems Involved in Norepinephrine Release and Effect in Heart Failure.” c. Inhibition of the Renin-angiotensins System in the Treatment of Cardiovascular Disease: “Effects on Neurohormone Mechanisms.”
116. XV Congress of the European Society of Cardiology Symposium: Genetic variations in the renin-angiotensin- aldosterone system and cardiovascular risk: potential evidence and clinical evidence (Chairman). “Review of potential mechanisms by which ACE inhibitors reduce coronary ischemic events”. Nice, France. August 31, 1993. August 29 - September 2, 1993.
117. Cardiovascular Board Review (American College Cardiology). Pathophysiology and Therapy of Heart Failure. Indianapolis, IN. September 11, 1993.
118. Third Autumn Symposium on Coronary Artery Disease. “Lessons from Clinical Trials”, Lisbon, Portugal. October 9, 1993.
119. Japanese Society of Applied Physiology. “Lessons from SOLVD and other CHF Survival Trials.” Tokyo, Japan, October 15, 1993.
23
Gary S. Francis, M.D. Curriculum Vitae
120. 66th Scientific Sessions. American Heart Association. Chairman: CHF-Heart rate variability and neurohumoral mechanisms. Atlanta, GA. November 8, 1993.
121. Plenary Session: Neurohumoral Factors: Implications for treatment and survival. American Heart Association. 66th Scientific Session; Atlanta, GA, November 10, 1993.
122. International Meeting on Prostacyclin. “Pathophysiological aspects of end-stage heart failure.” Bologna, Italy. November 20, 1993.
123. American College of Cardiology Annual Meeting, Atlanta, Georgia, March 14-17, 1994. a. Luncheon Panel - “How should heart failure be treated in 1994?" b. Core Curriculum Chairman - “Mechanisms Contributing to the Development of Heart Failure.” c. Original Contributions Co-Chairman - “Cardiomyopathy, Prognosis, Diagnosis and Function.” d. Core Curriculum Speaker - “For the Patient with Chronic Heart Failure, should we be using a Vasodilator or a Converting Enzyme Inhibitor?”
124. Optimal Medical Therapy in Severe CHF Patients. ACC Course; Cardiology Fiesta in San Antonio; University of Texas at San Antonio, TX. April 23, 1994.
125. Pharmacological Interventions in Experimental Remodeling: ACE inhibitors and AT1 blockers. International Conference on Heart Failure, Winnipeg, Canada. May 23, 1994.
126. Aggressive Management of Cardiovascular Emergencies. Treatment of hypertensive crisis, vasopressors, vasodilators and inotropics in the acutely ill patient optimal therapy of patients with advanced chronic heart failure. Cardiogenic shock. Heart House - Bethesda, MD. (Dr. Gordon Ewy-Chairman). June 1-3, 1994.
127. XII World Congress of Cardiology - XVI Congress of the European Society of Cardiology - Beta-blockers and nitrates: their role in preventing ventricular remodeling and heart failure. Molecular cardiology: biological cascade at the origin of hypertrophy. Direct acting vasodilators - do they have anything to add? Drug therapy for heart failure - the gap between knowledge and application. Berlin, Germany. September 10-14, 1994.
128. The Eleventh Annual ACC Santa Fe Colloquium on Cardiovascular Therapy - Contemporary treatment of congestive heart failure and left ventricular dysfunction. Jonathan Abrams, M.D. - ACC Course Director. Neurohumoral Activation in Heart Failure. The Major Clinical Trials in CHF. Santa Fe, NM. October 6-8, 1994.
129. Is post-MI cardiac remodeling inhibited by bradykinin? Chairman: Role of bradykinin pathway in cardiac disease. AHA. Dallas, TX. November 12, 1994.
130. Inotropic support for the failing heart. AHA Council. Congestive Heart Failure in the 90's. AHA Annual Meeting, Dallas, TX. November 13, 1994.
131. Task Force on Heart Failure - European Society of Cardiology; molecular biology of cardiac failure - an integrated view for the clinician. Amsterdam, Netherlands. April 2-5, 1995.
132. European Society of Hypertension - Satellite Symposium Co-Chaired by Bertram Pitt, M.D. and Thomas Lüscher, M.D. Role of bradykinin in inhibiting the cardiac remodeling process. Milan, Italy. June 8, 1995.
133. Congestive Heart Failure: From Molecular Biology to the Clinic. XV World Congress of the International Society of Heart Research. Conventional Treatment of Cardiac Failure with ACE-inhibitors and Vasodilators. Venice, Italy. June 30, 1995.
24
Gary S. Francis, M.D. Curriculum Vitae
134. The 43rd Annual Scientific Meeting - The Cardiac Society of Australia and New Zealand; ACE inhibitors in the Prevention of Ischemic Events. Canberra, Australia. August 6, 1995.
135. Cardiovascular Board Review (American College of Cardiology): Pathophysiology and Therapy of Heart Failure. Indianapolis, IN. September 9, 1995.
136. Neurohumoral Factors in Congestive Heart Failure. XXXI Spanish Congress of Cardiology; La Coruna, Spain. October 19, 1995.
137. Vasodilators in Heart Failure. Annual Canadian Cardiovascular Society. Toronto, Canada. October 24, 1995.
138. How and Why the Heart Remodels after Myocardial Infarction. IV Inter-American Congress of Cardiology. XXXII Chilean Congress of Cardiology. Santiago, Chile. December 7, 1995.
139. Left Ventricular Dysfunction: Diagnostic Aspects and Prognostic Implications. 56th National Congress of the Italian Society of Cardiology. Rome, Italy. December 12, 1995.
140. Neurohormonal Response to Exercise. Scientific conference on exercise testing and training in patients with left ventricular dysfunction and after cardiac transplantation. American Heart Association. Clearwater, FL. February 16, 1996
141. Master Lecture: Congestive Heart Failure - Pathophysiology and Treatment in 1996. University of Miami 24th Annual Conference. Orlando, FL. May 26, 1996.
142. Left Ventricular Remodeling: Cellular and Morphometric Considerations. International Society for Heart Research. Chicago, IL. June 13, 1996.
143. What the V-HeFT trials have taught us. Cardiomyopathy and Heart Failure Summit. University of Toronto; Toronto, Ontario, Canada. June 15, 1996.
145. Novel Approaches to Neurohormonal Modulation. MRC - Canada; HOPE Investigators Meeting. Ottawa, Canada. October 5, 1996.
146. Symposium on Acute Coronary Syndromes (Chairman): Pathogenesis of Myocardial Infarction. Barcelona University, Barcelona, Spain. October 25, 1996.
147. ACE Inhibitors/Vasodilators. AHA Evening Conference. AHA Annual Scientific Sessions. New Orleans, LA. November 10, 1996.
148. The ventricular remodeling era in heart failure. AHA Satellite Symposium: A new era in heart failure: transforming mechanism into management. New Orleans, LA. November 9, 1996.
149. Isolated myocytes and ventricular remodeling. Working Group of Transplant Cardiologists. New Orleans, LA. November 9, 1996.
150. XXXIII Annual Meeting - Chilean Society of Cardiology and Cardiovascular Surgery. Beta-blockers in Heart Failure - Where are we in 1996? Neuroendocrine Inhibitors as Therapy for Heart Failure. New Directions. Management of Heart Failure 1996 (Plenary Session). Valdivia, Chili. December 5-7, 1996.
151. 3rd International Symposium: Progress in Hypertensive Heart Disease. Pathways for the development of myocyte hypertrophy. Bilbao, Spain. February 20, 1997.
25
Gary S. Francis, M.D. Curriculum Vitae
152. American College of Cardiology Annual Meeting, Anaheim, CA. March 16-19, 1997. a. Chairman - Plenary Session - Late Breaking Clinical Trials. b. Luncheon Panel - How should heart failure be treated?
153. How to prevent heart failure. Heart Failure ‘97. Second International Meeting - European Working Group on Heart Failure. Cologne, Germany. May 25, 1997.
154. Neurohumoral activation and progression of heart failure. Treatment of Heart Failure: current insights and new treatment options. Amsterdam, Holland. May 31, 1997.
155. Approach to Advanced Heart Failure. Jack G. Copeland III, Maria Rosa Costanzo, Lynne Warner Stevenson - Directors. Less or more? Beta-blockers and oral inotropes. Controversies in managing advanced heart failure. Newer agents under development. Components of a heart failure program. Heart House - Bethesda, MD. June 9-11, 1997.
156. Morphological and functional alterations in the myocyte in heart failure. Cardiomyopathy and Heart Failure Summit: From Pathophysiology to Clinical Practice. University of Toronto, Toronto, Canada. June 12-14, 1997.
157. Emerging data from heart failure trials: clinical application. Vascular Biology Working Group. C. Pepine, G. Mancini, Directors. Whistler, British Columbia, Canada. August 15, 1997.
158. The evolution of medical therapies for heart failure. Heart Failure Summit III. Cleveland Clinic. Cleveland, OH. September 4, 1997.
159. Neurohormones in the progression of heart failure. Satellite Symposium. Heart Failure Society of America 1st Annual Meeting. Baltimore, MD. September 3, 1997.
160. Advanced heart failure: current status and new frontiers. Plenary Session, Co-Chairman. 70th Annual AHA scientific sessions. Orlando, FL. November 10, 1997.
161. Lessons from clinical trials. Plenary Session. 70th Annual AHA Scientific Sessions. Orlando, FL. November 11, 1997.
162. Comparison of ACE inhibitors and Ang II blockers. (Paul M. Vanhoutte, M.D. – Chairman Capetown & Johannesburg, South Africa). March 14, 1998. (Lionel Opie, M.D. - Chairman).Swakopmund, Namibia - March 21, 1998.
163. American College of Cardiology Annual Meeting, Atlanta, GA. March 29-31, 1998. a. Mini-Course: Progression of heart failure and clinical implications. b. Luncheon Panel: Drug therapy for heart failure.
164. Sixth Antwerp-La Jolla-Kyoto Research Conf. Horizons in Heart Failure: Genes, hormones and cytokines. Neurohumoral effects and their inhibition at the cellular level; Special Lecture: current and future directions in clinical trials; Chairman - Roundtable discussion on clinical trials. Dr. John Ross, Jr - Director. La Jolla, CA. April 26-27, 1998.
165. Neurohumoral interaction in heart and kidney failure. In Symposium “Cardiorenal interaction in chronic heart failure and kidney failure.” Groningen University, Groningen, Netherlands. June 5, 1998.
166. Cardiac remodeling: from myocyte to man. In “Cardiomyopathy and Heart Failure Summit: from pathophysiology to clinical practice”. ACC extramural course. Toronto, Ontario, Canada. June 11-13, 1998.
26
Gary S. Francis, M.D. Curriculum Vitae
167. Left ventricular remodeling: morphometric and pharmacologic implications. University North Carolina Heart Failure Program. Heart Failure Management 1998: Established Therapy and New Frontiers. Amelia Island, FL. July 18, 1998.
168. Therapeutic management of the patient with CHF in the ER. Heart Failure Society of America. Bethesda, MD. September 13, 1998.
169. Improving quality of life in patients with heart failure. Heart Failure Society of America. Boca Raton, FL. September 15, 1998.
170. Role of cardiac troponins. Annual International Preceptorship in Interventional Cardiology. Eric Topol - Chairman. Cleveland Clinic. Cleveland, OH. September 25, 1998.
171. A new model of heart failure. 2nd Annual Japanese Heart Failure Society. Sapporo, Japan. October 16, 1998.
172. Neurohormones in congestive heart failure: implications for new therapy. Plenary Session. 2nd Annual Japanese Heart Failure Society. Sapporo, Japan October 17, 1998.
173. Molecular/cellular events in myocardial remodeling and therapeutic implications for heart failure. AHA Satellite Symposium on Biotechnology in Cardiovascular Innovations. R. Califf and D. Weaver - Chairmen. Dallas, TX. November 7, 1998.
174. Anticoagulation: when it is indicated? Cardiovascular Seminar. American Heart Association. 71st Scientific Sessions. Dallas, TX. November 9, 1998.
175. Mechanism of agents interfering with the renin-angiotensin system (Chairman). American College of Cardiology - 48th Annual Scientific Session. New Orleans, LA. March 10, 1999.
176. Angiotensin Receptor Antagonists vs. ACE Inhibitors-a debate with Arthur Feldman, MD, PhD. ACC Satellite Symposium. New Orleans, LA. Thomas Giles-Chairman. March 6, 1999.
177. Remodeling in the Progression and Regression of Heart Failure: From Myocyte to Man. The Second Toronto International Heart Failure Summit- From Pathophysiology to Clinical Practice at the Turn of the Millennium. Toronto, Canada. ACC Course. June 10, 1999.
178. The neurohormonal hypothesis- Proof of principle. Diagnostic myocardial biopsy in idiopathic dilated cardiomyopathy. Is it necessary? Endothelial dysfunction in heart failure. Newer pharmacological approaches and gene therapy. Rocky Mountain Heart Failure Symposium- Carlos Duran, M.D., Chairman Missoula, MT. July 10, 11; 1999.
179. Heart Failure - from molecular mechanisms to clinical trials - a look back at 20 years. Heart Failure Management 1999: Established Therapy and New Frontiers. University of North Carolina. Amelia Island, FL. July 24, 1999.
180. Argentine-InterAmerican Congress of Cardiology XXVI, Buenos Aires, Argentina. August 21-23, 1999. - Treatment of Ambulatory Heart Failure. - Treatment of Acute Heart Failure. - Organization of a Heart Failure Clinic. - Plenary Session: Treatment of AMI and Heart Failure. - Closing Lecture: Treatment of Heart Failure Current and Future.
181. Heart Failure Society of America 4th Annual meeting. San Francisco, CA. September 22-25, 1999. - Chairman, How to Manage Acute Heart Failure in the CCU/ICU 27
Gary S. Francis, M.D. Curriculum Vitae
- Chairman, Can We Prevent Heart Failure?
182. Cardiology Board Review Course. Heart Failure I and II. Louisiana State University Medical Center; New Orleans, LA. Oct. 25, 1999.
183. Clinical Advances Conference - Reversal of Heart Failure, Hypertension, and Renal Failure - Featured Speaker, MCP Hahnemann University School of Medicine. Philadelphia, PA. Dec. 7 - 8, 1999. - Role of angiotensin in heart failure: from systemic compensatory responses to local myocardial injury. - Clinical trials in heart failure: towards total suppression of the renin-angiotensin-aldosterone axis. - Medical management of “incipient” and mild heart failure.
184. Heart Failure 2000. University of Southern California; Uri Elkayam, Chairman. New Targets for the Treatment of Heart Failure - BNP, Cytokines, TNF- alpha inhibitors. Action Heart Failure: New Guidelines for the Treatment of Heart Failure. Los Angeles, CA. Jan. 29, 2000.
185. ACC Course - 5th Annual Cardiology at Cancun Mayo Clinic Course. Left Ventricular Remodeling: from Molecules to Clinical Trials. Medical Management of Heart Failure in 2000 and Beyond. Cancun, Mexico. Feb. 28, 2000.
186. ACC 2000 - Annual Meeting; Core Curriculum-Diabetes and the Heart. Plenary Session - Angiotensin Converting Enzyme Inhibitors. Anaheim, CA. March 12-15, 2000.
187. Review of Recent Clinical Trials: Is Heart Failure Reversible? Annual AHA Congestive Heart Failure Conference, Douglas Mann-Chairman. Houston, TX. April 1, 2000.
188. CHF: Matching Therapy to Pathophysiology. XXXV Middle East Medical Assembly. Beirut, Lebanon. May 6, 2000.
189. Heart Failure: from molecular mechanisms to clinical trials – a look back at 20 years. Univ. North Carolina-Heart Failure Management 2000. Amelia Island, FL. July 22, 2000.
190. Unloading the heart in acute, decompensated heart failure. European Society of Cardiology. Amsterdam, Netherlands. Aug. 29, 2000.
191. Clinical Markers for Heart Failure: Insight in Treatment Strategies. Heart Failure Society of America 4th Annual Scientific Meeting. Boca Raton, FL. Sept. 10, 2000.
192. Debate: The time has come for long-term LVAD treatment of heart failure (beyond bridge to transplant) (CON) vs. Leslie Miller, MD. Heart Failure Society of America 4th Annual Scientific Meeting. Boca Raton. FL. Sept. 11, 2000.
193. Cleveland Clinic Board Review Course. Cleveland, OH. Sept. 26, 2000. - Heart Failure: Scope of the problem and pathophysiology. - Congestive Heart Failure; Review of Clinical Trials – What trials have changed the way we practice? 194. Cardiology 2000 – Annual Teaching Day for Physicians (AHA). New Pharmacologic Approaches to Heart Failure. Syracuse, NY. October 5, 2000.
195. Angiotensin II in Cardiac Remodeling. 2000 American Society of Nephrology Meeting. Toronto, Canada. October 15, 2000.
196. ACE Inhibition in cardiac Disease (HOPE); Long-Term Risk Factors for Solid Organ Transplant Recipients. Sponsored by University of Minnesota. Phoenix, AZ. November 2, 2000.
28
Gary S. Francis, M.D. Curriculum Vitae
197. Maximal Suppression of the Renin Angiotensin System in Heart Failure. In: Angiotensin II: Road Map to Vascular Injury. AHA Meeting. Victor Dzau, Chairman. November 11, 2000. New Orleans, LA.
198. A Master Clinician’s Approach to High-Risk Hypertension: Integrating the Science of Medicine and the Art of Practice. AHA Meeting. Victor Dzau, Chairman. New Orleans, LA. November 11, 2000.
199. Co-Chairman with Dr. Douglas Mann. Bench to Bedside: Myocardial Remodeling in CHF as a Therapeutic Target. AHA Meeting – Sunday Morning Programs. New Orleans, LA. November 12, 2000.
200. Current/Future Medical and Surgical Methods Which Alter Growth Regulation. Cardiovascular Seminar. AHA Meeting. New Orleans, LA. November 13, 2000.
201. 25th Annual Richter Lecture; Indiana Heart Institute. Heart Failure: A look back at 20 years and what the future might bring over the next 20 years. Indianapolis, IN. December 8, 2000.
202. Pathophysiology of CHF. Society of Cardiovascular Anesthesiologists. San Diego, CA. February 16, 2001.
203. American College of Cardiology. 50th Annual Scientific Session. Orlando, FL. March 20-23, 2001. Chairman - What are the options for patients with end-stage heart failure? Luncheon. March 19, 2001. Co-chair - Cardiac transplantation, rejection and graft vasculopathy. March 19, 2001. Co-chair - Symposium. Impact and limitations of heart failure clinical trials. Speaker - Evening Session. Cardiac Pathology. Left ventricular remodeling in congestive heart failure.
204. ACE inhibition and endothelial dysfunction. Preventing Heart Disease. Update 2000 Cleveland Clinic Foundation. Cleveland, OH. March 23, 2001.
205. Mechanisms of congestive heart failure. Society of Cardiac Anesthesiologists. Vancouver, B.C., Canada. May 8, 2001.
206. ACC 4th Annual Toronto International Heart Failure Summit. Toronto, Canada. July 4- 6, 2001. - Heart Failure and Outcomes in America. - The Renin-Angiotensin System and Left Ventricular Remodeling. - Managing End-Stage Heart Failure Patients.
207. Expansion of the neuroendocrine hypothesis. Jay N. Cohn Symposium. XVII World Congress of the International Society for Heart Research. (Symposium organizer and chairman). Winnipeg, Canada. July 7, 2001.
208. Cellular and sub-cellular basis of remodeling. Chairman. Post-conference Satellite Meeting of the XVII World Congress of ISHR. Minneapolis, MN. July 14, 2001.
209. Pathophysiology of Heart Failure. Evaluation and Management of Heart Failure. 18th Congress-Society of Cardiology Annual Meeting. Santa Domingo, Dominican Republic. August 3, 2001.
210. New Options in the Management of Patients with Decompensated Heart Failure. Heart Failure Society of America. Chairman and Presenter. Washington, DC. Sept. 9, 2001.
211. Case Histories in Heart Failure. HFSA. Washington, DC. September 11, 2001.
212. Work Shop: Managing Acute Heart Failure. HFSA. Washington, DC. Sept 11, 2001.
213. ACC Board Review Course. Treatment of Heart Failure. Chicago, IL. Sept 10, 2001.
29
Gary S. Francis, M.D. Curriculum Vitae
214. Cleveland Clinic Heart Failure Summit VI. Cleveland, OH. October 5, 2001.The Vasodilator Hypothesis is Dead. Long-live the neurohormonal hypothesis.
215. Cleveland Clinic Board Review Course: An Intensive Review of Cardiology. Cleveland, OH. October 9, 2001. - Plenary Lecture: The Failing Heart - What we really know and where we are going. - Trials of the Failing Heart - - A practical guide to the clinical trials in heart failure.
216. Neurohormonal Factors in the diagnosis and treatment of syncope. October 20, 2001. Cleveland Clinic – Syncope: Recent Advances in Diagnosis & Management.
217. Reverse Remodeling: Definitions and demonstrations in heart failure. American Heart Association Scientific Session. Anaheim, California. Nov. 22, 2001.
218. Pathophysiological Basis of Heart Failure 2001. 34th Annual New York Cardiovascular Symposium – ACC. New York, New York. December 15, 2001.
219. The neurohormonal hypothesis: Have we reached the limits? What does the Future hold? In Genomics, Proteomics and Mechanisms of Heart Failure 2002. Ochsner Clinic Foundation. February 16, 2002.
220. Distinguished Visitors Seminar Series. University of Ottawa Heart Institute. “Pathophysiology of Heart Failure.” Ottawa University. Ottawa, Canada. May 6, 2002.
221. Management of Patients with Chronic Heart Failure. University of Miami Master Teacher Award. Miami, Florida. May 25, 2002.
222. Annual Symposium on Biomedical Engineering – Support for the Failing Heart: From Device to Molecules. University of Minnesota. May 22, 2002. - Myocardial recovery with mechanical support.
223. The Fifth Annual Toronto International Heart Failure Summit – From Pathophysiology to Clinical Practice. June 13 – 15, 2002. Toronto, Canada. - Reverse remodeling with ß-blockers. - How do we treat diastolic heart failure today? - Debate with Prof. Michael White – ARBs vs. ACE inhibitors.
224. Cardiostim 2002; June 19-22, 2002; Nice, France. - Neurohormones. - Does drug treatment prevent remodeling?
225. Heart Failure Management 2002 – Established Therapy and New Frontiers; Univ. of North Carolina, July 19-21, 2002; Amelia Island, Florida. - Heart failure: from molecular mechanisms to clinical trials – a look back at 20 years.
226. Heart Failure and Circulatory Support Summit – Cleveland Clinic Foundation; August 22, 2002. Cleveland, Ohio. - An overview of the most recent understanding of the pathophysiology of heart failure.
227. Cleveland Clinic Board Review Course: An Intensive Review of Cardiology: Fundamentals of Heart Failure. Clinical Trials in Heart Failure, Sept 26, 2002; Cleveland, Ohio.
228. American Heart Association 2002; Nov. 17-20, 2002. Chicago, IL. Plenary Session: Heart Failure. Pharmacologic Therapy. State-of-the-Art 2002.
30
Gary S. Francis, M.D. Curriculum Vitae
229. Chairman – Diagnostic and Prognostic Utility of NT-proBNP in Patients with Congestive Heart Failure and Acute Coronary Syndromes. - The Emergence of B-type natriuretic peptide measurements in the management of patients with heart failure. AHA Chicago, IL – Nov. 16, 2002.
230. Chairman – European Consensus Conference on B-Type Natriuretic Peptide. December 14, 2002; Versailles, France.
231. Heart Failure Society of America 2003: - How and When to Block the Sympathetic Nervous System. - Beyond Neurohormone Blockade; Novel Targets for Treating Heart Failure. Feb 1, 2003; New Orleans, LA.
232. 41st Annual Symposium on Critical Care, Trauma and Emergency Medicine; Feb 27-28, 2003; Las Vegas, Nevada. - Biomarkers in acute cardiac events. - Acute coronary syndromes. - Management of critical aortic stenosis with nitroprusside. - The role of intravenous BNP. - Hypertensive crisis.
233. American College of Cardiology, March 28 - April 2, 2003, Chicago Ill. - Does B-type Natriuretic Peptide Change My Practice in 2003?
234. Acute Coronary Syndromes. Washington Hospital Center, 1st Annual Symposium on Coronary Care Units. May 2, 2003. Washington, DC.
235. 2003 Forum on Heart Failure. Henry Ford Hospital, Neurohoromonal activation in heart failure. June 6, 2003.
236. European Heart Failure Working Group of ESC Annual Meeting. Current Role of BNP in the Diagnosis and Management of Heart Failure, The American Perspective. June 22, 2003, Strausbourg, France.
237. The Dr. Salomon Jorge Lecture. Congestive Heart Failure – Lessons from Mega Trials. XIX Congress of Dominican Cardiology. Santo Domingo, Dominican Republic. August 21, 2003.
238. Evaluation of Transplant Candidates: New Devices for Advanced Heart Failure. XIX Congress of Dominican Cardiology. Santo Domingo. August 22, 2003.
239. Post-MI patients with heart failure: a look forward to VALIANT. Heart Failure Society of America. Satellite Symp. 7th Annual Meeting. Sept. 21, 2003. Las Vegas, Nevada.
240. Devices in heart failure: modulating symptoms or modifying disease. HFSA/ESC Joint Session. 7th Annual Meeting. Sept. 23, 2003. Las Vegas, Nevada.
241. Fundamentals of heart failure. Fourth Annual Intensive Review of Cardiology Board Review Course at Cleveland Clinic Foundation. Sept. 25, 2003. Cleveland, Ohio.
242. The progression of heart failure: why are we in so much trouble? Heart Failure Summit VIII. October 10, 2003. Cleveland, Ohio.
243. Inhibition of the RAS in Cardiovascular Disease – The expanding role of ARBs B-Type BNP – how do I use it in practice in 2004? 5th Panhellenic Congress on Heart Failure. Athens, Greece; Feb 6-8, 2004.
244. American College of Cardiology, March 7, 2004; New Orleans, LA. - Guidelines and Management of Heart Failure: Stage D: Late Stage Therapeutic Options. 31
Gary S. Francis, M.D. Curriculum Vitae
245. Atrial Fibrillation in CHF. Update in Atrial Fibrillation Symposium. March 26, 2004. Coburg, Germany.
246. Assessing Heart Failure: The Role of Biochemical Markers. 26th Arnold O. Beckman Conf. Cardiac Markers: Guidelines and Improving Results. May 22, 2004. Massachusetts Institute of Technology, Cambridge, MA. M.I.T.
247. Neurohormonal Systems in Remodeling. Forges-Les-Eaux, France. May 28, 2004. Prof. Komadja, Chairman.
248. Recent and Futuristic Developments in the Treatment of Heart Failure. University of North Carolina Annual Course. Amelia Island, July 15, 2004.
249. Annual Congress of Cardiology of Puerto Rico. San Juan, Puerto Rico. July 17, 2004. - Reverse Remodeling. - The Role of the RAAS in Heart Failure.
250. Fundamentals of Heart Failure. Fifth Annual Intensive Cardiology Board Review Course at the Cleveland Clinic Foundation. Sept. 23, 2004. Cleveland, Ohio.
251. XXXI Argentina Congress of Cardiology, Buenos Aires, Argentina, October 7-11, 2004 - Heart Failure 2004: Where are we going? - From Failure to Success: What is missing? - Neurohormonal activation in Heart Failure. - Expanding use of ARBs in Patients with Heart Failure. - Assessing Heart Failure: Role of Biochemical Markers. - Recent and Futuristic Strategies in the Management of Heart Failure.
252. 37th Annual Cardiovascular Symposium New York City, N.Y. Dec. 11, 2004. Valentine Fuster, MD, PhD Director. Systolic Dysfunction and Pathogenesis: Two Conceptual Pathways – Humoral, Neurogenic and Hemodynamic Pathways.
253. Joint Session-American College of Cardiology and the German Cardiac Society, Mannheim, Germany. April 1, 2005. Debate: BNP should be used in patients to identify heart failure in the emergency room (Pro) – Prof. Gaitrigger (con).
254. 2nd Annual International Acute Heart Failure Syndromes Meeting. April 2-4, 2005. Cannes, France. Chair: Session on Guidelines.
255. ARBs plus ACE inhibitors. Forges-Les-Eaux, France. May 11-13, 2005. Prof. Komajda, Chairman.
256. Update: Stem-cell therapy for heart failure. Victor Dzau and Helmet Drexler, Chairman: GS Francis. Eplerenone in heart failure. European Society of Cardiology-Working Group on Heart Failure. Lisbon, Portugal. June 11-13, 2005.
257. Tissue-ACE inhibitors vs. non-tissue ACE inhibitors: is there a difference? Special Lecture. Heart Forum. Annual Symposium on Heart Failure. Henry Ford Hospital. June 23, 2005. Detroit, Michigan. Prof. Hani Sabbah-Chairman.
258. New and Futuristic Strategies for the Management of Heart Failure. Heart Failure Management 2005. University of North Carolina. Amelia Island, July 16, 2005.
259. Foro Internacional de Cardiologia – Mexico City, Mexico; August 25-26, 2005. - Medical Treatment in Heart Failure: which drugs and when? - Heart Failure: surgical options, revascularization, remodeling and transplantation
260. Heart Failure Society of America – 9th Annual Scientific Meeting; Boca Raton, Florida; Sept 18-21, 2005 32
Gary S. Francis, M.D. Curriculum Vitae
- Opening Presidential Welcome - Managing the Cardiorenal Syndrome - Moderator: Acute Heart Failure: Guidelines for End-of-Life Care: The European and American Perspective - Case Discussions; panelist - Critical Issues in the Management of Complex Heart Failure; Devices in Heart Failure: indications and expectations
261. 6th Annual Intensive Board Review of Cardiology; Cleveland Clinic Foundation; Cleveland, Ohio; Sept 18-23, 2005 - Fundamentals of Heart Failure
262. Conferenza Internazionale per lo Scompenso Cardiaco, Montecatini, Italy. Oct. 27, 28, 2005. - The ACC/AHA 2005 Guidelines
263. AHA Annual Scientific Sessions 2005; Nov 13-16, 2005. Dallas, Texas. - New ACC/AHA Heart Failure Guidelines 2005 (Spotlight Session). - Symposium on Fluid Management in the Heart Failure Patient (Chairman), Cardiorenal Syndrome. - Cleveland Clinic Heart Failure Summit, What are our options? Trials shaping heart failure therapeutics. - Chairman: Heart Failure – Markers of the Pathophysiologic Process.
264. 38th Annual New York Cardiovascular Symposium (Val Fuster-Chairman); Dec. 10, 2005. - Chairman: Heart and Electrical Failure 2005. - Conventional heart failure therapy.
265. Treatment of heart failure in the elderly in the office setting. Heart Failure Society of America – Awareness week. Houston, TX. February 11, 2006.
266. American College of Cardiology 55th Annual Scientific Session. March 11-14, Atlanta Georgia, 2006. - Chairman: Unresolved Problems in Heart Failure-Cardiorenal Syndrome, March 11, 2006. - Compelling Controversies in Heart Failure: Debate 1: Race should influence the choice of therapeutic agent in heart failure. Gary S. Francis-Con (Peter Carson-Pro). Milton Packer-Chairman. March 11, 2006. - Co-Chair: Symposium on Biomarkers in Heart Failure, March 13, 2006.
267. Prognostic value of atrial fibrillation in heart failure patients. International Symposium- Update on Atrial Fibrillation 2006. March 31-April 1, 2006. Coburg, Germany.
268. 5th Annual Ray W.Gifford, Jr. M.D. Hypertension Symposium. Cardiorenal Syndrome: Definitions, Pathophysiology and Treatment. Gleacher Center-University of Chicago, Chicago, Ill. April 19, 2006.
269. 12th Annual UCSD Heart Failure Symposium. Use of neurohormonal blocking agents to treat heart failure: What we’ve accomplished and what the future holds. San Diego, Ca. June 3, 2006.
270. Heart Failure Association of the European Society of Cardiology Helsinki, Finland, June 17-20, 2006. - Cardio-Renal Problems in Acute Heart Failure. - Management of Acute Heart Failure. - Chair, HFSA-HFA Joint Session.
271. Heart Failure Management 2006: Established Therapy and New Frontiers. University of North Carolina, Amelia Island, FL. July 22, 2006. - Management of the Cardio-Renal Syndrome.
272. Presidential Address – Heart Failure Society of America, Seattle, WA. Creativity in Science. September 11, 2006.
33
Gary S. Francis, M.D. Curriculum Vitae
273. Fundamentals of Heart Failure. 7th Annual Intensive Review of Cardiology, Cleveland Clinic. September 21, 2006.
274. Cardio-Renal Syndrome. William H. Gaasch Lecture. University of Massachusetts, October 12, 2006.
275. Pathophysiology of Acute Decompensated Heart Failure. 5th Annual Henry Ford Heart and Vascular Institute on Heart Failure. October 24, 2006.
276. Annual Distinguished Lecturer. The Cardio-Renal Syndrome. University of British Columbia, Vancouver, British Columbia. November 3, 2006.
277. Annual Laennec Lecture. American Heart Association. Acute Decompensated Heart Failure. Chicago, IL, November 13, 2006.
278. Highlights of the Annual HFSA Meeting. AHA Annual Meeting, Nov. 13, 2006.
279. 33rd Annual Williamsburg Conference on Heart Disease. William Roberts. Dec. 6, 2006. - Recent Clinical Trials in Chronic Heart Failure: Past, present and future. - Management Issues in Patients with Acute Decompensated Heart Failure: Are we really succeeding? - Cardiorenal Syndrome Heart Failure: Definition, pathophysiology and management.
280. Co-Chairman with Pat OGara, MD. ACC Annual Meeting. Spotlight Session: Clinical Cardiology, Sunday, March 25, 2007. New Orleans, LA.
281. ACC Annual Meeting. ACC Symposium. Role of Imaging in Heart Failure: How can imaging help the heart failure specialist? March 27, 2007. New Orleans, LA.
282. Clinical Evidence with Valsartan: Focus on V-HeFT. 1st International Congress of Cardiomyopathies and Heart Failure. March 11, 2007. Kyoto, Japan.
283. Acute Heart Failure: Patient Management of Growing Epidemic. 1st International Congress of Cardiomyopathies and Heart Failure. March 13, 2007. Kyoto, Japan.
284. Heart Failure Management 2007. University of North Carolina, Amelia Island, FL. July 14, 2007. - Management of the Cardio-Renal Syndrome
285. Fundamentals of Heart Failure. 8th Annual Intensive Review of Cardiology, Cleveland Clinic. Aug. 23, 2007.
286. Dialysis – To start or Not to Start? European Society of Cardiology. Vienna, Austria. Sept 3, 2007.
287. Foro Internacional de Cardiologia Mexico City, Mexico; Sept. 28, 2007. - Renin blockage: the future in hypertension control. - BNP: diagnostic method or therapeutic opportunity?
288. Inaugural ACC West Coast Cardiovascular Forum; Valentine Fuster-Chairman. San Francisco, CA. October 7, 2007. - Hemodynamic patterns: relevant in tailoring therapy? - Myocarditis, biopsy and immunotherapy.
289. AHA Annual Scientific Sessions 2007; Orlando, FL; Nov. 6, 2007. Co-Chairman: Biomarkers Session.
290. Prognostic Effects of Atrial Fibrillation in Heart Failure. Western Atrial Fibrillation Symposium. Park City, UT. Dec. 13-14, 2007. 34
Gary S. Francis, M.D. Curriculum Vitae
291. Acute Decompensated Heart Failure: Who, When and Why? Society of Critical Care Medicine Annual Meeting. Honolulu, HI. Feb. 4th, 2008.
292. The Pipeline of New Therapies for CHF. What Can We Expect? Current Topics in Cardiology Practice. Newport Beach, CA. Feb 5, 2008.
293. Foro Internacional de Cardiologia – Mexico City, Mexico. April 9, 2008. - Heart Transplantation. - Systolic Hypertension in the Elderly.
294. Atrial Fibrillation and Heart Failure. Update on Atrial Fibrillation 2008. Coburg, Germany. April 18-19, 2008.
295. University of North Carolina Annual Meeting on Heart Failure Management 2008, July 19, 2008. Amelia Island, FL. - Cardiorenal Syndrome, Definition, Pathophysiology and Management.
296. Fundamentals of Heart Failure. 9th Annual Intensive Review of Cardiology. Cleveland Clinic. August 21, 2008.
297. Internal Medicine Grand Rounds, Cleveland Clinic – Cardiorenal/Syndrome, Sept. 11, 2008.
298. Heart Failure Society of America-12th Annual Scientific Meeting, Toronto, Canada. Sept. 21-24, 2008. - Late Breaking Clinical Trials-Moderator and Commentator. - Heart Failure Court of Appeals-Judge. - Heart.org Evaluation of ICD and CRT Clinical Trials-Round Table. - Cardiorenal Syndrome in ADHF-Chairman of Symposium.
299. Chairman: “Beyond the Guidelines” and “The Heart-Kidney Interface.” AHA Annual Scientific Sessions. New Orleans, LA. November 9-10, 2008.
300. Mentoring in Heart Failure and Heart Transplant. ACC-Heart House. Valentine Fuster, Chairman. Dec. 6, 2008. Wash. D.C.
301. Management based on contractile, hemodynamic and BNP patterns: left ventricular systolic and diastolic dysfunction; pulmonary hypertension and right ventricular dysfunction. Chairman: Heart Failure and Basis for Management. 2008 New York, NY. ACC Annual Cardiovascular Symposium. Dec 13, 2008.
302. Co-Chairman – Advances in the Treatment of Acute Decompensated Heart Failure. ACC – 58th Annual Scientific Session. Orlando, FL. March 30th, 2009.
303. ACC-AHA Heart Failure Focused Update Guidelines with Prof. Mariell Jessup (5 lectures) Beijing, Guangzhou, and Shanghai, China. May 26 – June 2, 2009.
304. ACC 2009 West Coast Cardiovascular Forum, Chairman-Valentine Fuster, MD, PhD - Detection of early/subclinical ventricular distinction: How to do it, how to follow it, how to manage it, what to expect? - Significant left ventricular systolic and diastolic dysfunction: Management based on contractile, hemodynamic and BNP patterns. San Francisco, CA. June 20, 2009.
305. Heart Failure Management 2008 (University of North Carolina) Cardio-Renal Syndrome. Amelia Island Plantation, FL. July 18, 2009.
306. Heart Failure Society of America; 13th Annual Meeting; Boston, MA. September 13-16, 2009. 35
Gary S. Francis, M.D. Curriculum Vitae
- Chairman – Opening Session: Heart Failure Court of Appeals: Case II: Appeal against: Exercise training is a required recommendation for all heart failure patients.
307. Mechanical Circulatory Support Meeting -5th Berlin Symposium (Prof. Hetzer-Chairman). Berlin, Germany. November 6-8, 2009. - Perspectives in Therapy of Heart Failure – drugs, cells, devices or heart transplant? Opening address.
308. AHA Annual Scientific Sessions. Orlando, FL. Session on “mentoring” – my personal experience. November 14, 2009.
309. Mentoring for an Academic Career in Heart Failure and Heart Transplantation. ACC-Heart House. Valentine Fuster, Chairman. December 5, 2009.
310. Prognostic Effect of Atrial Fibrillation in Heart Failure. 3rd Annual Western Atrial Fibrillation Symposium. Park City, UT. February 26–27, 2010.
311. ACC Annual Scientific Sessions. Atlanta, GA. Meet the Expert Session on right ventricular failure, March 14, 2010; Co-Chairman – Session on Reverse Remodeling, March 15, 2010.
312. Atrial Fibrillation and Heart Failure. Update on Atrial Fibrillation 2010. Coburg, Germany. April 23-24, 2010.
313. Cardiac Transplantation Research for the Next Decade: A Goal to Evidence-Based Outcomes. NHLBI, Bethesda, MD. August 5–6, 2010.
314. Neurohumoral Control of Heart Failure. Heart-Brain Summit. Cleveland Clinic Lou Ruvo Center for Brain Health. September 24, 2010.
315. American Heart Association Scientific Sessions 2010. Chicago, IL. Chairman: Heart Failure with Preserved Systolic Function. November 14, 2010.
316. Prognostic Effect of Atrial Fibrillation in Heart Failure. 4th Annual Western Atrial Fibrillation Symposium. Park City, UT. Feb. 25-26, 2011.
317. Clinical Challenges of the Cardio-Renal Syndrome. Heart Failure Management 2011 – University of North Carolina Annual Meeting. July 23, 2011.
318. 9th Annual Center for Heart Failure Symposium – in honor of the 200th anniversary of the University of Oslo. Keynote Speaker: The Last 10 Years of Heart Failure Research: What will the future bring? Oslo, Norway. September 15, 2011.
319. 2011 AHA Scientific Sessions. Orlando, FL. Co-Chairman with Professor John McMurry. Plenary Session: State- of-the-Art-Trends in Treating Heart Failure. November 15, 2011.
320. Acute Decompensated Heart Failure. State of the Art Conference, University of California, San Diego, CA. December 3, 2011.
321. American College of Cardiology 62nd Annual Scientific Session, San Francisco, CA. How to Get Involved with Research Data-Base, Outcomes vs. Clinical (Fellows and Early Career Physician Symposium) - March 9, 2013. Systolic and Diastolic Dysfunction – Clinical/Hemodynamic Management - March 10, 2013.
322. Royal College of Physicians, Dublin Ireland. HFpEF – What is it? How do you manage it? August 29, 2013.
36
Gary S. Francis, M.D. Curriculum Vitae
323. How to get a paper published in American Journals. Chongqing Medical University, Congqing, China. October 9, 2013.
324. Great Wall Cardiac Symposium – Cardiorenal Syndrome; Beijing, China. October 11, 2013.
325. Great Wall Cardiac Symposium – HFpEF; Beijing, China. October 11, 2013.
326. AHA Scientific Sessions 2013; Dallas, TX. - Joint AHA/ACC Session on Guidelines: Heart Failure Pharmacology: An Update. November 17, 2013. - AHA Cardiovascular Evening Symposium – Moderator: Heart Failure Challenges: Old and New.
327. ACC Sponsored Symposium (Valentin Fuster – Chair); New Delhi, India. February 2, 2014. - Systolic Heart Failure. - Diastolic Heart Failure. - Pulmonary Hypertension
328. ACC 62rd Annual Session. Washington, D.C. March 31, 2014. - Chairman – Cardio-Renal Syndorme: Tip of the Iceberg? - Pathophysiology of the Cardio-Renal Syndrome.
329. ACC Sponsored Symposium (Valentin Fuster – Chair). São Paulo, Brazil. May 25, 2014. - Systolic Heart Failure. - Diastolic Heart Failure. - Pulmonary Hypertension.
330. HFSA Moderator-Late Breaking Clinical Trials with J.V. McMurray. 19th Annual Heart Failure Society of America Meeting, Washington, DC; September 27, 2015
331. HFSA Moderator-The “Hidden Gems” of Heart Failure Publishing. 19th Annual Heart Failure Society of America Meeting, Washington, DC; September 28, 2015
332. American Heart Association 2015 Scientific Sessions, Orlando, FL, November 6 through 11, 2015, 1. Poster Professor: November 9, Ventricular Function / Hemodynamics and Biomarkers. 2. Moderator: November 11, Plenary Session – Navigating the complex landscape of heart failure.
333. HFSA Moderator with Dr Jay Cohn: Meet the Experts. Questions and Answers with Editors-in-Chief, Sept. 19, 2016, 20th Annual Heart Failure Society of America Meeting, Orlando, FL.
334. Dual Presentation with Dr. Milton Packer on HFpEF, Amgen, September 23, 2016, Philadelphia, PA.
335. Top 10 papers of 2018-19 in Heart Failure. HFSA Annual meeting (22nd) of the Heart Failure Society of America. September 15, 2019, Philadelphia, PA.
Audio-Visuals: 27
1. The sympathetic response to exercise in patients with congestive heart failure. ACCEL, Volume 13, No. 10, October 1981.
2. The treatment of angina pectoris. CIBA film, 1982.
3. Congestive Heart Failure - London Scientific Films LTD, 1986.
37
Gary S. Francis, M.D. Curriculum Vitae
4. Neurohumoral Mechanisms. ACCEL, Volume 19, No. 2, February 1987.
5. Sympathetic nervous system and the renin-angiotensin-aldosterone system in congestive heart failure. Tele-Lecture presentation, April 1988.
6. The sympathetic nervous system and heart failure. Life-line Cable T.V. Network; ACC-Atlanta, GA. March 26, 1988.
7. Controversies in Cardiology: Post-MI Arrhythmias. Moderator of discussion with J. Thomas Bigger, M.D. and Craig M. Pratt, M.D., 1989.
8. Sudden death in patients with heart failure. ACCEL, Volume 22, No. 1, January 1990.
9. Clinical Trials in CHF. ACCEL, Volume 25, No. 7, July 1993.
10. Cardiac Dysfunction: The role of left ventricular hypertrophy (Chairman). Euro Trans Med Broadcast. The London Television Centre, October 5, 1993.
11. Neurohormones in Heart Failure. American Heart Association 66th Scientific Session. Physicians Video Journal. Atlanta, GA. November 8-11, 1993.
12. Neurohumoral Factors: Implications for treatment and survival. ACCEL, Vol 26, January, 1994.
13. Clinical significance of bradykinin pathway in reversing cardiovascular disease (Chairman). Euro Trans Med Broadcast. The London Television Centre, June 21, 1994.
14. Therapeutic choices in cardiovascular pharmacology for chronic CHF: vasodilators or ACE inhibitors. ACCEL, Vol. 26 No. 8, August 1994.
15. Bradykinin and left ventricular remodeling, with Drs. Salvatore Moncada, Douglas Vaughan, Marc Pfeffer and Kenneth McDonald. Health Science Media, Inc. Atlanta, GA. October 27, 1994.
16. Do ACE inhibitors influence myocardial ischemia or myocardial infarction? Rural Health Satellite Network in conjunction with the 43rd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand; Canberra, Australia. August 8, 1995.
17. What’s new in heart failure? Clinical trials. ACCEL Tape. AHA. November 1997; Interviewed by Dr. Valentin Fuster. Vol 30 #5, May, 1998.
18. Diabetic cardiomyopathy. ACCEL Tape. ACC March 2000. Vol. 32(5), May 2000.
19. ACCSAP V: 2002 II. Basic mechanisms and pathophysiology of heart failure. Mohamad Yamani, MD Gary S. Francis, MD III. Evolution of Disease progression in heart failure. Gary S. Francis, MD
20. ACC Live Teleconference on ACC Annual Meeting – Update on Heart Failure 2002.
21. Treatment of Advanced Heart Failure in the CCU. ACCEL tape. ACC 2002. Interviewed by Mervyn Gottsman. Vol. 54, No. 10, Oct. 2002. 38
Gary S. Francis, M.D. Curriculum Vitae
22. Use of Plasma BNP. ACCEL tape. ACC 2003. Vol. 35, No. 6, June 2003.
23. New 2005 ACC/AHA Guidelines for Heart Failure. ACCEL tape. AHA 2005. Vol. 38, No. 5, May 2006.
24. Imaging for the Heart Failure Specialist. ACCEL tape. ACC March 24, 2007.
25. Dialysis: To start or Not. ACCEL tape Dec. 2007.
26. ACCEL tape, November 2013, New Guideline Update on Heart Failure. Vol. 46. Feb. 2014.
27. ACCEL tape, April 2014, Cardio-Renal Syndome. Vol. 47, October 2015.
Peer Reviewed Publications: Total 560
Citations: 47,618 Views on Internet: 382,539
H-Index May 2019
h-Index: 88 (Research Gate), 81 (Manifold) RG Score > 97.5% (among top 1% of all scientists in the world – SCOPUS)
Original Investigations: 150
1. Hagan AD, Francis GS, Sahn DJ, Karliner JS, Friedman WF, O’Rourke RA. Ultrasound evaluation of systolic anterior septal motion in patients with and without right ventricular volume overload. Circulation 1974; 50:248-254.
2. Francis GS, Hagan AD, Oury J, O’Rourke RA. Accuracy of echocardiography for assessing aortic root diameter. Br Heart J 1975; 37:376-378.
3. Francis GS, Hagan AD. Echocardiographic criteria of normal left atrial size in adults. J Cardiac Cath Cardiovasc Diag 1976; 2:69-75.
4. Alpert JS, Johnson AD, Francis GS, Vieweg WVR, Ockene I, Hagan AD. Assessment of left ventricular function in severe aortic regurgitation. Circulation 1976; 54:975-979.
5. Cohn IM, Alpert JS, Francis GS, Vieweg HVR, Hagan AD. Safety of hot and cold liquids in patients with acute myocardial infarction. Chest 1977; 71:450-452.
6. Crowley WF, Ridgway CE, Bough EW, Francis GS, Daniels GH, Kourides IA, Myers GS, Maloof F. Non-invasive evaluation of cardiac function in hypothyroidism: Response to gradual thyroxine replacement. N Engl J Med 1977; 296:1-6.
7. Henning H, Hardarson T, Francis GS, O’Rourke RA, Ross J Jr. Approach to the estimate of myocardial infarct size by analysis of precordial ST segment and R wave maps. Am J Cardiol 1978; 41:1-8.
8. Rourke T, Asinger RW, Mikell FL, Francis GS, Hodges M. Sector echocardiographic technique. A systematic technique. Med Ultrasound 1979;3:51-57.
9. Schuler G, Peterson K, Johnson A, Francis G, Dennish G, Utley J, Daily P, Ashburn W, Ross J Jr. Temporal response of left ventricular performance to mitral valve surgery in patients with chronic mitral regurgitation or stenosis. Circulation 1979; 59:1218-1231. 39
Gary S. Francis, M.D. Curriculum Vitae
10. Mikell FL, Asinger RW, Rourke T, Hodges M, Sharma B, Francis G. Two-dimensional echocardiographic demonstration of left atrial thrombi in patients with prosthetic mitral valves. Circulation 1979; 60:1183-1190.
11. Schuler G, Peterson K, Johnson AD, Francis GS, Dennish G, Daily PO, Ross J Jr: Serial noninvasive assessment of left ventricular hypertrophy and function after surgical correction of aortic regurgitation. Am J Cardiol 1979; 44:585- 594.
12. Francis GS, Sharma B, Collins AJ, Helseth HK, Comty CM. Coronary artery bypass surgery in end-stage renal failure, chronic dialysis, and transplant patients. Ann Intern Med 1980;92:499-503.
13. Sharma B, Hoback J, Francis GS, Hodges M, Asinger RA. Cohn JN, Taylor CR. Pirbuterol: A new oral sympathomimetic amine for the treatment of congestive heart failure. Am Heart J 1981;102:533-541.
14. Pierpont GL, Francis GS, Cohn JN. Effect of captopril on renal function in patients with congestive heart failure. Br Heart J 1981; 46:522-527.
15. Francis GS, Sharma B, Hodges M. Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J 1982; 103:995-1000.
16. Francis GS, Goldsmith SR, Cohn JN. The relationship of exercise capacity to resting left ventricular performance and vasal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J 1982; 104:725-731.
17. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin- angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart. Am J Cardiol 1982; 49:1659-1666.
18. Francis GS, Goldsmith SR, Ziesche SM, Cohn JN. The response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol 1982; 49:1152-1156.
19. Cohn JN, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, Montero A, Cintron G, Clarke J, Hager D, Saunders R, Cobb F, Smith R, Loeb H, Settle H. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure. Results of a Veterans Administration co- operative study. N Engl J Med 1982; 306:1129-1135.
20. Goldsmith SR, Francis GS, Cowley AW, Cohn JN. Response of vasopressin and norepinephrine to lower body negative pressure in man. Am J Physiol 1982; 243:H970-H973.
21. Asinger RW, Hodges M, Rourke T, Sharma B, Francis GS. Abnormal left ventricular filling in concentric hypertrophy: an echocardiographic study. J Cardiovasc Ultrasonography 1982; 1:223-234.
22. Levine TB, Francis GS, Goldsmith SR, Cohn JN. The neurohumoral and hemodynamic response to orthostatic tilt in patients with congestive heart failure. Circulation 1983; 67:1070-1075.
23. Francis GS, Parks R, Cohn JN. The effects of bromocriptine in patients with congestive heart failure. Am Heart J 1982; 106:100-106.
24. Goldsmith SR, Francis GS, Cowley A, Levine B, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1:1385-1390.
25. Goldsmith SR, Francis GS, Levine TB, Cohn JN. Regional blood flow response to ortho stasis in congestive heart failure. J Am Coll Cardiol 1983; 1:1391-1395. 40
Gary S. Francis, M.D. Curriculum Vitae
26. Sharma B, Behrens TW, Erlein D, Hodges M, Asinger RW, Francis GS. Left ventricular diastolic properties and filling characteristics during spontaneous angina pectoris at rest. Am J Cardiol 1983; 52:704-709.
27. Francis GS, Olivari MT, Goldsmith SR, Levine TB, Pierpont G, Cohn JN. The acute response of plasma norepinephrine, renin activity and arginine vasopressin to short-term nitroprusside and nitroprusside withdrawal in patients with congestive heart failure. Am Heart J 1983; 106:1315-1320.
28. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Abnormal response of plasma vasopressin to orthostatic stress in congestive heart failure. J Am Coll Cardiol 1983; 2:1080-1083.
29. Pierpont GL, Francis GS, DeMaster EG, Levine TB, Bolman RM, Cohn JN. Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy. Am J Cardiol 1983; 52:1033-1035.
30. Francis GS, Goldsmith SR, Pierpont G, Cohn JN. Free and conjugated plasma catecholamines in patients with congestive heart failure. J Lab Clin Med 1984; 103:393-398.
31. Goldsmith SR, Cowley AW, Francis GS, Cohn JN. Effect of increased intracardiac and arterial pressure on plasma vasopressin in humans. Am J Physiol 1984; 246:H647-H651.
32. Petein M, Peirpont GL, Francis GS, Cohn JN, From AHL. In vivo interaction of AR-L 115-BS (Vardax) with the adrenergic nervous system. J Cardiovasc Pharmacol 1984; 6:1020-1026.
33. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon A, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823.
34. Francis GS, Goldsmith SR, Ziesche S, Nakajima H, Cohn JN. Relative attenuation of sympathetic drive during exercise in patients with congestive heart failure. J Am Coll Cardiol 1985; 5:832-839.
35. Francis GS, Siegel R, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. The acute vasoconstrictor response of intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med 1985; 103:1-6.
36. Goldsmith SR, Cowley AW, Francis GS, Cohn JN. Reflex control of osmotically stimulated vasopressin in normal man. Am J Physiol 1985;248:R660-663.
37. Chesler E, Weir EK, Braatz GA, Francis GS. Normal catecholamine and hemodynamic response to orthostatic tilt in subjects with mitral valve prolapse: correlation with psychological testing. Am J Med 1985; 78:754-760.
38. Goldsmith SR, Francis GS, Cohn JN. Norepinephrine infusions in patients with congestive heart failure. Am J Cardiol 1985; 56:802-804.
39. Goldsmith SR, Francis GS, Cohn JN. Effect of head down tilt on plasma norepinephrine and plasma renin activity in normal humans. J Appl Physiol 1985; 59:1068-1072.
40. Goldsmith SR, Cowley AW Jr, Francis GS, Cohn JN. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986;58:295-299.
41. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Oliveri MT, Goldenberg I, Cohn JN. Hemodynamic effects of arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986; 8:779-783.
41
Gary S. Francis, M.D. Curriculum Vitae
42. Johnson GJ, Leis LA, Francis GS. The calcium channel blockers, nifedipine and verapamil, have different effects on alpha 2 adrenergic receptors and thromboxane-induced aggregation of human platelets. Circulation 1986; 73:847- 854.
43. Kappler JH, Ziesche SM, Nelson JA, Francis GS. Reproducibility of exercise testing in patients with congestive heart failure. Heart Failure 1986;2:157-163.
44. Cohn JN, Archibald D, Ziesche S, Franciosa JA, Harston WE, Tristani F, Dunkman B, Jacobs W, Francis GS, Flohr K, Goldman S, Cobb F, Shah P, Saunders R, Fletcher R, Loeb H, Hughes V, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 1986; 314:1547-1552.
45. Feske W, Finkelstein SM, Francis GS, Cohn JN. Arterial vascular compliance response to exercise in hypertension. Instrument Soc of Amer Biomedical Sciences Instrumentation 1986; 24:161-165.
46. Pierpont GL, Francis GS, DeMaster EG, Olivari MT, Ring WS, Goldenberg IF, Reynolds S, Cohn JN. Heterogenous myocardial catecholamine concentrations in patients with congestive heart failure. Am J Cardiol 1987; 60:316-321.
47. Chesler E, Pierpont G, Weir EK, Francis GS, Shafer R. Limitations of echocardiography in measuring left ventricular ejection fraction in coronary artery disease. J Non-invasive Cardiol 1987; 1:166-170.
48. Cohn JN, Archibald DG, Francis GS, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Veterans Administration Cooperative study on vasodilator therapy of heart failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 1987; 75(Suppl IV): 49- 50.
49. Sharma B, Asinger R, Francis GS, Hodges M, Wyeth R. Demonstration of exercise induced painless myocardial ischemia in patients who survived out of hospital ventricular fibrillation. Am J Cardiol 1987; 59:740-745.
50. Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN. Predicting survival for an individual with congestive heart failure using plasma norepinephrine concentration. Am Heart J 1987;114:148-152.
51. Feske W, Finkelstein SM, Francis GS, Cohn JN. Vascular compliance after nitroprusside in hypertension. IEEE Proceed 1987; 227-228.
52. Rector TS, Francis GS, Cohn JN. Patients’ self-assessment of their congestive heart failure. Part I: Patient perceived dysfunction and its poor correlation with maximal exercise. Heart Failure 1987; 4:192-196.
53. Feske W, Finkelstein SM, Francis GS, Cohn JN. Arterial vascular compliance response to vasodilators by Fourier and pulse contour analysis. Instrument Soc of Amer Biomedial Sciences Instrumentation 1988; 24:161-165.
54. Francis GS, Rector TS, Cohn JN. Sequential neurohumoral measurements in patients with congestive heart failure. Am Heart J 1988; 116:1464-1468.
55. Francis GS, Wilson BC, Rector TS. Hemodynamic, renal and neurohumoral effects of a selective oral DA1 agonist (fenoldopam) in patients with congestive heart failure. Am Heart J 1988; 116:473-479.
56. Francis GS, Rucinska EJ. Long-term effects of once-a-day versus twice-a-day regimen of enlapril for congestive heart failure. Am J Cardiol 1989; 63:17D-21D.
42
Gary S. Francis, M.D. Curriculum Vitae
57. Goldsmith SR, Francis GS, Cohn JN. Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure. Am J Cardiol 1989; 64:1382-1385.
58. Cohn JN, Johnson GJ, and Collaborative Investigators. Heart failure with normal ejection fraction: the V-HeFT study. Circulation 1990; 81(Suppl III):III48-III53.
59. Francis GS, Boosalis PJ. Mechanism of death in patients with congestive heart failure: The change in plasma norepinephrine and its relation to sudden death or death from progressive pump failure. Cardio Science 1990; 1:29- 32.
60. Francis GS, Johnson TH, Boosalis P, Ziesche SM, Berg M, Cohn JN. Marked spontaneous improvement in ejection fraction in patients with congestive heart failure and low ejection fraction. Am J Med 1990; 89:303-307.
61. Francis GS, Benedict C, Johnston DE, Kirlin PC, Nicklas J, Liange C-S, Kubo SH, Toretsky-Rudin E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990:82; 1724-1729.
62. Johnson GJ, Leis L, Francis GS. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46610. Thrombosis Research 1990; 59:139-148.
63. The SOLVD Investigators. Studies of Left Ventricular Dysfunction (SOLVD) Rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 1990; 66:315-322.
64. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis GS, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Carson P, Cintron G, Shabetai R, Haakenson, C. A comparison of enalapril with hydralazine - isosorbide dinitrate in the treatment of chronic congestive heart failure: V-HeFT II. N Engl J Med 1991; 325:303-310.
65. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
66. Packer M. and the PROMISE Study Investigators. Effect of oral milrinone on mortality in severe chronic heart failure. The Prospective Randomized Milrinone Survival Evaluation (PROMISE). N Engl J Med 1991; 325:1468- 1475.
67. McDonald KM, Francis GS, Carlyle PF, Hauer K, Mathews J, Hunter DW, Cohn JN. Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. JACC 1992; 19:460-467.
68. McDonald KM, Parrish T, Wennberg P, Stillman A, Francis GS, Cohn JN, Hunter D. Rapid accurate and simultaneous assessment of right and left ventricular mass using high speed magnetic resonance imaging. J Am Coll Cardiol 1992; 19:1601-1607.
69. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327:685-691.
70. McDonald KM, Francis GS, Mathews J, Hunter D, Cohn JN. Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. J Am Coll Cardiol 1993; 21:514-522.
71. Kubo SH, Ormaza S, Francis GS, Holmer SC, Olivari MT, Bolman RM III, Shumway SJ. Trends in patient selection for heart transplantation. J Am Coll Cardiol 1993; 21:975-981.
43
Gary S. Francis, M.D. Curriculum Vitae
72. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity and congestive heart failure: relationships to survival and the effects of therapy in V-HeFT II. Circulation 1993; 87:VI-40-VI-48.
73. Cintron G, Johnson G, Francis GS, Cobb F, Cohn JN. Prognostic significance of serial changes in ejection fraction in patients with congestive heart failure. Circulation 1993; 87:VI-17-VI-23.
74. Goldman S, Johnson G, Cohn J, Cintron G, Smith R, Francis G. Mechanism of death in heart failure: results of the vasodilator-heart failure trials. Circulation 1993; 87:VI-24-VI-33.
75. Johnson G, Carson P, Francis GS, Cohn JN. Veterans Affairs Co-operative Study on Vasodilator therapy of heart failure: influence of prerandomization (baseline) variables on mortality and on reduction of mortality by enalapril. Circulation 1993; 87:VI-32-VI-39.
76. Connelly TP, Francis GS, Williams KJ, Beltran AM, Cohn JN. Acute effects of furosemide and atrial natriuretic factor on systemic and pulmonary vasculature in patients with congestive heart failure. American Heart Journal 1994; 127:392-399.
77. McDonald KM, Yoshiyama M, Francis GS, Ugurbil K, Cohn JN, Zhang J. Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction. J Am Coll Cardiol 1994; 23:786-793.
78. McDonald KM, Carlyle PF, Francis GS, Cohn JN. The relative effects of angiotensin converting enzyme inhibition and 1-adrenoceptor blockade regress established cardiomegaly in a canine model of discrete myocardial damage. J Am Coll Cardiol 1994; 24:1762-1768.
79. McDonald KM, Garr M, Carlyle PF, Francis GS, Hauer K, Hunter DW, Parish T, Stillman A, Cohn JN. Relative effects of 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype-1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90:3034-3046.
80. Kirlin PC, Benedict C, Shelton B, Francis GS, Nicklas J, Liang C-S, Kubo S, Johnstone D, Probstfield J, Yusuf , S for the SOLVD Investigators. Neurohumoral variability in left ventricular dysfunction. Am J Cardiol 1995; 75:354- 359.
81. McDonald KM, Mock J, D’Alio A, Parrish T, Hauer K, Francis GS, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium following discrete transmural myocardial necrosis. Circulation 1995; 91:2043-2048.
82. Benedict CR, Francis GS, Shelton B, Johnstone DE, Kubo SH, Kirlin P, Nicklas J, Liang C-S, Konstam M, Greenberg B, Yusuf S, for the SOLVD Investigators. Effect of long-term enalapril therapy on neurohormones in patients with heart failure. Am J Cardiol 1995; 75:1151-1157.
83. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohumoral activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-1585.
84. Rector TS, Tschumperlin LK, Kubo SH, Bank AJ, Francis GS, McDonald KM, Keeler CA, Silver MA. Use of the Living with Heart Failure questionnaire to ascertain patients’ perspective on improvement in quality of life vs. risk of drug-induced death. J Cardiac Failure 1995; 1:201-206.
85. Rector TS, Francis GS. Cost effectiveness analysis and clinical practice. J Am Coll Cardiol. 1995;26:920-921.
44
Gary S. Francis, M.D. Curriculum Vitae
86. Benedict CR, Shelton B, Johnstone DE, Francis GS, Greenberg B, Konstam J, Probstfield JL, Yusuf S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996; 94:690-697.
87. The Digitalis Investigation Group. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clin Trials 1996; 17:77-97.
88. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533.
89. Roman DD, Kubo SH, Ormaza S, Francis GS, Bank AJ, Shumway SJ. Memory improvement following cardiac transplantation. J Clin Exp Neuropsychology 1997; 19:692-697.
90. McDonald KM, Chu C, Francis GS, Carlyle W, Judd DL, Hauer K, Hartman M, Cohn JN. Effect of delayed intervention with ACE-inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model of myocardial infarction. J Mol Cell Cardiol 1997; 29:3203-3210.
91. McDonald K, Chu C, Francis GS, Judd D, Carlyle W, Toher C, Hauer K, Hartman M. The effect of delayed reperfusion following infarction in the rat on structural changes in viable myocardium. Cardiovasc Res 1997; 36:347-353.
92. McDonald KM, Stillman AS, Francis GS, Cohn JN. Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition. J Cardiac Failure 1998; 4: 203-212.
93. Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genther D, McLaughlin V, Francis GS. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792.
94. Tian B, Carlyle WC, McDonald KM, Judd DC, Francis GS, Cohn JN. Localization of changes in β-actin expression in remodeled canine myocardium. J Molecular and Cellular Cardiol 1999; 4: 751-760.
95. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 1999; 281:524-529.
96. Murakami Y, Zhang Y, Cho YK, Mansooy AM, Chung JK, Chu C, Francis GS, Ugurbil K, Bache RJ, From AHL, Jerosch-Herold M, Wilke M, Zhang J. Myocardial oxygenation during high work states in hearts with post infarction remodeling. Circulation 1999; 99:942-948.
97. Robbins M, Francis GS, Pashkow FJ, Snader CE, Hoercher K, Young JB, Lauer MS. Ventilatory and heart rate response to exercise: better predictors of heart failure mortality than peak oxygen consumption. Circulation 1999; 100: 2411-2417.
98. Francis GS, Anwar F, Bank AJ, Kubo SH, Jessurun J. Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing heart: observations made after implantation of left ventricular assist device. J Cardiac Failure 1999; 5: 308- 315.
99. Teerlink JR, Jalauddin M, Anderson S, Kukin ML, Eichhorn EV, Francis GS, Packer M, Massie BM on behalf of the PROMISE Investigators. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict sudden death. Circulation 2000; 101: 40-46.
45
Gary S. Francis, M.D. Curriculum Vitae
100. Yang J, Moravc CS, Sussman MA, DiPaola NR, Fu D, Hawthorn L, Mitchell CA, Young JB, Francis GS, McCarthy PM, Bond M. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high oligonucleotide density arrays. Circulation 2000; 102: 3046-3052.
101. Di Paola NR, Sweet WE, Stull LB, Francis GS, Moravec CS. ßeta-adrenergic receptors and ca++ cycling proteints in non-failing, hypertrophied and failing human hearts: transition from hypertrophy to failure. J Mol Cell Cardiol 2001; 33: 1283-1295.
102. Takagaki M, McCarthy PM, Tabata T, Dessoffy R, Cardon LA, Connor J, Ochiai Y, Thomas JD, Francis GS, Young JB, Fukamachi K. Induction and maintenance of an experimental model of severe cardiomyopathy with a novel protocol of rapid ventricular pacing. J Thoracic and Cardiovasc Surg 2002; 123: 544-549
103. Mahon NG, Blackstone EH, Francis GS, Starling RC, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance along side functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 40: 1106-1113.
104. Freda BJ, Tang WHW, VanLente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency. J Am Coll Cardiol 2002; 40: 2065 –2071
105. Tang WHW, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in patients with established chronic heart failure. J Am Coll Cardiol. 2003; 41: 1394-1398.
106. Khot UN, Norvaro GM, Popovic Z, Mills R, Thomas JD, Tuzcu EM, Hammer D, Nissen SE, Francis GS. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348:1756-1763.
107. Tang WHW, Girod JP, Lee MV, Starling RC, Young JB, Van Lente F, Francis GS. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003; 108: 2964-2966.
108. Popovic Z, Khot UN, Novaro GM, Greenberg NL, Garcia MJ, Francis GS, Thomas JT. Effects of sodium nitroprusside in aortic stenosis associated with severe heart failure: Pressure-volume loop analysis using a numerical model. Am J Physiol (Heart, Circ, Physiol) 2005; 288:H416-H423.
109. Tang WHW, Francis GS, Hsu A, Topol EJ, Moliterno DJ. Heightened long-term mortality and underuse of ACE inhibitors among patients undergoing contemporary percutaneous coronary intervention: insights from TARGET (submitted).
110. Aguilar D, Solomon SD, Kober L, Rouleau J-L, Skali H, McMurray JJV, Francis GS, Henis M, O’Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Effects of newly diagnosed and previously known diabetes mellitus on one-year outcomes of acute myocardial infarction: the VALIANT trial. Circulation 2004; 110:1572-1578.
111. Schenk S, McCarthy PM, Starling RC, Hoercher KJ, Hall MD, Ootaki Y, Francis GS, Doi K, Young JB, Fukamachi K. Neurohumoral response to left ventricular reconstruction surgery in ischemic cardiomyopathy. J Thorac Cardivasc Surg 2004;128 (1):38-43.
112. Parameswaran AC, Tang WHW, Francis GS, Gupta R, Young JB, Why do patients fail to receive beta-blockers for chronic heart failure over time? A “real world” single-center, two-year follow-up experience of B-blocker therapy in patients with chronic heart failure. Am Heart J 2005; 149: 921-926.
46
Gary S. Francis, M.D. Curriculum Vitae
113. Pfeffer M, McMurray JV, Velazquez EJ, et. al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Eng J Med 2003; 349: 1893-1906.
114. Jones RC, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group Trial. J Am Coll Cardiol 2004; 44:1025-1029.
115. Schenk S, McCarthy PM, Starling RC, Hoercher KJ, Hail MD, Ootaki Y, Francis GS, Doi K, Young JB, Fukamachi K. Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy. J Thorac Cardiovasc Surg 2004; 128:38-43.
116. Wazni OM, Martin DO, Marrouche NF, Latif AA, Ziada K, Shaaraoui M, Almahameed S, Schweikert RA, Saliba WI, Gillinov AM, Tang WHW, Mills RM, Francis GS, Young JB, Natale A. Plasma B-type natriuretic levels predict post-operative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110:124-127.
117. Zile M, Gaasch W, Little W, Francis GS, Tavazzi L, Cleland J, Davies M: A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability and safety of MCC-1356 in subjects with chronic heart failure, NYHA class II-III: rationale and design. J Cardiac Failure 2004; 10:193-199.
118. Pocock S, Wilhemsen L, Dickstein K, Wittes J, Meinert, L, Francis GS, Wright T. The Data Monitoring Experience in the MOXCON Trial. European Heart J 2004;25: 1974-1978. 119. Tang WHW, Thomas S, Kalaycio M, Sobecks R, Andresen S, Jarvis J, Rybicki L, Pohlman B, Francis GS, Bolwell BJ. Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction? Bone Marrow Transplantation 2004; 34, 603-607.
120. Velazquez EJ, Francis GS, Armstrong PW, Aylward PE, Diaz R, O’Connor CM, White HD, Henis M, Rittenhouse LM, Kilaru R, Gilst WV, Ertl G, Maggioni AP, Spac J, Weaver WD, Rouleau JL, McMurray JJV, Pfeffer MA, Califf RM. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. European Heart Journal 2004;25, 1911-1919.
121. Bhatheja R, Francis GS, Pothier CE, Lauer MS. Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms. Am J Cardiol 2005; 95:1159- 1164.
122. Tang WH, Philip K, Hazen SL, Cole CE, Pepoy M, Smith A, Neale S, Van Lente F, Francis GS, Wu AH. Comparative sensitivities between different B-type natriuretic peptide assays in patients with minimally symptomatic heart failure. Clinical Cornerstone; 2005; 7(Suppl 1):S18-S24.
123. Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. JAMA 2005 Oct 5; 294 (13): 1625-1633.
124. Amed A, Husain A, Love T, Gambassi G, Dell’Italia LJ, Francis GS, Gheorghiade M. Allman RM, Meleth S, Bounge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006; 27, 1-9.
125. Feldman AM, Silver MA, Francis GS, Abbottsmith CW, Fleischman BL, Soran O, de Lame P-A, Varrichione T and the PEECH Investigators. Enhanced external counter pulsation improve exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2006; 48: 1198-1205.
126. Tang WHW, Steinhubl SR, Van Lente F, Brennan D, McErlean E, Maroo A, Francis GS, Topol EJ. Risk stratification for patients undergoing non-urgent percutaneous coronary intervention using N-terminal pro-BNP 47
Gary S. Francis, M.D. Curriculum Vitae
natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. Am Heart J 2006; 36-41.
127. Abbottsmith CW, Chung ES, Varrichione T, deLame P-A, Silver MA, Francis GS, Feldman AM. Enhanced external counter pulsation improves exercise duration and peak oxygen consumption in older patients with heart failure: a subgroup analysis of the PEECH trial. Congestive Heart Failure 2006;12:307-311.
128. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction. A quantitative review from randomized trials. Archives of Int Med 2007; 167: 1930-1936.
129. Mullens W, Abrahams Z, Skouri HN, Taylor DO, Starling RC, Francis GS, Paganini E, Tang WHW. Elevated intra- abdominal pressure in acute decompensated heart failure: potential contributor to worsening renal function? J Am Coll Cardiology 2008;51:300-306.
130. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, Fonarow GC, Demarco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O’Conner CM. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Int Med 2007; 167: 1998- 2005.
131. Tang WH, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and long-term prognosis of new onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008;51:569-576.
132. Mullens W, Abrahams Z, Skouri HN, Taylor DO, Starling RC, Francis GS, Young JB, Tang WHW: Sodium nitroprusside for advanced decompensated heart failure. J Am Coll Cardiol 2008; 52:200-207.
133. Mullens W, Abrahams Z, Skouri HN, Taylor DO, Starling RC, Francis GS, Young JB, Tang WHW: Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Cardiac Failure 2008; Vol 14, No 6:508-514.
134. Lewis EF, Velazquez EJ, Soloman SD, Hellkamp AS, McMurray JJV, Methias J, Rouleau J-L, Maggioni AP, Swedberg K, Kaber L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J 2008, 29 (6):748-756, 2008.
135. Epelman J, Tang WH, Chen SY, Van Lente F, Francis GS, Sen J. Detection of soluble angiotensin converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin- aldosterone system. J Am Coll Cardiol 2008;52:750-754.
136. Xu-Cai YO, Brotman DJ, Phillips CO, Michota FA, Tang WHW, Whinney CM, Panneerselvam A, Hixon ED, Garcia M, Francis GS, Jaffer AK. Outcomes of patients with stable heart failure undergoing elective noncardiac surgery. Mayo Clin Proc 2008; 83:280-288.
137. Mullens W, Abrahams Z, Skouri HN, Taylor DO, Starling RC, Francis GS, Young JB, Tang WHW: Prognostic evaluation of ambulatory patients with advanced heart failure. Am J Cardiol 2008; 101:1297-1302.
138. Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJV, Califf RM, Velaquez EJ. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left dysfunction treated with valsartan captopril, or both. J Am Coll Cardiol 2008; S1:1865-1871.
48
Gary S. Francis, M.D. Curriculum Vitae
139. Mullens W. Abrahams Z, Francis GS, Sokos G, Taylor D, Starling R, Young J, Tang, WH. Importance of venous congestion for worsening or renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009; 53: 589-596.
140. Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, Martin MG, Boroski AG, Vasper S, Starling RC, Klein AC. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Cardiac Failure 2008;14:394-399.
141. Mullens W, Abrams Z, Sokos G, Francis GS, Starling RC, Young JB, Taylor DO, Tang WH. Gender differences in patients admitted with advanced decompensated heart failure. Am J Cardiol 2008; 101: 454-458.
142. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, Tang HWH. Soluble angiotensin converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J of Cardiac Fail 2009; 15: 1-7.
143. Mullens W, Francis GS, Tang HWH. Usefulness of isosorbide dinitrate and hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol 2009; 103: 1113-1119.
144. Kiernan MS, Wentworth D, Francis GS, Martinez FA, Dickstein K, Komajda M, Zannd F, Neaton JD, Konstam MA. Predicting adverse events during angiotensin blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Failure 2012; 14: 1401-1409.
145. Lu F, Eckman PM, Liao KK, Apostolidau I, John R, Chen T, Das GS, Francis GS, Benditt DG, Garry DJ. Catheter ablation of hemodynamically unstable ventricular tachycardia with mechanical circulatory support. International Journal of Cardiology 2013; 168(4):3859-3865.
146. John J.V. McMurray, M.D., Milton Packer, M.D., Akshay S. Desai, M.D., M.P.H., Jianjian Gong, Ph.D., Martin P. Lefkowitz, M.D., Adel R. Rizkala, Pharm.D., Jean L. Rouleau, M.D., Victor C. Shi, M.D., Scott D. Solomon, M.D., Karl Swedberg, M.D., Ph.D., and Michael R. Zile, M.D. for the PARADIGM-HF Investigators and Committees (Member of DSMB). Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993-1004 September 11, 2014 DOI:10.1056/NEJMoa1409077.
147. Chakravarty T, Makkar RR, Ascheim D, Traverse JH, Schatz R, DeMaria A, Francis GS, Smith R, Lima JA, Pagoda JM, Marban L, Henry TD. Allogenic Heart Stem Cells to Achieve Myocardial Regeneration (ALLSTAR): Rationale and Design. Cell Transplantation, August 12, 2016 (e-published ahead of print).
148. Packer MD, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petri MC, DeMets D, Kobrin I, Roux S, Swedberg K on behalf of the ENABLE Investigators and Committees (Member of DSMB). Long-Term Effect of Endothelin Receptor Antagonism with Bosentan on the Morbidity and Mortality of Patients with Severe Chronic Heart Failure: Primary Results of the ENABLE Trials. J Am Coll Cardiology Heart Failure 2017;5:317-326.
149. Skubitz KM, Blaes AH, Konety SH, Francis GS. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: Use of left ventricular rejection fraction is of unproven value. Cancer Chemotherapy and Pharmacology. Published online 30 August 2017. DOI 10.1007/S00280-017-3420-8.
150. Makkar R, Kereiakes DJ,, Aguirre F, Kowalchuk G, Chakravaty T, Konstantinos M, Francis GS, Povsic TJ, Schatz R, Traverse JH, Pagoda JM, Smith RR, Marban L, Ascheim DD, Lima J, De Maria A, Marban E, Henry TD. ALLogenic heart STem cells to Achieve myocardial Regeneration (ALLSTAR). A randomized placebo-controlled, double-blind trial. European Heart J 2020;0:1-8.
Editorials, Viewpoints, Perspectives: 66
49
Gary S. Francis, M.D. Curriculum Vitae
1. Francis GS. Sodium and water excretion in heart failure: Efficacy of treatment has surpassed knowledge of pathophysiology. (Editorial). Ann Intern Med 1986;105:272-274.
2. Francis GS. Heart failure management: The impact of drug therapy on survival. (Editorial). Am Heart J 1988; 115:699-702.
3. Francis GS. Should antiarrhythmic agents be used in the treatment of asymptomatic ventricular arrhythmias in patients with congestive heart failure. J Am Coll Cardiol 1988; 12:274-276.
4. Francis GS. Nitroglycerin, nitroprusside and endothelium-derived relaxing factor. (Editorial) J Am Coll Cardiol 1988; 11:1325-1326.
5. Francis GS. The relationship of the sympathetic nervous system and the renin-angiotensin-aldosterone system in congestive heart failure. Editorial. Am Heart J 1989;118:642-648.
6. Francis GS. Calcium channel blockers and congestive heart failure. Editorial. Circulation 1991; 83:336-338.
7. Francis GS, Rector TS. Maximal exercise tolerance as a therapeutic endpoint in heart failure - are we relying on the right measure? Editorial. Am J Cardiol 1994;73:304-306.
8. Rector TS, Francis GS. Cost-effectiveness analysis and clinical practice. J Am Coll Cardiol 1995; 26:920-921.
9. Francis GS. Commentary. Biochemical detection of left-ventricular systolic dysfunction (Lancet 1998;351:9-13) and value of natriuretic peptides in assessment of patients with possible new heart failure in primary care (Lancet 1997;350:1347-1351). Evidenced-based Cardiovasc Med 1998; 2:56.
10. Francis GS. Noblesse Oblige. J Cardiac Failure 1998; 4:91-93.
11. Francis GS. Heart Failure. 50th Anniversary Historical Article (by invitation). J Am Coll Cardiol 1999; 33:291- 294.
12. Francis GS. TNF-α and heart failure -- The difference between proof of principle and hypothesis testing. Circulation 1999; 99: 3213-3214.
13. Francis GS. , Gassler JP. On the interaction between grapefruit juice and cardiovascular medications. Cardiovasc Rev and Reports. 1999; 20: 408-409.
14. Francis GS. Resurrection of an old drug: a new treatment for heart failure. Evidence Based Cardiovascular Medicine 1999; 3:75.
15. Francis GS. Is there still a future for neutral endopeptidase inhibitors? Am Heart J 1999; 138: 1007-1008.
16. Francis GS. ACE inhibition in cardiovascular disease. N Engl J Med 2000; 342: 201-202.
17. Francis GS. Fibrinolytic therapy in the elderly: Making sense of troubling new findings. Cleveland Clinic Journal of Medicine 2000; 67: 574-576.
18. Francis GS. Can we prevent congestive heart failure? Clinical Cardiology. 2000, 23 (Suppl. IV) IV1-IV3.
19. Francis GS. Aldosterone inhibition and heart failure: too good to be true? Am Heart J 2001; 141: 1-2.
20. Francis GS. Diabetic cardiomyopathy: fact or fiction? Heart 2001; 85:247-248.. 50
Gary S. Francis, M.D. Curriculum Vitae
21. Tang WHW, Francis GS. Cardiovascular protection with ACE inhibitors – a clinician’s perspective. Medicographia 2001; 23: 3-5.
22. Francis GS, Gassler JP. What are the “tissue ACE inhibitors” and should they be used instead of other ACE inhibitors? Cleve Clinic J Med 2001; 68:185-186.
23. Acevedo M, Sprecher DL, Lauer MS, Francis GS. Routine statin treatment after acute coronary syndromes? Am Heart J 2002; 143: 940-942.
24. Francis GS, Tang WHW. ß-blockers and reverse remodeling – What are the implications? Am Heart J 2003; 145:200-202.
25. Tang WHW, Francis GS, Spironolactone in chronic heart failure: All’s well that ends well. J Am Coll Cardiol, 2003; 4:215-216.
26. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a crossroad: Are there limits to the neurohormonal model? J Am Coll Cardiol 2003; 41:1606-1610.
27. Francis GS. Cellular and subcellular basis for remodeling. J Cardiac Failure. 2002; 8:S450-S451.
28. Francis GS. Tang WHW. Vasopressin receptor antagonists. Will the “Vaptans” fulfill their promise? JAMA 2004; 291: 2017-2018.
29. Francis GS. It is an honor to serve (President’s Page). J Cardiac Failure 2005; 10:451.
30. Francis GS, Tang WHW. Should we consider aldosterone as the primary screening target for preventing cardiovascular events? J Am Coll Cardiol 2005; 45:1249-1250.
31. Tang WHW, Francis GS. The difficult task of how to monitor patients with heart failure. J Cardiac Failure. 2005; 6:422-424.
32. Tang WHW, Francis GS. The year in heart failure. J Am College of Cardiology 2005;46: 2125-2133.
33. Kanderian AS, Francis GS. Diagnosing cardiac ischemia in dialysis patients. Kidney International (mini review). 2006; 69:1112-1114.
34. Adams K, Lindenfeld J, Francis GS. Why another guideline? J Cardiac Failure (in press).
35. Henry TD, Atkins JM, Cunningham AS, Francis GS, Groh WJ, Hong RA, Kern KB, Larson DM, Ohman EM, Ornato JP, Peberdy MA, Rosenberg MJ, Weaver WD. Viewpoint: ST-segment elevation myocardial infarction: Recommendations on triage of patients to heart attack centers. Is it time for a national policy for the treatment of ST- segment elevation myocardial infarction? J Am Coll Cardiol 2006; 47:1399-1345.
36. Francis GS, Tang WHW. Histamine, mast cells, and heart failure: Is there a connection? J Am Coll Cardiology 2006; 48: 1385-1386..
37. Tang WHW, Francis GS. Cardiac resynchronization therapy in NYHA class IV heart failure: It’s all about selection. Circulation 2007; 115:161-162.
38. Tang WHW, Francis GS. The year in heart failure. J Am College of Cardiology.2006; 48:2575-2583.
51
Gary S. Francis, M.D. Curriculum Vitae
39. Francis GS, Kanderian AS. Anemia and heart failure: a new pathway? J Am Coll Cardiology 2007; 50: 1666-1667.
40. Tang WHW, Francis GS. Exploring new drugs for heart failure: The case of urocortin. European Heart J 2007; 28:2561-2562.
41. Tang WHW, Francis, GS. The year in heart failure. J Am Coll Cardiology 2007; 50:2344-2351.
42. Francis GS. In Memoriam-Edmund H. Sonnenblick, MD. J Cardiac Failure 2007; 13:697.
43. Francis GS. From BNP to green mambas – the process of discovery. J Am Coll Cardiology 2008; 52:69-70.
44. Tang WHW, Francis GS. The year in heart failure. J Am Coll Cardiol 2008; 52: 1671-1678.
45. Francis GS, Desai MY. Contractile reserve: are we beginning to understand it? J Am Coll Cardiol-Cardiovasc Imaging 2008; 1: 725-726.
46. Konstam M, Jessup M, Francis GS, Mann D, Greenberg B.. Advanced heart failure and transplant cardiology. J Cardiac Failure 2009; 15: 98-100.
47. Konstam M, Jessup M, Francis GS, Mann D, Greenberg B. Advanced heart failure and transplantation cardiology: a sub-specialty is born. J Am Coll Cardiology 2009; 53: 834-836.
48. Francis GS, Tang WHW. Early cardiac resynchronization therapy and reverse remodeling in patients with mild heart failure. Is it time? Circulation 2009; 120:1845 – 1846.
49. Tang WHW, Francis GS. The year in heart failure J Am Coll Cardiology 2010; 55: 688-696.
50. Francis GS. Editorship changes hands. J Cardiac Failure. 2010; 16:187.
51. Francis GS. Remembering Philip A Poole-Wilson, Helmut Drexler, and Kenneth L. Baughman. J Cardiac Failure. 2010; 16:453.
52. Francis GS. In praise of idleness. J Cardiac Failure 2011; 17:19.
53. Lew WY, Le Winter MM, Francis GS, Mann D. In Memoriam: Ralph Shabetai, MD. J Cardiac Failure 2011; 17:441- 442.
54. Francis GS. Where have all the clinical trials gone? J Cardiac Failure 2011; 17:701-702.
55. Francis GS. On being smart, J Cardiac Failure 2012; 18:89
56. Sarraf M, Francis GS. It Is All About the Heart Rate. Or Is It?* J Am Coll Cardiology 2012; 59: 1946-47
57. Francis GS. On Writing with Young People. J Cardiac Failure 2013;19:71-72.
58. Alpert JS, Francis GS. Practicing “check the box” medicine. Am J Med 2013; 126(12):1027-1028.
59. Hall JL, O’Connell T, Francis GS. Promising small molecule for heart failure targeting adrenal catecholamine release and B-adrenergic receptor signaling in the heart. J Am Coll Cardiol 2014; 63:2558-2559.
60. Francis GS, Cogswell R, Thenappan T: The heterogeneity of heart failure: will enhanced phenotyping be necessary for future clinical trial success? J Am Coll Cardiol 2014; 64:1775-1776. 52
Gary S. Francis, M.D. Curriculum Vitae
61. Francis GS, You’re always a doctor first! J Am Coll Cardiol 2015; 65:1149
62. Francis, GS, Thenappan T: β-blockers in heart failure – do we finally have the last word? Eur Heart J (retracted after primary paper was rejected-editorial error EHJ) – 2015
63. Francis, GS, Thenappan T: The end is near… do we know everything about cardiopulmonary exercise testing in HF patients? J Am Coll Cardiol 2016; 67(7):790-792
64. Francis GS. Cholesterol and heart failure: Is there an important connection? J Am Coll Cardiol 2017;70:2137-2138.
65. Francis GS, Alexy T. Furosemide reimagined. J Am Coll Cardiol-Heart Failure 2018;6:71-72.
66. Gottlieb S, Grabowsky T, Allen L, Kandel B, Apte J, Desai N, Ahmad T, Clark S, Psotka M, Lindenfeld J, Francis GS. The characteristics of out-patient use of intravenous milrinone in the United States. J Cardiac Failure 2019;25:S88-S89.
Review Papers: 141
1. Francis GS, Hagan AD. Nitroglycerin ointment: A review. Angiology 1977; 28:873-878.
2. Francis GS, Warren S. Nitroglycerin and nitrate esters: a review. Am J Med 1978; 65:53-62.
3. Asinger R, Rourke T, Hodges M, Sharma B, Francis GS. The role of echocardiography in emergencies. Minnesota Medicine 1979; 62:723-724.
4. Sunquist JM, Mikell FL, Francis GS, Hodges M. Right ventricular infarction: recognition, treatment, and nursing considerations. Heart and Lung 1980; 9:706-710.
5. Monson BK, Wickstrom PH, Haglin JJ, Francis GS, Comty CM, Helseth HK. Cardiac surgery and end-stage renal disease. Ann Thorac Surg 1980; 30:267-272.
6. Cohn JN, Franciosa JA, Francis GS. Nitroprusside infusion in acute myocardial infarction. Acta Med Scand 1981; (Suppl 652): 125-127.
7. Cohn JN, Levine TB, Francis GS, Goldsmith SR. Neurohumoral control mechanisms in congestive heart failure. Am Heart J 1981; 102:509-514.
8. Cohn JN, Mehta J, Francis GS. A review of the hemodynamic effects of labetalol in man. Br J Clin Pharmacol 1982; 13:19S.
9. Francis GS. Role of inotropic agents in the management of heart failure. In: Cohn JN, ed. Drug Treatment of Heart Failure. New York: Yorke Medical Books, 1983:125-149.
10. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Review. Ann Intern Med 1984; 101:370-377.
11. Francis GS. The role of the sympathetic nervous system, the renin-angiotensin system and arginine vasopressin in congestive heart failure. AHA Council on Clinical Cardiology Newsletter 1984; 10:1-8.
12. Francis GS. Neurohumoral mechanisms involved in congestive heart failure. Am J Cardiol 1985; 55:2:15A-21A.
53
Gary S. Francis, M.D. Curriculum Vitae
13. Francis GS. Plasma catecholamines in patients with congestive heart failure. Cardiovasc Rev Rep 1985; 6:444-454.
14. Francis GS, Cohn JN: The autonomic nervous system in congestive heart failure. In: Creger WP, ed. Annual Review of Medicine. Palo Alto: Annual Review, Inc., Vol. 37, 1986:235-247.
15. Francis GS. Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence, and prognosis. Am J Cardiol 1986; 57:3B-7B.
16. Francis GS. Clinical aspects of heart failure. Current Opinion in Card 1986;1:347-353.
17. Francis GS, Gornick C. Ventricular arrhythmias in patients with congestive heart failure. Cardio December 1986.
18. Francis GS. Current concepts in acute myocardial infarction. Acute Care Therapeutics 1987; 2:1-4.
19. Francis GS. Hemodynamic and neurohumoral responses to exercise: normal vs. heart disease. Circulation 1987; 76:(Suppl VI):VI-VII.
20. Francis GS. The survival hypothesis: How small uncontrolled trials should influence the design of large-scale clinical trials. Circulation 1987; 75(Suppl IV):75-79.
21. Francis GS. Therapeutic aspects of heart failure. Current Opinion in Cardiol 1987; 2:452-462.
22. Gornick CC, Almquist A, Benditt DG, Francis GS. A practical approach to diagnosis and initial management of cardiac dysrhythmias. Part I. Supraventricular tachycardia. Int Med 1987; 8:217-230.
23. Gornick CC, Almquist A, Benditt DG, Francis GS. A practical approach to diagnosis and initial management of cardiac dysrhythmias. Part II. Ventricular tachycardia. Int Med 1987; 9:224-232.
24. Francis GS. Vasodilators and congestive heart failure. Cardiovasc Rev Rep 1987; 8:46-49.
25. Francis GS. Neuroendocrine manifestations of congestive heart failure. Am J Cardiol 1988; 62:9A-13A.
26. Francis GS. Factors influencing survival in congestive heart failure. Osteopathic Annals 1988; 15:73-76.
27. Francis GS. Modulation of peripheral sympathetic transmission. J Am Coll Cardiol 1988;12:250-254.
28. Johnson TH, Francis GS. Electrolytes and arrhythmias in congestive heart failure. Prac Cardiol 1988; 14:79-83.
29. Francis GS. Extracardiac features of heart failure: Catecholamines and hormonal changes. Cardiology 1988;75 (Suppl I):19-29.
30. Francis GS, Ziesche SM. Congestive heart failure. Acute Care Therapeutics 1988; 3:1-12.
31. Francis GS. Practical therapeutics: The use of captopril in CHF. Int Med 1988; 9:143-154.
32. Francis GS. Neurohumoral aspects of heart failure. Current Opinion in Cardiol 1988; 3:331-335.
33. Cohn JN and the Veterans Administration Cooperative Study Group: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Eur Heart J 1988; 9(Suppl A):171-173.
34. Francis GS. The role of the sympathetic nervous system in heart failure. Masters in Cardiology 1989; 6:10-13.
54
Gary S. Francis, M.D. Curriculum Vitae
35. Francis GS, Johnson TH, Graven K. Acute cardiac pulmonary edema. Primary Cardiol 1989; 15:29-36.
36. Francis GS, Archer S. Management of congestive heart failure in the intensive and coronary care unit. J Int Care Med 1989;4:84-92.
37. Francis GS. Which drug for what patient with heart failure, and when? Cardiology 1989; 76:374-383.
38. Francis GS. Neuroendocrine mechanisms in heart failure. ACE Report 1989; 62:1-6.
39. Johnson TH, Francis GS. Influence of drug therapy on survival in patients with congestive heart failure. Practical Cardiology 1990; 16:37-51.
40. Francis GS. Sudden death and heart failure. Current Opinion in Cardiology 1990; 5:291-294.
41. Francis GS. Interaction of the sympathetic nervous system and electrolytes in heart failure. Am J Cardiol 1990;65:24-27E.
42. Francis GS, Cohn, JN. Heart failure: mechanism of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. Federation of American Societies for Experimental Biology (FASEB) 1990; 4:3068- 3075.
43. McDonald KM, Francis GS. Angiotensin converting enzyme inhibition and cardiac failure. ACE Report 1990; 69:1- 5.
44. Francis GS. Neuroendocrine activity in congestive heart failure. Am J Cardiol 1990; 66:33D-39D.
45. Cohn JN, Rajfer SI and Attendees: Evaluation of functional capacity in heart failure: a consensus conference. Heart Failure 1990; 6:169-173.
46. McDonald KM, Francis GS. Myocardial infarction with hypotension: Clinical problems in cardiopulmonary disease series. Chest 1991; 99:1012-1025.
47. Francis GS. Congestive heart failure in 1991. Cardiology 1991; 78:81-94.
48. McDonald KM, Francis GS. Syndromes of acute left ventricular failure. J Int Care Med 1991;6:1-11.
49. Francis GS. Vasodilators in the intensive care unit. Am Heart J 1991;121:1875-1878.
50. McDonald KM, Francis GS. The role of vasodilators in heart failure. Internal Medicine 1992;13:39-47.
51. Parmley WW, Chatterjee K, Francis GS, Firth BG, Kloner RA. Congestive heart failure. New frontiers. West J Med 1991;154(4):427-441.
52. Pitt B, Cohn JN, Francis GS, Kostis JB, Packer M, Pfeffer M, Swedberg K, Yusuf S. The effect of treatment on survival in congestive heart failure. Clinical Cardiology 1992;15:323-329.
53. Francis GS, McDonald KM. Left ventricular hypertrophy: An initial response to myocardial injury. Am J Cardiol 1992;69:3G-9G.
54. McDonald KM, Francis GS. Epidemiology of congestive heart failure and results of recent clinical trials. Current Opinion in Cardiology 1992;7:397-403.
55
Gary S. Francis, M.D. Curriculum Vitae
55. McDonald KM, Francis GS. Recent advances in the use of ACE inhibitors. Contemp Int Med 1992;September:35- 46.
56. Garr MD, McDonald KM, Francis GS. Neurohumoral activation and its relationship to the early stages of left ventricular dysfunction. Heart Failure 1992;8:167-176.
57. Toher CA, Francis GS. The use of angiotensin-converting enzyme inhibitors in the treatment and prevention of congestive heart failure. Coronary Artery Disease 1993; 4:37-43.
58. Francis GS. Management of congestive heart failure. ACC Learning Center Highlights 1993; 8:1-6.
59. Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in pre-clinical heart failure: remodeling and the potential of intervention. Circulation 1993;87:IV-90-IV-96.
60. Francis GS. Pharmacological treatment of congestive heart failure: standard drugs. Current Opinion in Cardiology 1993;8:404-410.
61. Francis GS. Neuroendocrine activation in left ventricular dysfunction. ACE Report 1992.
62. Francis GS. What is your approach to ventricular arrhythmias in patients with congestive heart failure? Choices in Cardiology 1993; 7:204-206.
63. Francis GS. Neurohormones in congestive heart failure. Cardiol Rev 1993; 1:5, 1-12.
64. Francis GS. Survival trials in congestive heart failure. Canadian Journal of Cardiology 1993;9(Suppl F):44F-48F.
65. Francis GS, Carlyle WC. Hypothetical pathways of cardiac myocyte hypertrophy: response to myocardial injury. European Heart Journal 1993;14:49-56.
66. Francis GS, Chu C. Compensatory and maladaptive responses to cardiac dysfunction. Current Opinion in Cardiology 1994;9:280-288.
67. Francis GS. Determinants of prognosis in patients with heart failure. J Heart Lung Transplantation 1994;13:S1-13- S1-16.
68. Francis GS. Vasodilators and inotropic agents in the treatment of congestive heart failure. Seminars in Nephrology 1994;14:464-478.
69. Francis GS, McDonald K, Chu C, Cohn JN. Pathophysiological aspects of end-stage heart failure. Am J Cardiol 1995;75:11A-16A.
70. Francis GS. Receptor systems involved in norepinephrine release in heart failure - focus on dopaminergic receptors. Clinical Cardiology 1995;18(Suppl I):I-13-I-16.
71. Francis GS. Review in Depth: ACE inhibitors in the treatment of congestive heart failure. Overview. Guest Editor. Coronary Artery Disease 1995;6:269-271.
72. Francis GS, Chu C. Compensatory and maladaptive responses to cardiac dysfunction. Current Opinion in Cardiology 1995;10:260-267.
73. Francis GS. Viral myocarditis. The Physician and Sports Medicine 1995;23:2-8.
56
Gary S. Francis, M.D. Curriculum Vitae
74. Cohn JN, Francis GS. Cardiac failure: a revised paradigm. J Cardiac Failure 1995;1:261-266.
75. Francis GS. The role of ACE inhibitors in preventing myocardial infarction: potential mechanisms and clinical implications. European Heart J 1995;16(Suppl K):1-3. Suppl. Editor.
76. Francis GS, Chu C. Post-infarction myocardial remodeling: Why does it happen? European Heart J 1995;16(Suppl N):31-36.
77. Francis GS. Ten questions physicians often ask about congestive heart failure. Consultant 1996;36:1436-1443.
78. Francis GS. Left ventricular dysfunction: diagnostic aspects and prognostic implications. Cardiologia 1995;40(Suppl 1):1-6.
79. Arnow WS, DiBianco R, Francis GS. Treatment priorities for heart failure. Patient Care. May 30, 1998. pp 68-95.
80. Baig MK, Mahon N, McKenna WJ, Caforio ALP, Bonow RO, Francis GS, Gheorghiade M. The pathophysiology of advanced heart failure. Am Heart J 1998;135:S216-S230.
81. Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medial therapy for advanced heart failure. Am Heart J 1998;135:S231-248.
82. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J 1998;135:S293-S309.
83. Francis GS. Changing the remodeling process in heart failure: basic mechanisms and laboratory results. Current Opinion in Cardiol 1998;13:156-161.
84. Francis GS. Emerging data from heart failure trials. Can J Cardiol 1998;14(Suppl D): 27D-29D.
85. Francis GS. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. J Cardiovasc Pharmacol 1998;32:S16-S21.
86. Van Velhuisen DJ, Van Gilst WH, Francis GS. Current insights and new treatment options in heart failure. J Cardiovasc Pharmacol 1998;32:Suppl 1:v-vi
87. Francis GS. What has been and can be achieved by pharmacological manipulation of neuroendocrine responses? Dialogues in Cardiovasc Med 1999; 4: 88-91.
88. Robbins M, Reginelli JP, Francis GS. Adjunctive medical therapy in the setting of acute coronary syndromes. Clev Clin J Med 2000; 67: 205-213.
89. Francis GS, Gassler JP. Surgical management options in chronic congestive heart failure. Up to Date in Cardiovascular Medicine. Phillip Podrid, M.D. (Editor). On Line Journal. 1999.
90. Baig MK, Mahon N, McKenna WJ, Caforio AL, Bonow RO, Francis GS. Gheorghiade M The pathophysiology of advanced heart failure. Heart and Lung. 1999; 28:87-99.
91. Francis GS, Lewis W, Parmley W, Weart CW. Beta blockers and ACE inhibitors: new data, old myths. Patient Care. July 15, 2000; 62-84.
92. Aikat S, Francis GS. Trastuzumab therapy and the heart: palliation at what cost? Congestive Heart Failure. 2001; 7: 188-190. 57
Gary S. Francis, M.D. Curriculum Vitae
93. Tang WHW, Francis GS. Cardiovascular protection with ACE inhibitors: a clinician’s perspective. Medicographia 2001; 23(1): 3-8.
94. Francis GS. Pathophysiology of chronic heart failure. Am J Med (Suppl 1A)2001, 110:37S-46S.
95. Francis GS. Evolution of disease progression in heart failure. In: Lewis RP, ed.ACCSAP V; Bethesda Md.: American College of Cardiology, 2002. Chapter 5 Syllabus. P. 5.8 - 5.14.
96. Francis GS. Nuggets, Pearls and Vignettes of Master CHF Clinicians . Congestive Heart Failure. Part 4. March/April 2002. 98-124.
97. Penn MS, Francis GS, Ellis SG, Young JB, McCarthy PM, Topol EJ. Autologous cell transplantation for the treatment of damaged myocardium .Prog in Cardiovasc Dis 2002; 44: 21-32.
98. Tang WHW, Francis GS. Chronic heart failure: 10 questions physicians often ask.Consultant. 2002; 42.678-686.
99. Jneid H, Bhatt DL, Corti R, Badiman JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Int Med. 2003; 163: 1145-1153.
100. Francis GS, Tang WHW. Pathophysiology of congestive heart failure. Reviews in Cardiovascular Medicine. 2003; 4 (Suppl 2): S14-S20.
101. Cowie MR, Joardain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis GS. Clinical applications of B-type natriuretic peptide (BNP) testing. European Heart J 2003; 24: 1710-1718.
102. Tang WHW, Francis GS. Trends and treatment of heart failure developing after acute myocardial infarction. Am Heart Hosp J, 2003; 1:216-218.
103. Maroo A, Tang WHW, Francis GS. Coronary revascularization for treatment of heart failure: optimal patient selection. American College of Cardiology Current Journal Review 2004; Feb.:35-39.
104. Tang WHW, Francis GS. Novel pharmacological treatments for heart failure. Expert Opinion in Invest. Drugs. 2003; 12 (11); 1791-1801.
105. Tang WHW, Militello, M, Francis, GS. In heart failure, all beta-blockers are not necessarily equal. Cleve Clin J Med 2003; 70:1081-1087.
106. Tang WHW, Francis GS. Evolving concepts in left ventricular systolic and diastolic remodeling: implications for therapy. Current Cardiology Reports 2004;6: 200-204.
107. Gring CN, Francis GS. Viewpoint. A hard look at ARBs in heart failure. J Am Coll Cardiol 2004;44:1841-1846.
108. Francis GS. Acute heart failure: patient management of a growing epidemic. Am Heart Hosp J 2004:2(4 suppl 1):10- 14.
109. Francis GS, Tang WHW. Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Prog in Cardiovasc Dis 2004;47: 196-206.
110. Tang WH, Francis GS. Plasma B-type natriuretic peptide in chronic heart failure. Cardiology Review 2004;21:41-43.
58
Gary S. Francis, M.D. Curriculum Vitae
111. Pocock S, Wilhelmsen L, Dickstein K, Francis G, Wittles J. The data monitoring experience in the MOXCON trial. European Heart J 2004; 25: 1974-1978.
112. Tang WH, Francis GS. Neurohumoral upregulation in heart failure. Heart Failure Clin North Am 2005;1:1.
113. Tang WH, Bhavnani S, Francis GS. Vasopressin antagonists in heart failure. Expert Opin Investig Drugs 2005;14 (5):1-8.
114. Feldman AM, Silver MA, Francis GS, DeLame P-A, Parmley WW. Treating heart failure with enhanced external counterpulsation (EECP): design of prospective evaluation of EECP in heart failure (PEECH) Trial. J Cardiac Failure 2005;11:240-245.
115. Tang WHW, Philip K, Hazen SL, Stevenson CE, Pepay M, Neale S, Francis GS. Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure. Clinical Cornerstone 2005;7[suppl 1]:S18-S24.
116. Tang WHW, Parameswaran AC, Maroo A, Francis GS. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clinic Proceedings 2005;80:1623-1630.
117. Georgehiade M, DeLuca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96 [suppl]: 11G-17G.
118. Francis GS. Acute decompensated heart failure: the cardiorenal syndrome. Cleve Clinic Med J 2006;73 [suppl 2]; S9- S13.
119. Francis GS, Tang WHW. Autonomic Biology: from beheaded animals to a spate of Nobel prizes. Dialogues in Cardiovascular Medicine. 2006;11:133-140.
120. Gottlieb SS, Mann DL, Francis GS. Highlights of the 2006 Scientific Sessions of the Heart Failure Society of America. J Am Coll Cardiol 2007; 49: 608-615.
121. Kalidindi SR, Tang WHW, Francis GS. Drug insight: aldosterone-receptor antagonists in heart failure-the journey continues. Nature Clinical Practice-Cardiovascular Medicine. 2007;4:368-378.
122. Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. Am J Med 2007; 120:1090e.
123. Francis GS. The contemporary use of digoxin for the treatment of heart failure. Circulation-Heart Failure (Masters Series). 2008; 1:208-209.
124. Kumar P, Francis GS, Tang WHW. Phosphodiesterase-5 inhibition in heart failure: mechanisms and clinical implications. Nat Rev Cardiol 2009; 6:349-355, 2009.
125. Senter S, Francis GS. A new, precise definition of acute myocardial infarction. Cleve Clin J Med 2009; 76: 159-166.
126. Thomas S, Boyle AJ, Francis GS. Optimizing clinical outcomes in acute decompensated heart failure. U.S. Cardiology. 2009; 6: 50 – 54.
127. Tang WH, Francis GS. Statin treatment for patients with heart failure. Nat Rev Cardiol 2010; 7:249-55.
59
Gary S. Francis, M.D. Curriculum Vitae
128. Tang WHW, Francis GS. Should cardiac resynchronization therapy be used in patients with class I-II heart failure with a wide QRS? Cardiac resynchronization therapy in patients with class I-II heart failure and a wide QRS. Circulation 2011: 123; 203-208.
129. Kamouh A, Francis GS. Contemporary management and research directions in advance heart failure: Where are we going? Congestive Heart Failure 2011; Sept-Oct: 241-247.
130. Francis GS. Neurohormonal control of heart failure. Cleveland Clinic Journ Med 2011: 78; Suppl. 1l S75-S-79.
131. Aponte MMP, Francis GS. Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in Atherosclerosis Prevention. Curr Cardiol Rep 2012:14;433-442.
132. Dickinson O, Chen LY, Francis GS. Atrial fibrillation and heart failure: Intersecting populations, morbidities and mortality. Heart Failure Reviews 2014; 19:285-293.
133. Bartos JA, Francis GS. The high-risk patient with heart failure with reduced ejection fraction. Clin Pharmacol Ther 2013; 94:509-518.
134. Francis GS, Bartos JA, Adatya S. Inotropes: State-of-the-Art. J Am College Cardiol 2014; 63:2069-2078.
135. Francis GS, Tang WH, Felker GM: A Test in Context: Critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol 2016; 67:330-337.
136. Chirakarnjanakorn S, Navaneethan SD, Francis GS, Tang WHW. Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. International Journal of Cardiology 2017;232:12-23.
137. Psotka MA, Gottlieb SS, Francis GS, Allen LA, Teerlink JR, Adams Jr. KF, Rosano GMC, Lancelloti P. Cardiac calcitropes, myotropes and mitotropes. J Am Coll Cardiol 2019;73:2345-2353.
138. Agdamag ACC, Edmiston JB, Charpentier V, Chowdury M , Fraser M, Maharaj VR, Francis GS, Alexy T. Update on COVID-19 myocarditis. Medicina (Kaunas) 2020; 56:678.
139. Agdamag ACC, Maharaj VR, Fraser M, Edmiston JB, Charpentier V, Francis GS, Alexy T. PCSK9 inhibitors and their use in advanced heart failure and heart transplant recipients. Vessel Plus 2020;4:22.
140. Chowdhury M, Majaraj VR, Francis GS, Alexy T, Fraser M. COVID cardiomyopathy: Is it time to involve the cardiologists? Indian J Med Res 2020;152:169-171.
141. Fraser M, Mutschler M, Newman C, Sackman K, Mehdi B, Duval S, Francis GS, Alexy T. Heart failure care delivery in the COVID-19 era: The patients’ perspective. Healthcare 2021;9:245.
Books Edited or Co-Edited: 23
1. Alpert JS, Francis GS. The CCU Manual. Boston: Little Brown and Company, 1977.
2. Alpert JS, Francis GS. Manual of Coronary Care. Japanese edition. Tokyo: Igaku-Shoin, Ltd, 1978.
3. Alpert JS, Francis GS. Manual De Cuidados Coronarios. Spanish edition. Barcelona: Salvat Editores, S.A., 1979.
4. Alpert JS, Francis GS. The CCU Manual. Boston: Little Brown and Company, 2nd edition, 1980.
60
Gary S. Francis, M.D. Curriculum Vitae
5. Alpert JS, Francis GS. Der akute Myokardinfarkt. German edition. New York: George Thieme Vrlag, Stuttgart, 1982.
6. Alpert JS, Francis GS. The CCU Manual. Boston: Little Brown and Company, 3rd edition, 1984.
7. Alpert JS, Francis GS. The CCU Manual. Boston: Little Brown and Company, 4th edition, 1987.
8. Francis GS, Alpert JS (editors). Modern Coronary Care. Boston: Little Brown and Company, 1990:1-797.
9. Alpert JS, Francis GS. Handbook of Coronary Care. Boston: Little Brown and Company. Fifth Edition, 1993; pp. 1-198.
10. Pouleur H, Barnett D, Francis GS. Editors. Congestive Cardiac Failure. New York, Basel, Hong Kong; Marcel Dekker. 1993; pp. 1-373.
11. Campbell R, Ball S, Francis GS (Eds): International Handbook on Heart Failure. Euromed Communications Ltd., Frankfurt 1994;1-86.
12. Francis GS, Alpert JS (Editors). Coronary Care. 2nd Edition. Boston;Little, Brown and Company, pp. 3-804, 1995.
13. Ball SG, Campbell RFW, Francis GS (Eds): International Handbook of Heart Failure. Second Edition. Euromed Communications Ltd., Frankfurt 1997;1-88.
14. Campbell RFW, Francis GS (Eds): International Handbook of Hypertension. Euromed Communications Ltd., Frankfort, 1997; 1-103.
15. Alpert JS, Francis GS. Handbook of Coronary Care. 6th Edition. Lippincott Williams & Wilkins, 2000: pp 1-222.
16. Kitabatake A, Sasayama S. Francis GS(eds). Heart Failure. Tokyo: Springer-Verlag, 2000: pp 1-261.
17. Alpert JS, Aurigemma GP, Balady GJ, Chaitman BR, Crawford MH, Epstein AE, Francis GS, Gersony WM, Harrington RA, Wenger NK. The AHA clinical cardiac consult. Philadelphia: Lippincott Williams & Wilkins; 2001: pp 1-311.
18. Nixon JV, Aurigemma GP, Bolger AF, Chaitman BR, Crawford MH, Fletcher GF, Francis GS, Gersony WM, Harrington RA, Ott P, Wenger NK, Alpert JS. The AHA clinical cardiac consult. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001: pp 1-311, 2007: pp 1-379, 2011: pp 1-361.
19. Nixon JV, Aurigemma GP, Bolger AF, Crawford MH, Fletcher GF, Francis GS, Gerber TC, Gersony WM, Ott P, Pape LA, Wenger NK. The AHA clinical cardiac consult. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2011: pp 1-361.
20. Nixon JV, Aurigemma GP, Bolger AF, Crawford MH, Fletcher GF, Francis GS, Gerber TC, Gersony WM, Ott P, Pape LA, Wenger NK. The AHA clinical cardiac consult. 3rd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010: pp 1- 361.
21. Shishehbor MH, Wang TH, Askari AT, Penn MS, Topol EJ. Management of the Patient in the Coronary Care Unit. Francis GS. Section Editor: Acute Decompensated Heart Failure. Philadelphia, PA. Wolters Kluwer/Lippincott Williams and Wilkins. 2008: pp 1-336.
22. Cohn JN, Francis GS, Eds. Stage B, a Pre-Cursor of Heart Failure, Part 1. Philadelphia PA. W.B. Saunders Co. Elsevier Inc. 2012. pp. 1-168. 61
Gary S. Francis, M.D. Curriculum Vitae
23. Cohn JN, Francis GS, Eds. Stage B, a Pre-Cursor of Heart Failure, Part II. Philadelphia PA. W.B. Saunders Co. Elsevier Inc. 2012. pp. 1-300.
Book Chapters: 114
1. Griffin F, Francis GS. Salmonellosis (other than typhoid fever). In: Conn EF, ed. Current Therapy. Philadelphia; WB Saunders, 1973.
2. Cohn JN, Levine TB, Francis GS. Responses of the sympathetic and renin angiotensin systems in congestive heart failure. In: Goodwin JF, Hjalmarson A, Olsen EGJ, eds. Congestive Cardiomyopathy. Molndal, Sweden: AB Hassle, 1981;319-322.
3. Francis GS, Comty CM, Sharma B, Helseth HK. Myocardial revascularization in chronic renal disease patients. In: Love JW, ed. Cardiac Surgery In Patients with Chronic Renal Disease. Mount Kisco, New York: Futura Publishing Company, 1982;115-133.
4. Cohn JN, Francis GS. Problems in clinical evaluation. In: Braunwald E, Mock MB, Watson J, eds. Congestive Heart Failure - Current Research and Clinical Applications. Grune and Statton, 1982; 367-376.
5. Francis GS, Cohn JN. Angina pectoris and chronic congestive heart failure: Pathophysiology and therapy. In: Antonaccio MJ, Ed. Cardiovascular Pharmacology, 2nd edition. New York: Raven Press, 1984; 295-327.
6. Francis GS, Cohn JN. Vasoactive drugs and the failing ventricle. In: Levine HJ, Gaasch W, eds. The Ventricle. Boston: Martinus Nijhoff, 1985;315-336.
7. Francis GS, Cohn JN: Afterload reduction. In: Maronde RF, ed. Clinical Pharmacology and Therapeutics. New York: Springer-Verlag, 1985;135-150.
8. Francis GS, Goldsmith SR. Adaptive neurohumoral mechanisms in dilated cardiomyopathy. In: O’Connell JB, Engelmeier RS, eds. Drug Therapy of Dilated Cardiomyopathy and Myocarditis. New York: Marcel Decker, Inc., 1988; 23-48.
9. Francis GS, Pierpont GL. Pathophysiology of congestive heart failure secondary to congestive and ischemic cardiomyopathy. In: Brest AN, Shaver JA, eds. Cardiomyopathy. Cardiovascular clinics. Philadelphia: F.A. Davis, 1988; 57-74.
10. Francis GS. New inotropic agents in the management of heart failure. In: Cohn JN, ed. Drug Treatment of Heart Failure. 2nd Edition. New York: York Medical Books, 1988;179-198.
11. Cohn JN and V.A. Cooperative Study Group: Treatment of congestive heart failure in acute myocardial infarction. In: Higgins MW, Lupker RV. Trends in Coronary Heart Disease Mortality. The Influence of Medical Care. New York: Oxford University Press, 1988;185-189.
12. Francis GS. Acute pulmonary edema. In: Rowlands DJ, ed. Emergency Cardiology. London: Wright, 1989; 63-69.
13. Francis GS. Routine management of acute myocardial infarction. In: Francis GS, Alpert JS, eds. Modern Coronary Care. Boston: Little, Brown and Company, 1990; 123-139.
14. Francis GS. Dobutamine in chronic congestive heart failure. In: Chatterjee K, ed. Dobutamine: a Ten Year Review. NMC Publishers, Inc., 1989; 97-108.
62
Gary S. Francis, M.D. Curriculum Vitae
15. Francis GS, Cohn JN. Congestive heart failure: Pathophysiology and therapy. In: Antonaccio MJ, ed. Cardiovascular Pharmacology, 3rd Edition. New York: Raven Press, 1990; 341-367.
16. Francis GS. The use of digitalis in the long-term treatment of cardiac insufficiency. IN: Iriate MM and Gorostiza JD, eds. Chronic Cardiac Insufficiency. Barcelona: Editorial MCR, 1989; 277-285.
17. Shah PK, Francis GS. Cardiogenic shock, mitral regurgitation, right ventricular infarct and ruptured myocardium in acute myocardial infarction. In: Francis GS, Alpert JS, eds. Modern Coronary Care. Boston: Little, Brown and Company, 1990; 295-331.
18. Boosalis PJ, Johnson TH, Francis GS. Congestive heart failure. In: Taylor RB, (ed). Difficult Medical Management. New York: W.B. Saunders Co, 1990; 161-169.
19. Francis GS, Goldsmith SR. Therapy of cardiovascular disorders - congestive heart failure. IN: Melmon KL, Morrelli HF, Hoffman B, Nierenberg DW, eds. Clinical Pharmacology Basic Principles in Therapeutics, 3rd Edition. New York: MacMillan 1992; 104-131.
20. Francis GS, Donat WE, Weinger BH. Syndromes of left ventricular failure. IN: Rippe JM, Irwin RS, Alpert JS, Fink MP eds. Intensive Care Medicine, 2nd Edition. Boston: Little Brown and Co., 1991; 391-406.
21. Francis GS. Vasodilators: A re-evaluation of their role in heart failure. In: Advances in diagnosis and treatment of chronic congestive heart failure: MM Iriarte, Ed. VR Prous, Barcelona, Spain, 1990; 199-212.
22. Francis GS. Neurohormonal interactions in cardiovascular disease. In: Ganguly PK, ed. Catecholamines and Heart Disease. Boca Raton: CRC Press, 1991; 87-102.
23. McDonald KM, Francis GS. Medical management and review of clinical trials in heart failure. In: Cortina A, (ed). Congestive Cardiac Failure. Oviedo, Spain, Prous Science 1992; 81-101.
24. Francis GS, Cohn JN. Cardiac failure and the autonomic nervous system. In: R. Bannister, ed. Autonomic Failure: A textbook of clinical disorders of the autonomic nervous system, 3rd edition. Oxford University Press, 1992; 822- 838.
25. Francis GS, McDonald KM. Overview of survival studies in left ventricular dysfunction. In: The Clinician’s Guide to ACE Inhibition. Cleland J (ed). Churchill Livingston, Inc., 1993; 150-163.
26. McDonald KM, Francis GS. Pathophysiology of heart failure: neuroendocrine factors. In: Pouleur H, Barnett D, Francis GS, eds. Congestive Cardiac Failure. New York, Basel, Hong Kong; Marcel Dekker, 1993; 49-70.
27. Barnett DB, Pouleur H, Francis GS. The changing face of heart failure: In: Barnett DB, Pouleur H, Francis GS. Congestive Cardiac Failure. New York, Basel, Hong Kong. Marcel Dekker, 1993; 1-8.
28. Francis GS, McDonald KM. Heart Failure: Current perspective of mechanisms, physiologic derangements and therapeutics. In: Cardiovascular pharmacology and therapeutics. Singh BN, Dzau VJ, Vanhoutte P, Woosley RL, (Eds). Churchill Livingstone, Inc., 1993; 765-778.
29. Francis GS. Routine management of acute myocardial infarction. In: Francis GS, Alpert JS, eds. Coronary Care. 2nd Edition. Boston; Little, Brown and Company, 123-140; 1995.
30. Francis GS. Unstable angina. In: Francis GS, Alpert JS, eds. Modern Coronary Care. 2nd Edition. Boston; Little, Brown and Company, 351-359; 1995.
63
Gary S. Francis, M.D. Curriculum Vitae
31. Pitt B, Francis GS. Percutaneous transluminal coronary angioplasty in acute myocardial infarction. In: Francis GS, Alpert JS, eds. Modern Coronary Care. 2nd Edition. Boston; Little, Brown and Company, 405-407; 1995.
32. Shah PK, Francis GS. Pump failure, shock, and cardiac rupture in acute myocardial infarction. In: Francis GS, Alpert JS, eds. Coronary Care. 2nd Edition. Boston; Little, Brown and Company, 289-324; 1995.
33. Francis GS, McDonald KM. Neurohumoral mechanisms in heart failure. In: McCall D, Rahimtoola SH, eds. Heart Failure. New York; Chapman and Hall, 90-116; 1995.
34. Francis GS, McDonald K, Cohn JN. Pharmacologic interventions in experimental remodeling: angiotensin converting enzyme inhibitors and angiotensin II subtype I receptor blockers. IN: Dhalla NS, Beamish RE, Takeda N, Nagano M, eds. The Failing Heart. Lippincott-Raven, 247-252; 1995.
35. Toher CA, Francis GS. The use of angiotensin converting enzymes in the treatment and prevention of congestive heart failure. In: Messerli F, ed. Cardiovascular Drug Therapy. 2nd Edition. Philadelphia; W.B. Saunders, 11-717, 1996.
36. Francis GS. Congestive heart failure: Inotropic agents. In: Parrillo JE, ed. Current Therapy in Critical Care Medicine. 3rd Edition. St. Louis; Mosby, 116-121; 1997.
37. Francis GS. Vasoactive hormone systems. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS, eds. Heart Failure. Scientific Principles and Clinical Practice. New York; Churchill Livingstone, 215-234; 1997.
38. Francis GS. Hypertension associated with stroke. In: Campbell RWF, Francis GS, eds. International Handbook of Hypertension. London. Euromed Communications, Ltd, 53-57; 1997.
39. Francis GS. The renin-angiotensin system. In: Parmley WW, Chatterjee K, eds. Cardiology. Lippincott-Raven, Philadelphia, New York, Vol 1. 1-16; 1997.
40. Francis GS. Neurohumoral responses to exercise in heart failure. In: Balady GJ, Pena IL, eds. Exercise and Heart Failure. AHA Monograph Series. Futura Publishing Co. Armonk, N.Y., 85-95; 1997.
41. Francis GS. Pathophysiology of the heart failure syndrome. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Lippincott-Raven, Philadelphia, New York, 2179-2303; 1998.
42. Francis GS. Congestive heart failure. In: Rakel R.E., ed. Conn’s Current Therapy. W.B. Saunders Co., Philadelphia, 292-296; 1998.
43. Francis GS. Congestive heart failure. In: Stein’s Internal Medicine. 5th Edition. Mosby, St. Louis, 156-175; 1998.
44. Francis GS. Approach to the patient with severe heart failure. In: Rose EA, Stevenson LW, eds. Management of End-Stage Heart Disease. Lippincott-Raven, Philadelphia, New York, 39-52; 1998.
45. Francis GS. Cardiac complications in the intensive care unit. In: Clinics in Chest Medicine. W.B. Saunders Co., Philadelphia, 269-285; 1999.
46. Francis GS, Cohn JN. Cardiac Failure and the Autonomic Nervous System. In: Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Eds. Bannister R, Mathias CJ. 4th Edition. Oxford Univ. Press. 477-486, 1999.
47. Francis GS, Gassler JP, Sonnenblick EH: Pathophysiology and Diagnosis of Heart Failure. In: Fuster V, ed. Tenth Edition of Hurst’s The Heart. McGraw-Hill. 655-685, 2001. 64
Gary S. Francis, M.D. Curriculum Vitae
48. Francis GS: SCD-HeFT: Critique. In: Woosley RL and Singh SN, eds. Arrhythmia Treatment and Therapy. Evaluation of Clinical Trial Evidence. Marcel Decker. New York, Basal, 343-349, 2000.
49. Francis GS. Neurohormones in Advanced Heart Failure. In: Kitabatake A, Sasyama S, eds. Heart Failure. Springer-Verlag; Tokyo, 3-23, 2000.
50. Francis GS, Bhatt, D. The AHA Clinical Cardiac Consult Ed. J.S. Alpert. Lippincott Williams & Wilkins. Philadelphia; Associate Editor. Pp1-311. 2001.
51. Tang, WHW, Francis GS. Polypharmacy of Heart Failure: Creating a Rational Pharmacotherapeutic Protocol. In: Young JB. Cardiology Clinics 2001; 19 (4):583-596.
52. Francis GS, Pathak A. Congestive heart failure due to systolic dysfunction. In: Crawford MH, DiMarco JP, eds. Cardiology. Mosby. London. 4.1-4.10, 2001.
53. Tang WHW, Francis GS. Natural history of heart failure. In: Oxidative Stress and Heart Failure. Eds. M. Kukin and V. Fuster, Armonk, New York: Futura pp 3-47, 2003.
54. Francis, GS, Young JB. The looming polypharmacy crisis in the management of patients with heart failure: potential solutions. In: Young JB: Cardiology Clinics 2001; 19(4) 541-545.
55. Francis GS, Tang WHW. Clinical evaluation of heart failure. In: D. Mann, ed. Heart Failure: A Companion to Braunwalds’ Heart Disease. W.B. Saunders, Philadelphia, pp 507-526, 2004.
56. Francis GS. Pathophysiology of the heart failure clinical syndrome. In: Topol EJ, Textbook of Cardiovascular Medicine. Lippincott-Raven, Philadelphia, New York 2nd Edition 1785-1802, 2002.
57. Francis GS. End-of-Life Care: In: Topol EJ, Ed. Textbook of Cardiovascular Medicine. Lippincott-Raven, Philadelphia, New York. 2nd Edition, pp 753-761, 2002.
58. Francis GS, Militello M: Cardiovascular Drug Therapy. In: Roffi M, Meier B, Topol E: Handheld Cardiovascular Medicine. CD 2004.
59. Francis GS, Tang W. Heart Failure due to systolic dysfunction. In Crawford MH, DiMarco JP, Paulus WJ. eds. Cardiology. Mosby. London. 2nd Edition, pp.869-877, 2004.
60. Francis GS, Tang WHW. Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone receptor blockers. In: Van Veldhuisen D, Pitt B, eds. Chronic Heart Failure. 9-27, 2002.
61. Francis GS, Tang WHW. Angiotensin – converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone receptor blockers. In: Manson JA, Buring J, Ridker P, Graziano M, eds. Clinical Trials in Heart Disease. A companion to Braunwald’s Heart Disease. W.B. Saunders 227-241, 2004.
62. Militello MA, Francis GS. Cardiovascular Drug Therapy. In: Roffi M, Meier B, Topol EJ,eds. CVM stat: A comprehensive handheld-based approach to cardiovascular medicine. Little Rock: Handheldmed, Inc. Chapt 19. 2004.
63. Tang WHW, Francis GS. Novel therapies in heart failure. In: McCarthy PM and Young JB, eds. Heart Failure: A combined Medical and Surgical Approach. Blackwell. Malden, MA pp 44-68, 2007.
64. Francis GS, Tang WHW, Sonnenblick EH. Pathophysiology and Diagnosis of Heart Failure. In: Fuster V, ed. Eleventh Edition of Hurst’s The Heart 697-721, 2004. 65
Gary S. Francis, M.D. Curriculum Vitae
65. Tang WHW, Francis GS. B-type natriuretic peptides in acute coronary syndromes. In: Topol EJ, ed. Third Edition. Acute Coronary Syndromes. Marcel Dekker. 309-323, 2004.
66. Francis GS, Tang WH. Natural history of cardiac remodeling. In: Greenberg B, ed. Myocardial Remodeling: Mechanisms and Treatment. Chapt. 16. Taylor and Francis, New York. 285-301, 2006.
67. Francis GS, Tang WHW, Adams KF Jr. Pathophysiology of the spectrum of acute heart failure: de novo heart failure, decompensated heart failure and advanced refractory heart failure. In: O’Conner CM, Stough WG, Gheorhiade M, Adams KF Jr., Eds. 1st Edition. Managing Acute Decompensated Heart Failure. Taylor and Francis. London. 87-93, 2005.
68. Pocock S, Wilhelmsen L, Dickstein K, Francis GS, Wittes J. Data monitoring experience in the Moxonidine Congestive Heart Failure Trial. In: DeMets DL, Furberg CD, Friedman LM, Eds. Data Monitoring in Clinical Trials. Springer. New York, N.Y. 260-268, 2005.
69. Francis GS, Kanderian AS. ACE inhibitors for prevention of cardiovascular events.In: Topol EJ, Ed. Textbook of Cardiovascular Medicine. WKH-Lippincott Williams and Wilkins. Updates. Vol. 8, Number 6, pp 1-12, 2005.
70. Francis GS, Kanderian AS. Pathophysiology: Neurohormonal and remodeling mechanisms. In: Adams KF, Ed. Chronic Heart Failure. Martin Dunitz (in press).
71. Kanderian AS, Bargava AJ, Francis GS. General treatment of diastolic heart failure. In: Klein AC and Garcia MJ, eds. Diastolic Heart Failure. Elsevier. Saunders, Philadelphia, PA. pp 415-427, 2008.
72. Freda BJ, Francis GS. Natriuretic peptides and renal insufficiency. Clinical significance and role of renal clearance. In: Burnett J, Mills RM, Tang WH, eds. Heart Failure Clinics of North America. 2 (2006), 277-290. Elsevier Saunders. Young JB, Narula J, Eds.
73. Kanderian AS, Francis GS. Pathophysiology of Congestive Heart Failure. In: Griffin PB, Rimmerman C, Topol EJ, eds. The Cleveland Clinic Cardiovascular Review Book. 3rd Edition. Lippincott, Williams and Wilkins, Philadelphia . Chapt.28, 2007; 317-324.
74. Francis GS, WHW Tang. Management of Acute and Decompensated Heart Failure. In: Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure. 3rd Edition. Lippincott Williams & Wilkins. Chapter 34, 2006; 602-619.
75. Francis, GS, Laveglia J. End-of-Life Care. In: Topol EJ, eds. Textbook of Cardiovascular Medicine. 3rd Edition. Lippincott Williams & Wilkins .Chapter 34, 2006; 587-594.
76. Francis, GS. Pathophysiology of the Heart Failure Clinical Syndrome. In: Topol EJ, eds. Textbook of Cardiovascular Medicine. 3rd Edition. Lippincott Williams & Wilkins. Chapter 85, 2006; 1339-1351.
77. Francis GS, Tang WHW. Pathophysiology of Heart Failure. In: Abraham WT, Krum H, eds. Heart Failure: a practical approach to treatment. McGraw Hill. Chapter 4, 2007 43-52.
78. Kamdar AR, Bhatt DL, Francis GS. Amyloid heart disease. In: Nixon JV, ed. The AHA clinical cardiac consult. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. p. 16-17.
79. Kamdar AR, Bhatt DL, Francis GS. Acromegaly and the heart. In: Nixon JV, ed. The AHA clinical cardiac consult. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. p. 2-3.
66
Gary S. Francis, M.D. Curriculum Vitae
80. Kamdar AR, Bhatt DL, Francis GS. Heart transplantation. In: Nixon JV, ed. The AHA clinical cardiac consult. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. p. 192-193.
81. Kamdar AR, Bhatt DL, Francis GS. Cardiomyopathy, dilated and congestive. In: Nixon JV, ed. The AHA clinical cardiac consult. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. p. 108-109.
82. Kamdar AR. Bhatt DL, Francis GS. Fabry’s disease and the heart. In: Nixon JV, ed. The AHA clinical cardiac consult. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. p. 184-185.
83. Francis GS. Section Editor: Acute decompensated heart failure. In: Shishehbor MH, Wang TH, Askari AT, Penn MS, Topol EJ, eds. Management of the patient in the coronary care unit. 1st Edition. Philadelphia: Lippincott Williams & Wilkins 2007. p 187-230.
84. Francis GS, Tang WHW, Poole-Wilson PA, Sonnenblick EH. Pathophysiology of Heart Failure. In: Fuster V, ed. 12th Edition of Hurst’s The Heart. McGraw-Hill, New York, Chapt. 24, 2008, 691-712.
85. Faulx MD, Pina IL, Francis GS. Adverse Cardiovascular Drug Interactions and Complications. In: Fuster V, ed. 12th Edition of Hurst’s The Heart. McGraw-Hill, New York , Chapt. 94, 2008, 2143-2168.
86. Francis GS, Cho L. Congestive Heart Failure. In: Cho L, Griffin BP, Topol EJ, eds. 2nd Edition of The Cardiology Intensive Board Review Question Book, Wolters Kluwer, Lippincott and Williams, Chapt 8, 2009, 219-234.
87. Unzek S, Francis GS, Management of heart failure: a brief review and selected update. In: Foody VM, Crawford MH. Cardiology Clinics: Cardiology Drug Update. Nov 2008. Vol 26. pp 561-571.
88. McCray R, Francis GS. Diagnosis and management of heart failure. In: O’Rourke R, Walsh R, Fuster V: Hurst’s the Heart. Manual of Cardiology. 12th Edition. McGraw-Hill, New York, Chapter 20, 2009, 231-236.
89. Francis GS, Tang WHW. Heart failure due to systolic dysfunction. In: Crawford MH, DiMarco JP, Paulus WJ, eds. Cardiology. Third Edition. Mosby Elsevier. Philadelphia. Chapter 71; 2009 pp. 969-977.
90. Tadros TM, Bhatt DL, Francis GS. Acromegaly and the heart. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 2-3.
91. Tadros TM, Bhatt DL, Francis GS. Alcohol and the heart. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 14-15.
92. Tadros TM, Bhatt DL, Francis GS. Amyloid heart disease. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 16-17.
93. Tadros TM, Bhatt DL, Francis GS. Anemia and the heart. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 18-19.
94. Tadros TM, Bhatt DL, Francis GS. Cardiac transplantation, adult. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 98-99.
95. Tadros TM, Bhatt DL, Francis GS. Cardiomyopathy, dilated or congestive. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp104-105.
96. Tadros TM, Bhatt DL, Francis GS. Cardiomyopathy, hypertrophic. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 106-107.
67
Gary S. Francis, M.D. Curriculum Vitae
97. Tadros TM, Bhatt DL, Francis GS. Cardiomyopathy, restrictive. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 112-113.
99. Francis GS, Bhatt DL. Eosinophilic heart disease. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 170-171.
100. Tadros TM, Bhatt DL, Francis GS. Fabry disease and the heart. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 174-175.
101. Francis GS, Bhatt DL. Heart failure, chronic systolic (diagnosis and management). In: Nixon JV, ed. The AHA Clinical Cardiac Consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 178- 179.
102. Tadros TM, Bhatt DL, Francis GS. Heart failure, high-output. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 180-181.
103. Francis GS, Bhatt DL. Myocarditis. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 226-277.
104. Francis GS, Bhatt DL. Paget disease and the heart. In: Nixon JV, ed. The AHA clinical cardiac consult. 3rd edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2010: pp 238-239.
105. Tang WHW, Francis GS. Clinical evaluation of heart failure. In: Mann DL, ed. Heart failure: a companion to Braunwald’s heart disease. Philadelphia: Elsevier/Saunders, 2010: pp511-525.
106. Francis GS, Tang WHW. Walsh RA. Pathophysiology of Heart Failure. In: Fuster V, Walsh R, Harrington R, eds. 13th Edition of Hurst’s The Heart. McGraw-Hill, New York, Chapt. 26, 2011, 719-738.
107. Tang WHW, Francis GS. Hemodynamic considerations in cardiorenal syndrome. In: Heywood TJ and Burnett JC Jr. The Cardiorenal Syndrome. A clinicians guide to pathophysiology and management. Cardiotext publishing, Minneapolis, Chapter 5, 2012, pp 73-81.
108. Sarraf M, Francis GS. ß-Blockers in Stage B: In: A Precursor of Heart failure. Stage B, Part II. Philadelphia PA. W.B. Saunders Co. Elsevier Inc. 2012. pp. 237-235.
109. Francis GS, Konety S. Vasodilators and Neurohormone Modulators. Cardiology: An Illustrated Textbook. Vol 1. In Chatterjee, Anderson M, Heistad D, Kerber Richard E (Eds.): Cardiology. An Illustrated Textbook. Jaypee Brothers Medical Publishers, New Delhi, India, Chapter 5, 2013, pp 71-88.
110. Kamouh A, Francis GS, Chatterjee K. Angiotensin converting enzyme inhibitors. In: Chatterjee K, Topol EJ, eds. Cardiac Drugs. An evidence-based ap138proach. Jaypee Publishers, New Delhi, India. Chapter 1.2013. pp. 1-33.
111. Francis GS, Garry DJ. Healed myocardial infarction. In: Vlodover Z, Wilson RF, Garry DJ, eds. Coronary Heart Disease. Springer, New York, Dordrecht, Heidelberg, London. Chapter 19, 2012, pp349-364.
112. Francis GS, Cohn JN: Cardiac failure and the autonomic nervous system. In: Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Eds: Mathias CJ, Bannister R. 5th Edition. Oxford University Press, 2013:761-769.
113. Francis GS, Bartos JA, Thenappan T, Konety SH: Vasodilators and neurohumoral moderators. In: Chatterjee K, Topol EJ, eds. 2nd Edition. Cardiac Drugs. Jaypec Publishers, New Delhi, India. Chapt. 1, 2015.pp 1-40.
68
Gary S. Francis, M.D. Curriculum Vitae
114. Francis GS, Alraies MC, Pritzker MR: Heart failure with preserved ejection fraction (HFpEF). In: Garry DJ, Wilson RF, Vlodaver Z, eds. Congestive Heart Failure and Cardiac Transplantation: Clinical Pathology, Imaging and Molecular Profiles. Springer Nature, Switzerland. Chapt. 13, 2017, pp 197-209.
Expert Guidelines, Competency Documents and Official Position Statements: 32
1. Francis GS, William SV, Achord JL, Reynolds WA, Fisch C, Friesinger GC, Klocke FJ, Akhtar M, Ryan TJ, Schlant RD: Clinical competence in insertion of a temporary transvenous ventricular pacemaker. ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. J Am Coll Cardiol 1994; 23:1254-1257.
2. Francis GS, William SV, Achord JL, Reynolds WA, Fisch C, Friesinger GC, Klocke FJ, Akhtar M, Ryan TJ, Schlant RC: Clinical competence in insertion of a temporary transvenous ventricular pacemaker. ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. Circulation 1994;89:1913-1916.
3. Williams JF, Bristow MR, Fowler MB, Francis GS, Garson Jr A, Gersh BJ, Hammer DF, Hlatky MA, Leier CV, Packer M, Pitt B, Ullyot DJ, Wexler LF, Winters Jr WL. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26:1376-1398. Circulation 1995;92:2764-2784.
4. Francis GS. Treatment of the patient with heart failure: recommendations of the ACC/AHA Task Force for the evaluation and management of heart failure. Congestive Heart Failure 1996; March/April:14-16.
5. Packer M, Cohn JN, et al. Consensus Recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83: (Suppl 2A) 1A-38A.
6. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2001;104:2996-3007. J Am Coll Cardiol 2001; 38:2101-13.
7. Executive Council of the Heart Failure Society of America. Implications of recent clinical trials for heart failure performance measures. J Cardiac Failure 2004; 10: 4-5.
8. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC, Francis GS, Mehra MR, Peacock WF, Fonarow G, Gibler WB, Marrow DA, Hollander J. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular disease. Congestive Heart Failure 2004; 10:1-27.
9. Konstam MA and the Executive Council for the Heart Failure Society of America. Heart Failure Training: A call for integrative, patient-focused approach to an emerging cardiology subspecialty. J Cardiac Failure 2004;10:366-367. J Am Coll Cardiol 2004;44:1361-1362.
10. Tang WH, Francis GS, Apple F, Christianson R, Wu A. Recommendations for the Use of Cardiac Biomarkers in Heart Failure. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Biomarkers of Acute Coronary Syndrome and Heart Failure. Chapt. 2. 2005.
11. Hunt SA, Abraham WT, Chin MH, Feldman Am, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MC, Stevenson LW, Yancy CW. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. A report of the American College of 69
Gary S. Francis, M.D. Curriculum Vitae
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the evaluation and management of Heart Failure). Circulation 2005:112:1825-1852. J Am Coll Cardiol 2005; 46:1116-43.
12. Executive Council and Committee Members-Heart Failure Society of America. Executive Summary: Adams KF, Lindenfeld J, Francis GS, et. al. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Cardiac Failure 12:10-38, 2006.
13. WHW Tang, GS Francis, DA Morrow, KL Newby, CP Cannon, RL Jesse, AB Storrow, RH Christenson. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. Circulation 116: 2007, e99-109.
14. Apple FS, Jesse RL, Newby LK, Wu AHB, Christenson RH, Cannon CP, Francis GS, Marrow DA, Ravkilde J, Storrow AB, Tang W, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Panteghini M, Tate J. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Clinical Chemistry 2007 Apr; 53(4):547-551.
15. Wu AHB, Jaffe AS, Apple FS, Jesse RL, Francis GS, Morrow DA, Newby LK, Ravkilde J, Tang WHW, Christianson RH (NACB Writing Group Members) and Christianson RH, Apple FS, Canon CP, Francis GS, Jesse RL, Morrow DA, Newby LK, Ravkilde J, Storrow AB, Tang WHW, Wu AHB (NCAB Committee Members). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007; 53:2086-2096.
16. Morrow DA, Cannon CP, Jesse RL, Newby LK, Raukilde J, Storrow AB, Wu AH, Christianson RH, Apple FS, Francis GS, Tang W. National Academy of Clinic Biochemistry Laboratory Medicine Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007; 53: 552-574.
17. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009; 14; 53:e1- e90.
18. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:1977-2016.
19. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:e391-479.
20. Francis GS, Greenberg BH, Hsu DT, Jaski BE, Jessup M, LeWinter MM, Pagani FD, Piña IL, Semigran MJ, Walsh MN, Wiener DH, Yancy CW Jr. ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. J Am Coll Cardiol 2010; 56:424-53. 70
Gary S. Francis, M.D. Curriculum Vitae
21. Francis GS, Greenberg BH, Hsu DT, Jaski BE, Jessup M, LeWinter MM, Pagani FD, Piña IL, Semigran MJ, Walsh MN, Wiener DH, Yancy CW Jr. ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. Circulation 2010; 122:664-72.
22. Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, Gibler WB, McCord JK, Parshall MB, Francis GS, Gheorghiade M; on behalf of the American Heart Association Council on Clinical Cardiology and Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Acute heart failure syndrome: Emergency department presentation, treatment, and disposition: Current approaches and future aims. A scientific statement from the American Heart Association. Circulation. 2010; 122:1975-1996.
23. Greenberg BH, Anand IS, Burnett JR, Chin J, Dracup KA, Fedlmen AM, Force T, Francis GS, Houser SR, Hunt SA, Konstam AM, Lindenfeld J, Mann DL, Mehra MR, Paul SC, Piano MR, Ross HJ, Sabbah HN, Starling RC, Udelson JE, Yancy CW, Zile MR, Massie BM. The Heart Failure Society of America in 2020: A Vision for the Future. Journal of Cardiac Failure 2012; 18, 90-93.
24. Holmes DR , Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoon JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012;59:1200-54
25. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Riegel B, Spertus JA; on behalf of the American Heart Association Council on Quality of Care and Outcomes research, Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Decision Making in Advanced Heart Failure. A Scientific Statement From the American Heart Association. Circulation. 2012;125:1928-1952.
26. Shah MR, Starling RC, Longacre LS, Mehra MR, Francis GS. State of the Art Paper; Heart Transplantation Research in the Next Decade – A Goal to Achieving Evidence-Based Outcomes. National Heart, Lung, and Blood Institute Working Group. J Am Coll Cardiol 2012;Vol 59, No.14:1263-1269.
27. Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD, Rockman HA, Kass DA, Molkentin JD, Sussman MA, Koch W. on behalf of the American Heart Association Council on Basic Cardiovascular Sciences, Council on Clinical Cardiology, and Council on Functional Genomics and Translational Biology. Animal Models of Heart Failure. A Scientific Statement From the American Heart Association. Journal of the American Heart Association. Circulation Research 2012; 111:131-150; originally published online May 17, 2012.
28. Peura JL, Colvin-Adams M, Francis GS, Grady K, Hoffman T, Jessup M, John R, Kiernan M, Mitchell J, O’Connell JB, Pagani F, Petty M, Ravichandran PS, Rogers J, Semigran M, Toole JM. Recommendations for the Use of Mechanical Circulatory Support: Device Strategies and Patient Selection. A scientific statement from the American Heart Association. Circulation 2012; 126: 2648-2667.
29. Colvin MM, Cook JL, Chang P, Francis GS, Hsu DT, Kiernan MS, Kobashigawa JA, Lindenfeld JA, Masri SC, Miller D, O’Connell J, Rodriguez ER, Rosengard B, Self S, White-Williams C, Zeevi A: on behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Antibody-mediated
71
Gary S. Francis, M.D. Curriculum Vitae
rejection in cardiac transplantation: emerging knowledge in diagnosis and management. A scientific statement from the American Heart Association. Circulation 2015;131;1608-1639.
30. Bozkurt B, Aguilar D, Deswal A, Dunbar S, Francis GS, Howwich T, Jessup M, Pritchett A, Ramasubbu K, Rosendorff C, Yancy C: On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council of Hypertension: and Council on Quality and Outcomes Research. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016;134-00:00. DOI: 10.1161/CIR.000000000000450
31. Bozkurt B, Colvin M , Cook J , Cooper LT, Deswal A, Fonarow GC, Francis GS, Lenihan D, Lewis EF, McNamara DM, Pahl E, Vasan RS, Ramasubbu K, Rasmusson K, Towbin JA and Yancy C and On behalf of the American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association Circulation 2016: 10.1161/CIR.0000000000000455
32. Cook JL, Colvin M, Francis GS,Grady KL, Hoffman TM, Jessup M, John R, Kiernan MS, Mitchell JE, Pagani FD, Petty M, Ravichandran P, Rogers JG, Semigran MJ, Toole JM; on behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the use of mechanical circulatory support: ambulatory and community patient care: a scientific statement from the American Heart Association. Circulation 2017;135:e1145-e1158. doi: 10.1161/CIR.0000000000000507.
Monographs: 9
1. Francis GS, Cohn JN. The Role of Cathecholamines in Cardiovascular Disease. Current Concepts, Scope Publications, Kalamazoo, MI. 1988.
2. Francis GS. Survival in Congestive Heart Failure. Management Strategies in Heart Failure. London. 1989;4:116 (Forward by Prof. John Goodwin).
3. Francis GS, Kubo SH. Prognostic Factor Affecting Diagnosis and Treatment of Congestive Heart Failure. Current Problems in Cardiology. Edited by Robert A. O’Rourke. November 1989.
4. Francis GS. Neurohormones in congestive heart failure. In: Advanced concepts in the treatment of heart failure. Sugimoto T, Yasuda H and Kawai C (eds). Proceeding of an International Symposium, Tokyo, June 29, 1991.
5. Mirvis D, Francis GS. An opportunity to make a difference: angiotensin converting enzyme inhibiting in congestive heart failure. Postgraduate Institute for Medicine. January 2001. Pp. 1-24.
6. Young JB, Correia NG, Francis GS, Maisel A, Michota F. Testing for B-type natriuretic peptide in the diagnosis and assessment of heart failure: What are the nuances? Cleve Clinic J Med 71:Suppl 5; pp S1-S17, 2004.
7. Francis GS. Editor. Peer Perspectives in Cardiology: The role of Angiotensin II in Patients with Left Ventricular Dysfunction Post-myocardial Infarction. Annenberg Center for Health Sciences. Sept. 2004.pp1-14.
8. Faulx MD, Francis GS. Adverse drug reactions in patients with cardiovascular disease. Current Problems in Cardiology. 2008; 33:703-768. 72
Gary S. Francis, M.D. Curriculum Vitae
9. Tang WHW, Francis GS, Young JB. ACCSAP 7, 2009. Heart Failure: 17.2: Disease Progression in Heart Failure. 17.2.1 – 17.2.9.
Book Reviews: 6
1. Francis GS. Book Review: Vasodilator Therapy for Cardiac Disorders. By Lawrence Gould and C.V.R. Reddy. Mount Kisco, New York: Futura, 1979 N Engl J Med 1980;303:650-651.
2. Francis GS. Book Review: Cardiovascular Therapy: A Systemic Approach, Vol. 1: Circulation. By Raymond E. Phillips. Philadelphia: WB Saunders, 1979 N Engl J Med 1980;303:650-651.
3. Francis GS. Book Review: Progress in Cardiology, Volume 3, Number 2. Edited by Douglas P. Zipes and Derek J. Rowlands. Lea and Febiger, Philadelphia, 1990; 187 pages. For Journal of Cardiovascular Electrophysiology April, 1991.
4. Francis GS. Book Review: Challenges in Acute Coronary Syndromes. Edited by deBono D and Sobel BE. Blackwell Science. Oxford, U.K. 2001. Congestive Heart Failure. March/April, 2002, 97.
5. Francis GS. Book Review: Atlas of Heart Failure: Cardiac Function and Dysfunction. 3rd Edition. Edited by Wilson S. Colucci and Eugene Braunwald. 286 pages. Philadelphia, PA; Current Med, Inc.; 2002. Congestive Heart Failure. Jan/Feb, 2004, 63.
6. Francis GS. Book Review: Cardiac Remodeling and Failure. Edited by Singal PK, Dixon IMC, Kirshenbaum LA, Dhalla NS, Kluwer. Boston 2003. Congestive Heart Failure. March/April, 2004, 116.
Case Histories: 7
1. Tretheway DG, Francis GS, MacNeil DJ, Vieweg WVR. Single left pulmonary vein with normal pulmonary venous drainage: a roentgenographic curiosity. Am J Cardiol 1974;34:237-239.
2. Francis GS, Vieweg WVR, O’Sullivan JM, Morgan JR. Thymoma masquerading as congenital partial absence of the left pericardium. Am Heart J 1975;89:91-93.
3. Belott PH, Vieweg HVR, Alpert JS, Iacovonni VE, Francis GS, Hagan AD. Single pulmonary vein with normal pulmonary venous drainage. J Cardiac Cath Cardiovasc Diag 1977;3:67-72.
4. Alpert JS, Francis GS, Vieweg HVR, Thompson SI, Stanton KC, Hagan AD. Left ventricular function in massive pulmonary embolism. Chest 1977;71:108-111.
5. Yuh DD, Kubo SH, Francis GS, Bank A, McDonald KM, Jessuran J, Verfaille C, Shumway SJ. Primary cardiac lymphoma treated with orthotopic heart transplantation: a case report. J of Heart and Lung Transplantation 1994;13:538-542.
6. Latif AB, Jneid H, Isada CM, Francis GS. A 34-year-old man with facial droop and dysarthria. Cleve Clinic J Med 2003; 70:602-613.
7. Dickinson O, Sakaguchi S, Benditt D, Francis GS, Chen LY, Zakharova M, Detloff B. Isolated Left Ventricular Non-Compaction Cardiomyopathy Associated with Polymorphous Ventricular Tachycardia Mimicking Torsades de Pointes. Journal of Arrhythmia. 2013; 29:43-46
Protocols: 2 73
Gary S. Francis, M.D. Curriculum Vitae
1. The Digitalis Investigation Group: Rationale, design, implementation and baseline characteristics in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials 17:77-97, 1996.
2. Zile M. Gaasch W, Little W, Francis G, Tanazzi L, Cleland J, Davies M. A phase II, double-blind, randomized, placebo-controlled, dose-comparative study of the efficacy, tolerability and safety of MCC-135 in subjects with chronic heart failure NYHA class II/III (MCC-135-G01 study). Rationale and design. J Cardiac Failure 10: 193-199, 2004.
Letters to Editor: 10
1. Cohen IM, Mottet MM, Francis GS, Alpert JS. Danger in nitroprusside therapy. Ann Intern Med 1976;85:206.
2. Francis GS. Rotating tourniquet for acute cardiogenic pulmonary edema. JAMA 1995;274:1192 (questions and answers - by invitation).
3. McClellan MB, Loeb JM, Clancy CM, Francis GS, Jacobs AK, Kizer KW, O’Kane MF, Wolk MJ. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic heart failure. Ann Int Med 2005; 142: 386- 387.
4. Mohler KM, Murray KM, Mann DL, Francis G. Use of targeted anticytokine treatments in heart failure. Circulation 103:e 65, 2000.
5. Francis GS. Effects of ramipril on cardiovascular events in high risk patients. New Eng J Med 343; 66:2000.
6. Khot UN, Novaro GM, Francis GS. Nitroprusside in critically ill patients with aortic stenosis. New Engl J Med 349: 811-813, 2003.
7. Tang WHW, Francis GS, Hoogwerf BJ, Young JB. Is the tolerability of long-term thiazolidinedione therapy overstated? J Am Coll Cardiology 42: 1334-1335, 2003.
8. Tang WHW, Starling RC, Young JB, Francis GS, Girod JP, Lee MJ, Van Lente F. Plasma brain natriuretic peptide levels indicate the distance from decompensated heart failure-response. Circulation 109; e329-330, 2004.
9. Kanderian AS, Francis GS. Response to ‘Cardiac troponins and chronic kidney disease’. Kidney International. 70:1526; 2006.
10. Mullens W, Francis GS, Tang WH. Vasodilator therapy in cardiac failure. What was new was old. J Am Coll Cardiol 2009; 53:898-899.
Abstracts: 185 (selected from several hundred)
1. Hagan AD, Francis GS, Sahn DJ, Karliner JS, Friedman WF, O’Rourke RA. Systolic anterior septal motion: an unreliable echocardiographic finding. Circulation 1972;33:October.
2. Francis GS, Hagan AD, Oury J, O’Rourke RA. The accuracy of continuous echocardiographic recording method for assessing aortic root size. Am J Cardiol 1974;33:January.
3. Hagan AD, Francis GS, Sahn DJ, Karliner JS, Friedman WF, O’Rourke RA. The evaluation of systolic anterior septal motion in patients with and without right ventricular volume overload. Am J Cardiol 1974;33:January.
74
Gary S. Francis, M.D. Curriculum Vitae
4. Francis GS, Hagan AD. Echocardiographic criteria of normal left atrial size in adults. Circulation 1975;50:October.
5. Theroux P, Francis GS, Hagan AD, Johnson A, O’Rourke RA. Echocardiographic study of interventricular septal motion in the Wolff-Parkinson-White syndrome. Circulation 75; 52: October.
6. Alpert JS, Francis GS, Vieweg WVR, Johnson AD, Hagan AD. Echocardiographic assessment of left ventricular function in aortic insufficiency. Circulation 1975;52: October.
7. Francis GS, Theroux P, O’Rourke RA, Hagan AD, Johnson AD. An echocardiographic study of interventricular septal motion in the Wolff-Parkinson-White syndrome. Circulation 1976;54:174.
8. Schuler G, Peterson KL, Francis GS, Johnson A, O’Rourke RA, Daily P, Oury J, Ross J Jr. Temporal changes in left ventricular function and hypertrophy post-aortic valve replacement for pressure overload. Am J Cardiol 1977;39:February.
9. Schuler G, Francis G, Dennish G, Johnson A, Ross J Jr. Comparative changes in left ventricular function post-valve replacement for mitral as opposed to aortic regurgitation. Clin Res 1977;25(2):February.
10. Schuler G, Ross J Jr, Johnson A, Dennish G, Shelbert H, Francis GS, Peterson K. Factors affecting recovery of left ventricular function after mitral valve surgery. Am J Cardiol 1978;41:February.
11. Hoback J, Hodges M, Francis G, Sharma B, Asinger R. Flecainide (R-1818), a new antiarrhythmic agent: effects on ventricular premature beats. Circulation 1978;57,58(Suppl II):II-80.
12. Mikell F, Asinger R, Rourke T, Hodges M, Sharma B, Francis G. Detection of intracardiac thrombi by two- dimensional echocardiography. Circulation 1978;57,58 (Suppl II):II-80.
13. Rourke T, Asinger R, Francis G, Hodges M. A systematic 2-D examination using a wide angle phased array sector scanner. Am Inst Ultrasound Med Reflection 1978;4:177.
14. Sharma B, Mikell F, Hodges M, Asinger R, Francis G. Left ventricular function during exercise and following nitroglycerin in patients with acute recurrent pulmonary edema of clinically undefined etiology. Am J Cardiol 1979;43:427.
15. Francis G, Sharma B, Collins A, Helseth H, Comty C. Coronary artery bypass surgery in end-stage renal failure, renal dialysis, and transplant patients. Circulation 1979;60(Suppl II):II-240.
16. Sharma B, Reed M, Hodges H, Francis G. Change in the diastolic properties of the left ventricle during spontaneous angina pectoris. Circulation 1979;60(Suppl II): II-120.
17. Sharma B, Hoback J, Francis G, Hodges M, Asinger RW, Cohn JN, Taulor C. Pirbuterol: an oral beta agonist for therapy of congestive heart failure. Circulation 1979;60(Suppl II) II-229.
18. Mikell FL, Asinger RW, Sharma B, Francis G, Hodges M. Serial evaluation of left ventricular thrombi (LVT) by two-dimensional echocardiography (2DE): effect of anticoagulant therapy. Circulation 1979;60(Suppl II): II-19.
19. Asinger RW, Hodges M, Sharma B, Francis G, Peterson D. Filling characteristics of hypertrophied left ventricles: comparison of patients with chronic pressure overload (CPO) and long distance runners (LDR). Circulation 1979;60(Suppl II):II-236.
20. Francis GS, Sharma B, Hodges M. Comparison of dobutamine and dopamine in acute low output cardiac failure. Circulation 1979;60:(Suppl II):II-183. 75
Gary S. Francis, M.D. Curriculum Vitae
21. Sharma B, Hodges M, Asinger RW, Francis GS. Lack of effect of associated myocardial infarction on long-term survival of out-of-hospital ventricular fibrillation. Am J Cardiol 1980;45:443.
22. Sharma B, Francis GS, Tsai SH. Comparison of radionuclide and contrast techniques in assessing ejection fraction at rest and during exercise. Am J Cardiol 1980;45:422.
23. Mikell FL, Francis GS, Elsperger KJ, Hodges M, Sharma B. Serial evaluation for left ventricular thrombus during acute transmural myocardial infarction using two-dimensional echocardiography (2DE). Am J Cardiol 1980;45:483.
24. Francis GS, Goldsmith SR, Ziesche S, Cohn JN. Plasma norepinephrine levels in congestive heart failure. Clin Res 1980;28:710-A.
25. Goldsmith SR, Francis GS, Levine TB, Cowley A, Cohn JN. Elevated plasma arginine vasopressin levels in congestive heart failure and neurohumoral response to tilt. Clin Res 1980;28:710-A.
26. Goldsmith SR, Francis GS, Levine TB, Cowley A, Cohn JN. Plasma arginine vasopressin and orthostasis in normal subjects. Circulation 1980;62:(Suppl III):III-135.
27. Pierpont GL, Francis GS, Cohn JN. Effect of captopril on renal function in congestive heart failure. Circulation 1980;62(Suppl III):III-28.
28. Goldsmith SR, Francis GS, Levine TB, Cowley A, Cohn JN. Elevated arginine vasopressin levels in congestive heart failure and response to nitroprusside and captopril. Clin Res 1981;29:495-A.
29. Cohn JN, Levine R, Levine TB, Gross K, Francis GS. Prognostic significance of plasma norepinephrine in congestive heart failure. Clin Res 1981;29:562A.
30. Francis GS, Goldsmith SR, Cohn JN. The sympathetic response to exercise in patients with congestive heart failure. Am J Cardiol 1981;478:395.
31. Goldsmith SR, Francis GS, Cowley AW, Cohn JN. Reflex control of vasopressin and norepinephrine release in normal man. Clin Res 1981;29:693A.
32. Johnson GJ, Francis GS. Calcium channel antagonists inhibit epinephrine potentiation of thromboxane A2-induced human platelet aggregation. Clin Res 1981;29:751A.
33. Goldsmith SR, Francis GS, Cowley AW, Cohn JN. Reflex control of vasopressin and norepinephrine release in normal man. Circulation 1981;64(Suppl II):IV-155.
34. Goldsmith SR, Francis GS, Cohn JN. Regional blood flow response to orthostasis in congestive heart failure. Circulation 1981;65(Suppl II):IV-299.
35. Francis GS, Goldsmith SR, Pierpont G, Cohn JN. The acute effects of nitroprusside on plasma norepinephrine, renin activity, and arginine vasopressin in patients with congestive heart failure. Am J Cardiol 1982;49(Suppl IV-2):937.
36. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma vasopressin in patients with congestive heart failure. Clin Res 1982;30:190A.
37. Johnson GJ, Francis GS. Calcium channel blockers inhibit epinephrine potentiation of thrombaxane A2-induced human platelet aggregation. Clin Res 1982;30:19A.
76
Gary S. Francis, M.D. Curriculum Vitae
38. Goldsmith SR, Cowley AW, Francis GS, Cohn JN. Effects of increased central venous and aortic pressure on plasma vasopressin in man. Circulation 1982;66(Suppl II):II-34.
39. Levine TB, Olivari MT, Carlyle P, Francis GS, Cohn JN. Reversibility by heart transplantation of abnormal neurohumoral control mechanisms in chronic congestive heart failure. Circulation 1982;66(Suppl II):II-134.
40. Johnson GJ, Francis GS. Differential effect of verapamil and nifedipine on thromboxane A2-induced human platelet aggregation and alpha adrenergic receptors. Circulation 1982;66(Suppl II):II-192.
41. Goldsmith SR, Francis GS Cowley AW, Levine TB, Cohn JN. Increased plasma vasopressin in patients with congestive heart failure. Circulation 1982;66(Suppl II):1 -249.
42. Francis GS, Satoh P, Goldsmith SR, Cohn JN. Conjugated plasma norepinephrine in patients with congestive heart failure. Clin Res 1982;30:708A.
43. Goldsmith SR, Cowley AW, Francis GS, Cohn JN. Response of vasopressin to increased central venous and arterial pressure in normal man. Clin Res 1982;30:708A.
44. Goldsmith SR, Francis GS, Cohn JN. Hemodynamic effects and elimination of infused norepinephrine in patients with congestive heart failure. Clin Res 1982;30:759A.
45. Francis GS, Parks R, Cohn JN. Neurohumoral and hemodynamic response to bromocriptine in patients with congestive heart failure. Clin Res 1982;30:759A.
46. Goldsmith SR, Francis GS, Cohn JN. Hemodynamic effects of military antishock trouser. Clin Res 1982;30:709A.
47. Johnson GJ, Francis GS. Differential effect of verapamil and nifedipine on thromboxane A2-induced human platelet aggregation and alpha adrenergic receptors. Clin Res 1982;30:772A.
48. Fletcher R, Archibald D, Cohn J and VA Study Group, Washington, D.C.. Day 1 and day 14 24-hour electrocardiogram as predictors of post myocardial infarction mortality. Circulation 1982;66(Suppl II):II-41.
49. Francis GS, Goldsmith SR, Satoh PS, Cohn JN. Conjugation and clearance of norepinephrine in patients with congestive heart failure. Fed Proc 1983;42:380.
50. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Abnormal response of plasma vasopressin to orthostatic stress in congestive heart failure. Circulation 1983;68(Suppl II): II-248.
51. Francis GS, Goldsmith SR, Ziesche S, Nakamima H, Cohn JN. Heart rate, blood pressure and plasma norepinephrine as a function of oxygen use during exercise in congestive heart failure. Circulation 1983;68(Suppl II): II-132.
52. Goldsmith SR, Cowley AW, Francis GS, Cohn JN. Reflex control of osmotically stimulated vasopressin in normal man. Circulation 1983;68(Suppl II):III-77.
53. Goldsmith SR, Cowley A, Francis GS, Cohn J. Response of plasma vasopressin to water loading in patients with congestive heart failure. Fed Proc 1983;42:2611.
54. Johnson CJ, Leis LA, Francis GS. The calcium channel blockers, verapamil and nifedipine, have different effects on thromboxane A2-induced human platelet aggregation and alpha adrenergic receptors. Throm Haemost 1983;50:893.
77
Gary S. Francis, M.D. Curriculum Vitae
55. Goldsmith SR, Siegel R, Francis GS, Cohn JN. Response of plasma vasopressin to furosemide in patients with congestive heart failure. Clin Res 1984;32:730A.
56. Goldsmith SR, Francis GS, Cowley AW, Cohn JN. Hemodynamic effects of arginine vasopressin in patients with congestive heart failure. Circulation 1984;70(Suppl II): II-192.
57. Francis GS, Siegel RM, Olivari MT, Goldsmith SR, Cohn JN. The acute vasoconstrictor response to intravenous furosemide in patients with congestive heart failure. Circulation 1984;70(Suppl II): II-302.
58. From AHL, Francis GS, Pierpont GL, Petein M. DPI 201-106: a novel new inotropic agent. Circulation 1984;70(Suppl II): II-167.
59. Goldsmith SR, Francis GS, Cohn JN. Effects of infused norepinephrine on hemodynamics and renin in patients with congestive heart failure. Circulation 1984;70(Suppl II): II-309.
60. Chesler E, Weir EK, Braatz GA, Francis GS. Normal catecholamine and hemodynamic response to orthostatic tilt in subjects with mitral valve prolapse: correlation with psychologic testing. J Am Coll Cardiol 1985;5:504.
61. Goldsmith SR, Francis GS, Dodge DL, Cowley AW Jr. Vasopressin and water excretion in human congestive heart failure. Circulation 1985;72(Suppl III): III-282.
62. Cohn JN, Rector T, Olivari MT, Levine TB, Francis GS. Plasma norepinephrine, ejection fraction and maximal oxygen consumption as prognostic variables in congestive heart failure. Circulation 1985;72 (Suppl III): III-285.
63. Petein M, From AHL, Francis GS, Pierpont GSL. DPI 201-206: a new nonadrenergic inotropic agent with possible beta adrenergic blocking activity. Circulation 1985;72(Suppl III):II-304.
64. From AHL, Pierpont GL, Francis GS, Petein M. DPI 201-106 has Na+ channel agonist properties. Circulation 1985;72(Suppl III):II-312.
65. Ziesche SM, Nelson J, Francis GS. The influence of atrial fibrillation on exercise capacity in patients with congestive heart failure. Circulation 1985;72(Suppl III):II-464.
66. Kappler JH, Ziesche SM, Nelson JA, Francis GS. Reproducibility of exercise testing in patients with congestive heart failure. Circulation 1985;72 (Suppl III):II-482.
67. Wilson BC, Francis GS, Ziesche SM, Nelson JA. Acute hemodynamic responses to oral fenoldopam, a dopamine receptor agonist, in chronic congestive heart failure. J Am Coll Cardiol 1986;7:70A.
68. Goldsmith SR, Francis GS, Siegel R, Olivari MT, Cohn JN. Attenuation by converting enzyme inhibition of acute hemodynamic and neurohumoral response to furosemide in congestive heart failure. Clin Res 1986;34:303A.
69. Pierpont GL, Francis GS, DeMaster EG, Olivari MT, Ring WS, Cohn JN. Heterogenous adrenergic response of the myocardium to congestive heart failure. J Am Coll Cardiol 1986;7:120A.
70. Fletcher RD, Archibald D, Orndorf J, Cohn JN and the Cooperative Study Group. Dysrhythmias on short term Holter as an independent predictor of mortality in congestive heart failure. J Am Coll Cardiol 1986;7:143A.
71. Francis GS, Archibald DG, Cohn JN and the V.A. Cooperative Study Group: Mortality reduction by hydralazine- isosorbide dinitrate therapy in congestive heart failure: The V-HeFT Study. Circulation 1986;74(Suppl II):II-446.
78
Gary S. Francis, M.D. Curriculum Vitae
72. Francis GS, Rector T, Nelson JA, Ziesche SM, Cohn JN. Plasma norepinephrine increases over time in patients with congestive heart failure despite treatment with converting enzyme inhibitors. Circulation 1986;74(Suppl II): II-508.
73. Cohn JN, Dunkman WB, Archibald DG, and the V.A. Cooperative Study Group: Heart failure in patients with normal left ventricular ejection fraction: the V-HeFT Study. Circulation 1986;(Suppl II): II-138.
74. Archibald DG, Cohn JN, and the V.A. Cooperative Study Group: A treatment associated increase in ejection fraction predicts long-term survival in congestive heart failure: the V-HeFT Study. Circulation 1986;74(Suppl II):II-309.
75. Cohn JN, Ziesche SM, Archibald DG and the V.A. Cooperative Study Group: Quantitative exercise tolerance as a predictor of mortality in congestive heart failure: the V-HeFT Study. Circulation 1986; 74 (Suppl II): II-447.
76. Tristani F, Archibald D, Hughes CV, Sheldahl L, Fletcher R, Cohn JN and the V.A. Cooperative Study Group: Safety of graded exercise testing in congestive heart failure (V-HeFT). Circulation 1986;74(Suppl II): II-395.
77. Tristani F, Archibald DG, Hughes CV, Sheldahl LM, Francis CS, Johnson GR, Cohn JN: Reproducibility of the graded exercise test in congestive heart failure (V-HeFT). Circulation 1987;76(Suppl IV): IV-458.
78. Cohn JN, Archibald D, Johnson G and the V.A. Cooperative Study Group: Effects of vasodilator therapy on peak oxygen consumption in heart failure: V-HeFT. Circulation 1987;76(Suppl IV): IV-443.
79. Feske WI, Finkelstein Sm, Mock JE, Francis GS, Cohn JN: Reduced arterial compliance in hypertension. Hypertension 1988;12:343.
80. Dunkman WB, Johnson GR, Cohn JN and the V. A. Cooperative Study Group: Incidence of thromboembolic events in congestive heart failure. The V-HeFT study. Circulation 1988;78(Suppl II): II-617.
81. Cohn JN, Johnson G and the V.A. Cooperative Study Group: Mechanism of death and its relationship to baseline variables and treatment in V-HeFT. Circulation 1988;78(Suppl II): II-347.
82. Fletcher R, Johnson G, Cohn JN. Increased risk of ventricular arrhythmia with mild ventricular dysfunction in CHF. Circulation 1988;78(Suppl II):II-346.
83. Fletcher R, Johnson G, Cohn JN. Vasodilator improvement of mortality in CHF is dependent on the presence of ventricular arrhythmia. Circulation 1988;78 (Suppl II):II-347.
84. Francis GS, Benedict C, Johnstone D, Kirlin P, Neuberg G, Kubo S, Hosking J, Liang C-S, Yusuf S. Investigators for studies of left ventricular dysfunction (SOLVD). Differences in neurohumoral activation in patients with left ventricular dysfunction. J Am Coll Cardiol 1989;13:246A.
85. Goldsmith SR, Francis CS. Attenuation of the pressor response to furosemide by captopril in congestive heart failure. Circulation 1989;80 (Suppl II): II-8.
86. McDonald KM, Francis GS, Mathews J, Hauer K, Carlyle P, Hunter D, Cohn JN. Increased right ventricular mass following left ventricular damage. Clin Res 1990;38:883A.
87. McDonald KM, Francis GS, Carlyle P, Matthews J, Hauer K, Cohn JN. Time course of ventricular remodeling after non-ischemic myocardial damage in the dog. Clin Res 1990;38.
88. McDonald KM, Francis GS, Matthews J, Carlyle PF, Hauer K, Wennberg P, Hunter D, Cohn JN. The effect of a1- adrenoceptor blockade on ventricular remodeling in the dog. Clin Res 1990;38:813A.
79
Gary S. Francis, M.D. Curriculum Vitae
89. McDonald K, Francis GS, Mathews J, Carlyle PF, Hauer K, Wennberg P, Hunter D, Cohn JN. The effect of a1- adrenoceptor blockade on ventricular remodeling in the dog. Circulation 1990;82:III-48.
90. Francis GS, Ziesche S, Johnson G, Cohn JN. Determinant of reduced peak 02 consumption in patients with heart failure: V-HeFT II. Circulation 1990:82:III-383.
91. Cohn JN, Jonson G, Francis GS. Sympathetic and renin stimulation in heart failure: the absence of homogeneity : V- HeFT II. Circulation 1990;82:III-382.
92. Ziesche S, Johnson G, Francis GS, Cohn JN. Peak exercise 02 consumption vs. New York Heart Association Class in heart failure: V-HeFT II. Circulation 1990;82:III-41.
93. McDonald K, Francis GS, Carlyle P, Matthews J, Hauer K, Cohn JN. T9ime course of ventricular remodeling after non-ischemic myocardial damage in the dog. Circulation 1990;82:III-41.
94. McDonald K, Zhang J, Yoshiyama M, Francis GS, Ugurbil K, Cohn JN. Altered substrate utilization for ATP production in a canine model of left ventricular dysfunction. Circulation 1990;82:III-256.
95. McDonald KM, Francis GS, Matthews J, Hunter DW, Cohn JN. Oral nitrate therapy prevents early left ventricular mass increase following left ventricular damage. Clin Res 1991;39:346A.
96. McDonald KM, Zhang J, Yoshiyama M, Francis GS, Ugurbil K, Cohn JN. Reversal of abnormal myocardial bioenergetics with adenosine in a pre-heart failure model of canine left ventricular dysfunction. Clin Res 1991;39:711A.
97. Mancini DM, Benotti JR, Chesebro JH, Elkayam U, Francis GS, Hess ML, Massie BM, Tandon pK, Packer M. Antiarrhythmic drug use and high serum levels of digoxin are independent adverse prognostic factors in patients with chronic heart failure. Circulation 1991;84(Suppl II): 243.
98. Packer M, Francis GS, Abrams J, Cobb FR, Eichhorn EJ, Giles TD, Kahl FR, Tandon PK. Oral milrinone increases the risk of sudden death in severe chronic heart failure: The PROMISE Trial. Circulation 1991;84(Suppl II):II-310.
99. McDonald KM, Francis GS, Mathews J, Hauer K, Hunter D, Cohn J. Nitrate therapy prevents long-term ventricular remodeling in the dog. Circulation 1991;84(Suppl II):II-733.
100. McDonald KM, Parrish T, Wennberg P, Francis GS, Stillman A, Cohn JN, Hunter D. Accurate estimation of right ventricular mass in the dog using magnetic resonance imaging. Circulation 1991;84(Suppl II):II-158.
101. McDonald KM, Zhang J, Yoshiyama M, Francis GS, Ugurbil K, Cohn JN. Improvement of abnormal myocardial bioenergetics with adenosine in a canine model of left ventricular dysfunction. Circulation 1991;84(Suppl II):II-277.
102. Johnson TH, Ziesche SM, Berg MM, Chesler E, Beltran AM, Francis GS. Saline load and sodium excretion in patients with left ventricular dysfunction: Relationship to neuroendocrine activity. Circulation 1991;84(Suppl II):II- 55.
103. Connelly TP, Francis GS, Williams KJ, Beltram AM, Cohn JN. Acute effects of furosemide and atrial natriuretic factor on systemic and pulmonary vasculature in patients with congestive heart failure. Circulation 1991;84(Suppl II):II-525.
104. Cohn JN, Simon A, Johnson G, and V-HeFT Study Group. Relationship of plasma norepinephrine and plasma renin activity to mortality in heart failure: V-HeFT II. Circulation 1991;80(Suppl II):II-310.
80
Gary S. Francis, M.D. Curriculum Vitae
105. Fletcher R, Cintron G, Johnson G, Cohn JN and V.A. Co-operative Study. Enalapril decreased ventricular tachycardia in heart failure. Circulation 1991;84(Suppl II):II-310.
106. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Kinan D, Ahn S, Yusef S, Pouleur H and the SOLVD Investigators. Effects of enalapril on the progression of left ventricular dysfunction in heart failure. Circulation 1991;84(Suppl II):II-310.
107. Udelson JE, Konstam MA, Dronenberg MW, Pouleur H, Rousseau M, Kilcoyne L, Edems TR, Ahn S, Stewart D, Yusef S and the SOLVD Investigators. Effects of enalapril on right ventricular performance in patients with heart failure and left ventricular dysfunction. Circulation 1991;84(Suppl II):II-310.
108. Rogers WJ and the SOLVD Investigators. Functional status and quality of life of 2569 patients with symptomatic CHF randomized between enalapril and placebo in the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. Circulation 1991;84(Suppl II):II-310.
109. Cintron G, Johnson G, Francis GS, Cohn JN and the V-HeFT Study Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with heart failure. XIV Congress of the European Society of Cardiology. Aug 30 - Sept 3, 1992, Barcelona, Spain.
110. Cohn JN, Francis GS, Simon A, Johnson G and the Veterans Administration Study Group. Response of plasma norepinephrine to long-term administration of enalapril or hydralazine-isosorbide dinitrate in heart failure: V-HeFT II. J Am Coll Cardiol 1992;19:216A.
111. Garr MD, McDonald KM, Francis GS, Cohn JN. The influence of an angiotensin II inhibitor (DUP 532) on ventricular remodeling in a canine model of discrete myocardial damage. Clin Res 1992;40:702A.
112. McDonald KM, Garr MD, Francis GS, Cohn JN. Dose-dependent effect of ramipril on early left ventricular remodeling in the dog. Clin Res 1992; 40:705A.
113. Cintron CB, Johnson G, Francis GS, Cohn JN and the VA Cooperative Study Group. Prognostic significance of serial changes in left ventricular ejection fraction in heart failure: V-HeFT I and II. Circulation 1992;86(Suppl I):I- 251.
114. Kubo SH, Ormaza S, Francis GS, Holmer SC, Olivari MT, Boleman RM, Shumway SJ. Trends in patient selection for heart transplantation. Circulation 1992;86(Suppl I):I-435.
115. McDonald KM, Garr MD, Francis GS, Cohn JN. The effects of ramipril on early left ventricular remodeling in the dog are dose-dependent. J Am Coll Cardiol 1993;21:300A.
116. Benedict CR, Francis GS, Johnstone D, Shelton B, Kubo S, Kirlin P, Nicklas J, Liange C-S, Konstam MS, Greenberg B, Yusuf S for the SOLVD Investigators. Effect of enalapril on plasma norepinephrine in patients with congestive heart failure. J Am Coll Cardiol 1993;21:314A.
117. Massie BM, Francis GS, Tandon PK, Anderson S, DeMets D, Packer M, on behalf of the PROMISE Investigators. Asymptomatic ventricular arrhythmias do not identify patients with severe heart failure at risk for sudden death: Results of the PROMISE Trial. J Am Coll Cardiol 1993;21:459A.
118. Bolman RN, Kubo SH, Francis GS, Hertz MI. Transplantation for pulmonary hypertension: heart-lung versus lung transplantation. Circulation 1993;88(Suppl I):I-40.
119. Nootens M, Kaufmann E, Thoer C, Francis GS, Rich S. Neuroendocrine activity in primary pulmonary hypertension. Circulation 1993;88(Suppl I):I-109. 81
Gary S. Francis, M.D. Curriculum Vitae
120. Benedict CR, Shelton B, Francis GS, Probstfield V, Johnstone D, Liang C-S, Nicklas J, Yusef S, for the SOLVD Investigators. Plasma norepinephrine and atrial natriuretic peptide levels predict prognosis in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol 1994 (Feb).
121. Toher C, Carlyle W, Vandervelde J, McDonald K, Francis GS, Cohn JN. Transcriptional upregulation of -actin gene in a model of canine left ventricular hypertrophy. International Conference on Heart Failure, Winnipeg, Canada. May 20-23, 1994.
122. McDonald KM, Mock J, D’Aloia A, Parrist T, Francis GS, Cohn JN. Inhibition of early increase in left ventricular mass by ramipril in a canine model of ventricular remodeling is negated by bradykinin antagonism. Circulation 1994;90(Suppl I):I-106.
123. Carlyle WC, Toher C, McDonald KM, Francis GS, Cohn JN. Change in -actin mRNA in a canine model of left ventricular remodeling. J Am Coll Cardiol 1995;414A.
124. Ghali JK, Nicklas JM, Quinones MA, Benedict CR, Adams KF, Greenberg BH, Konstam MA, Weiner D, Francis GS. Prognostic value of atrial natriuretic peptide in patients with heart failure. Circulation 1997;96 (Suppl I):I-266.
125. Min SH, Kshettry VR, Kubo SH, Boleman RM III, Park S, Francis GS, Bank AJ. Effects of the Heart Mate left ventricular assist device in clinical outcomes and cost in status I heart transplantation patients. Circulation 1997 (Suppl I): I-367.
126. Robbins MA, Francis G, Snader CE, Hoercher K, Young J, Lauer MS. Ventilatory and chronotropic responses to exercise: better predictors of heart failure mortality than peak V02 . J Am Coll Cardiol 1999;33:190A.
127. Yang J, Moravec CS, DiPaola NR, Hawthorn LA, Young JB, Francis GS, McCarthy PM, Bond M. Analysis of mitochondrial gene expression in failing human hearts by high density oligonucleotide arrays. Circulation 1999 (Suppl 1): I-4040.
128. Khot UN, Novaro G, Hammer D, Mills R, Nissen S, Francis GS. The use of Nitroprusside in patients with left ventricular dysfunction and obstructive aortic valve disease: the UNLOAD study. Circulation 2001 (Suppl 2): II-360.
129. Tang WHW, Tan F-L, Francis GS, Moravec CS, Jianbo L, Apperson-Hansen C, McCarthy PM, Young JB, Bond M. Clusters of differential gene expression of structural proteins between failing and non-failing hearts: preliminary insights from oligonucleotide micro arrays. J Am Coll Cardiol 2002; 39:157A.
130. Tan F-L, Moravec CS, Conklin BR, McCarthy PM, Young JB, Francis GS. A complete assessment of the expression profile of heart failure on multiple human hearts. Circulation 2002 (Suppl 2): II – 207.
131. Tang WHW, Francis GS, Young JB. Thiazolidinediones and fluid retention: Prevalence and tolerability in patients with chronic heart failure. Circulation 2002 (Suppl 2): II – 513.
132. Velazquez EJ, Weaver WD, Armstrong PW, Kilaru R, Diaz R, White HD, Van Gilst WH, Spac J, O’Conner CM, Francis GS, Drexler H, Mareev VY, Manggioni AP, Leimberger JD, Myers M, Henis M, Califf R. Heart failure and/or left ventricular dysfunction complicating myocardial infarction is common and accounts for the majority of in- hospital myocardial infarction mortality: results of the VALIANT registry-J Am Coll Cardiol 2003; 1038-71:148A.
133. Thambidorai SK, Troughton RW, Parakh K, Tang WHW, Francis GS, Klein AL. Utility of B-type natriuretic peptide in primary diastolic dysfunction: a quantitative comparison with Doppler echocardiographic indices. J Am Coll Cardiol 2003; 817-3:173A.
82
Gary S. Francis, M.D. Curriculum Vitae
134. Jones RC, Blackstone EH, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group Trial. J Am Coll Cardiol 2003; 874-3:219A.
135. Tang WHW, Girod JP, Lee MJ, Starling RC, Young JB, Francis GS. Prevalence and clinical characteristics of patients with chronic systolic heart failure and normal plasma levels of B-type natriuretic peptide. J Am Coll Cardiol 2003;888-3:221A.
136. Aquilar D, Solomon SD, Kober L, Rouleau J-L, Skali H, McMurray JJ, Francis GS, Henis M, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Califf RM, Pfeffer MA. Impact of known and newly diagnosed diabetes mellitus after a myocardial infarction. J Am Coll Cardiol 2003;1068A-MP-204:345A.
137. Tang WHW, Troughton RW, Agler DA, Morris K, Francis GS, Qin J, Griffin BP. B-type natriuretic peptide predicts left ventricular response to surgery in patients with severe mitral regurgitation in asymptomatic patients with preserved left ventricular function. J Am Coll Cardiol 2003;1134-25:509A.
138. Lee MJ, Tang WHW, Girod JP, Starling R, Young JB, Francis GS. Using B-type natriuretic peptide (BNP) in ambulatory patients with chronic heart failure and concomitant chronic renal insufficiency. European Society of Cardiology – Heart Failure 2003- ISHR. Strasbourg, France. June 23, 2003.
139. Tang WHW, Girod JP, Miller M, Partin M, Harris CM, Francis GS, Young JB. Dyslipidemic profile of the metabolic syndrome is highly prevalent and under treated in patients with chronic heart failure: A single-center, electronic medical record clinical experience. ESC. Vienna, Austria; Aug. 2003.
140. Tang WHW, Militello M, Barcelona R, Francis GS. Drug utilization guidelines in implementing a new drug therapy. The Cleveland Clinic experience with nesiritides for the first 92 patients. ESC. Vienna, Austria; Aug. 2003.
141. Lee MJ, Tang WHW, Starling RC, Young JB, Francis GS. Using plasma B-type natriuretic peptide levels to monitor ambulatory patients with chronic heart failure and concomitant renal insufficiency. J Cardiac Failure 2003; 9:S31; Abst.111.
142. Lee MJ, Tang WHW, Van Lente F, Francis GS. Comparative measurement of plasma B-type natriuretic peptide (BNP) and N-terminal-pro-BNP in the clinical setting: pilot observations. J Cardiac Failure 2003; 9; S37; Abst. 132.
143. Tang WHW, Moliterno DJ, Francis GS, Hsu A, Goormastic M, Topol EJ. History of heart failure and left ventricular ejection fraction strongly predicts adverse outcomes among patients undergoing contemporary percutaneous coronary intervention: insights from TARGET. J Cardiac Failure 2003; 9; 361; Abst. 220.
144. Thomas S, Tang WHW, Bowell B, Francis GS. Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation. J Cardiac Failure 2003; 9; 3105. Abstr. 392.
145. Tang WHW, Lee MJ, Van Lente F, Francis GS. Sequential plasma B-type natriuretic peptide (BNP) and N-terminal pro-BNP (proBNP): how does their performance differ? Circulation 2003; suppl IV-1-IV-1050; vol 108, no 17. IV- 344. Abstr. 1614.
146. Popovic ZB, Knot UN, Novaro GM, Garcia M, Francis GS. Beneficial effects of sodium nitroprusside in aortic stenosis associated with severe heart failure are not due to pure afterload reduction: pressure-volume loop analysis using a numerical model. Circulation 2003; suppl IV-1-IV-1050; vol 108, no 17. IV-368. Abstr. 1719.
147. Fedak PW, Altamentova SM, Moravec CS, McCarthy PM, Francis GS, Weisel RD, Li RK. Novel mechanisms of cardiac remodeling and failure: role of ADAM enzymes in human cardiomyopathy. Circulation 2003; suppl IV-1-IV- 1050; vol 108, no 17. IV-388. Abstr. 1797.
83
Gary S. Francis, M.D. Curriculum Vitae
148. Chacko M, Francis GS. Massive pulmonary embolism with a low probability V/Q scan presenting as cardiogenic shock in a patient with severe aortic stenosis. Circulation 2003; suppl IV-1-IV-1050; vol 108, no 17. IV-395. Abstr. 1827.
149. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Effects of newly diagnosed and previously known diabetes mellitus on 1-year outcomes of acute myocardial infarction: the VALIANT trial. Circulation 2003; suppl IV-1-IV-1050; vol 108, no 17. IV-745. Abstr. 3367.
150. Lee MJ, Tang WHW, Starling RC, Young JB, Francis GS. Using plasma B-type natriuretic peptide levels to monitor ambulatory patients with chronic heart failure and concomitant renal insufficiency. J Cardiac Failure 2003; suppl vol 9, no 5. Abstr. 111.
151. Lee MJ, Tang WHW, Van Lente F, Francis GS. Comparative measurement of plasma B-type natriuretic peptide (BNP) and N-terminal Pro-BNP in the clinical setting: Pilot observations. J Cardiac Failure 2003; suppl vol 9, no 5. Abstr. 132.
152. Tang WHW, Moliterno DJ, Francis GS, Hsu A, Goormastic M, Topol EJ. History of heart failure and left ventricular ejection fraction strongly predicts adverse outcomes among patients undergoing contemporary percutaneous coronary intervention: Insights from TARGET. J. Cardiac Failure 2003; suppl vol 9, no 5. Abstr. 220.
153. Thomas S, Tang WHW, Bolwell B, Francis GS. Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation. J. Cardiac Failure 2003; suppl vol 9, no 5. Abstr. 392.
154. Maroo A, Tang WH, Francis GS, Ellis SG. Identification of risk factors for in-hospital complications in patients with severe left ventricular dysfunction undergoing percutaneous coronary intervention. J Am Coll Cardiol 2004; 43:1138- 65: 82A.
155. Parameswaran A, Tang WH, Francis GS, Gupta R, Young JB: B-blocker utilization in patients with heart failure: a single-center, two-year follow-up. J Am Coll Cardiol 2004; 43:821-6: 196A.
156. Tang WH, Militello M, Barcelona R, Young JB, Francis GS. Hypotension associated with nesiritide infusion in patients with decompensated heart failure is related to large volume diuresis: implications for monitoring and dose adjustments. J Am Coll Cardiol 2004; 43:1088-127:192A.
157. Wazni O, Martin D, Marrouche N, Latif AA, Saliba W, Schweikert R, Gillinov MA, Francis GS, Young JB, Natale A. B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. J Am Coll Cardiol 2004; 43:408-4:535A.
158. Tang WH, Steinhubl S, Van Lente F, Brennan D, McErlean ES, Marso SP, Francis GS, Topol EJ. Risk stratification for patients undergoing elective percutaneous coronary intervention using plasma n-terminal pro-b-type natriuretic peptide assay: a clopidogrel for reduction of events during observation (CREDO) sub-study. J Cardiac Failure 2004;10:S44.
159. Sandhu R, Tang WH, Mills RM, Francis GS. Does the underlying etiology influence plasma b-type natriuretic peptide levels of patients with isolated chronic aortic regurgitation and preserved left ventricular function? J Cardiac Failure 2004;10:S52.
160. Velazquez EJ, Califf RM, White H, Zelenkofske S, Francis GS, Lewis EF, Pfeffer MA, McMurray JJV. Is the combination of valsartan and captopril better than captopril alone in patients with heart failure and left ventricular systolic dysfunction after myocardial infarction? Results of VALIANT. J Cardiac Failure 2004;10:S76.
84
Gary S. Francis, M.D. Curriculum Vitae
161. EF Lewis, Velazquez EJ, McMurray JJV, Rouleau JL, Solomon SD, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Pieper KS, Zannad F, Califf RM, Pfeffer MA. Heart failure post-myocardial infarction in the new millennium: how often does it occur, can we predict it, and what are the consequences? J Cardiac Failure 2004;10:S101.
162. Tang WH, Velazquez EJ, Kilaru R, Maroo A, White H, Kober L, Rouleau JL, McMurray JJV, Califf RM, Francis GS. Patterns and outcomes of revascularization in patients with heart failure and/or left ventricular systolic dysfunction following acute myocardial infarction: observations from the VALIANT registry. J Cardiac Failure 2004;10:S104.
163. Tang WH, Francis GS, Miller H, Partin M, Harris CM, Young JB. Prevalence and clinical significance of “transient anemia” in ambulatory patients with chronic heart failure. J Cardiac Failure 2004:10:S109.
164. Tang WH, Steinhubl S, Van Lente F, Brennan DM, MR Erlean E, Marso SP, Francis GS, Topol EJ. Risk stratification for patients ongoing planned elective percutaneous coronary intervention using plasma N-terminal pro- BNP natriuretic peptide (NF-pro BNP) assay. A clopidogrel for the reduction of events during observation (CREDO) substudy. Circulation 2004; suppl III-110, abst #2729.
165. VALIANT Investigators. Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the VALIANT study. Circulation 2004; Suppl III-110, abst. #2985.
166. Tang WH, Troughton RW, Nash P, Bhavnani S, Francis GS, Starling RC, Richards AM, Yandle T, Klein AL. Reduction of natriuretic peptides in obese patients with systolic heart failure is independent of peptide types and echocardiographic indices of myocardial performance: analysis from ADEPT neurohormonal substudy. J Am Coll Cardiol 2005;45;suppl A, abst.#1048-179.
167. Gheorghiade M, Hellkamp AS, Pina IL, Fonarow GC, De Marco T, Pauly DF, Rogers J, DiSalvo T, Butler J, Hare JM, Francis GS, O’Connor CM. Hemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. J Am Coll Cardiol 2005;45; suppl A, abst.# 1075-149.
168. Butler J, Young JB, Abraham WT, Bourge RC, Adams KF, Hasan MA ,Heroux A, Russell SD, Francis GS, Clare R, O’Connor CM. Beta-blocker use and associated outcomes among hospitalized heart failure patients. J Am Coll Cardiol 2005;45; suppl A, abst.#1103-176.
169. Mezu UL, Philip K, Francis GS, Starling RC, Taylor DO, Tang WH. The impact of baseline glomerular filtration rate on the incidence of worsening renal failure in patients admitted for acute decompensated heart failure. J Am Coll Cardiol 2005;45;suppl A,abst.#1133-178.
170. Hasselblad V, Stough WG, Shah MR, Lokhnygina Y, Burnett JC, Gheorghiade M, Rayburn BK, Adams KF, Francis GS, Califf RM. Relationship between diuretic dose and outcome in a heart failure population: Results of the ESCAPE trial. J Cardiac Failure 2005;11:S6 Abst.250.
171. Drazner MH, Yancy CW, Shah MR, Nohria A, Leier CV, Miller W, Francis GS, DiSalvo TG, Califf RM, Stevenson JW. Utility of the history and physical examination in assessing hemodynamics in patients with advanced heart failure: The ESCAPE trial. J Cardiac Failure 2005:11:S6 Abst.307.
172. Drazner MH, Yancy CW, Shah MR, Nohria A, Leier CV, Miller W, Francis GS, DiSalvo TG, Califf RM, Stevenson JW. Utility of the history and physical examination in assessing hemodynamics in patients with advanced heart failure: The ESCAPE trial. Circulation 2005;112: Suppl II; abst 3018.
85
Gary S. Francis, M.D. Curriculum Vitae
173. Tang WH, Bhatheja R, Shrestha K, Van Lente F, Budd GT, Pohlman B, Andresen S, Francis GS, Weng DE. Is there a role in routine biomarker screening for cardiotoxicity in patients receiving doxorubicin chemotherapy? Pilot observation. J Cardiac Failure 12; Suppl 1, 2006.
174. Tong W, Van Lente F, Troughton RW, Francis GS, Starling RC, Klein AL, Tang WH. Relation of cystatin C to natriuretic peptide, creatinine clearance, and prognosis in patients with chronic systolic heart failure. J Cardiac Failure 12; Suppl 1, 2006.
175. Rogers JG, Tasissa G, Francis GS, DiSalvo TG, Leier CV, Wagoner LE, Pina IL, Stevenson LW, Sopko G, O’Connor CM. Sustained reduction in symptoms related to reduction of filling pressures during hospitalization for heart failure. J Cardiac Failure 12; Suppl 1, 2006.
176. Rogers JG, Tasissa G, Francis GS, DiSalvo TG, Leier CV, Wagoner LE, Pina IL, Stevenson LW, Sopko G, O’Connor CM. Reduction of filling pressures during hospitalization predicts sustained reduction in heart failure symptoms. Circulation 2006; Vol 114, No 18, abst 2560.
177. Thomas KL, Prisant LM, Lewis, EF, Huang Z, Francis, GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. Circulation 2006, Vol 114, No 18, abst 3171.
178. Tang WHW, Tong W, Van Lente F, Troughton RW, Francis GS, Starling RC, Klein AL. Relation of cystatin C to natriuretic peptide, creatinine clearance, and prognosis in patients with chronic systolic heart failure. Circulation 2006, Vol 114, No 18, abst 3616.
179. Cai OX, Phillips CO, Brotman DJ, Tang WHW, Michota FA, Whinney CM, Panneersalvana A, Garcia M, Francis GS, Jaffer AK. Short-term clinical outcome of compensated heart failure patients undergoing elective major non- cardiac surgery. J Am Coll Cardiol 2007, Vol 49, No 9, abst# 1006-181.
180. Almahameed S, Novaro GM, Asher CR, Zurek R, Bhatt DL, Francis GS, Topol EJ. Predictive value of high- sensitivity C-reactive protein in the diagnosis and prognosis of acute aortic syndromes. J Am Coll Cardiol 2007, Vol 49, No 9, abst# 1008-84.
181. Epelman S, Tang WHW, Young D, Chen SY, Van Lente F, Francis GS, Sen S. Soluble angiotensin converting enzyme 2 is released in patients with heart failure. J Cardiac Failure 2007; 13 (Suppl 2); abst #006, 5-73. Young Investigators Award Competition-Heart Failure Society of America Annual Meeting: Tie for 1st Prize.
182. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, Tang WHW. Release of soluble angiotensin converting enzyme 2 into the plasma of patients with chronic systolic heart failure is not related to systemic inflammation. J Cardiac Failure 2008, Vol 14, No 6, Supp 1, Abst 122.
183. Mullens W, Abrahams Z, Francis GS, Sokos G, Starling RC, Young JB, Taylor DO, Tang WHW. Isosorbide dinitrate and hydralazine as add-on therapy in patients admitted with advanced decompensated heart failure. J Cardiac Failure 2008, Vol 14, No 6, Suppl 1, Abst 294.
184. Tang WHW, Thakur A, Kumar P, Kanderian A, Borowski AG, Francis GS. Increased exhaled nitric oxide levels in ambulatory patients with chronic systolic heart failure following exercise: importance of pulmonary venous hypertension. J Am Coll Cardiol 2010, Vol 55, No 9, Suppl A, Abst 1180-75.
185. Hong W, Tang W, Thakur A, Kumar P, Kanderian A, Borowski AG, Francis GS. Increased exhaled nitric oxide levels in ambulatory patients with chronic systolic heart failure following exercise: importance of pulmonary venous hypertension. J Am Coll Cardiol 2010; 55(10):A34.E325.
86